Airdoc 鷹瞳

Beijing Airdoc Technology Co., Ltd.

北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

（於中華人民共和國註冊成立的股份有限公司）

Stock Code 股份代號 : 2251

2025

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

環境、社會及管治報告



CONTENTS 目錄

MESSAGE FROM MANAGEMENT			管理層致辭	
01	ABOUT THIS REPORT	6	01	關於本報告
	Report Preparation Principles	6		報告編製原則
	Report Preparation Basis	7		報告編製依據
	Obtaining and Responding to This Report	7		獲取及回應本報告
	Disclaimer	8		免責聲明
02	ABOUT US	8	02	關於我們
2.1	"WanYu" Large Language Model: The Unified Technological Foundation	9	2.1	「萬語」大模型：醫療AI普惠化的核心技術底座
2.2	Three Core AI Product Lines	10	2.2	三大核心AI產品線
	Myopia Prevention and Control AI (PBM-AI)	10		近視防控AI（PBM-AI）
	Retinal Detection AI (Retina-AI)	11		視網膜檢測AI（Retina-AI）
	Stress Resilience Monitoring AI (Neuro-AI)	12		抗壓能力監測AI（Neuro-AI）
2.3	External Recognition Obtained in 2025	13	2.3	2025年我們獲得的外部認可情況
03	BOARD STATEMENT	17	03	董事會聲明
04	SUSTAINABLE DEVELOPMENT MANAGEMENT SYSTEM	20	04	可持續發展管理體系
4.1	Actions Corresponding to the United Nations Sustainable Development Goals (SDGs)	21	4.1	聯合國可持續發展目標(SDGs)對應行動
4.2	Stakeholder Engagement	23	4.2	持份者參與
4.3	Materiality Assessment	26	4.3	重要性評估
4.4	Materiality Issues Matrix	27	4.4	重要性議題矩陣
4.5	Material Issues List	28	4.5	重要性議題清單

CONTENTS 目錄

05	CORE TECHNOLOGY AND R&D INNOVATION	32	05	核心技術與研發創新
5.1	Technology Platform and Competitive Advantages	34	5.1	技術平台與競爭優勢
5.2	Core Technology: AI Deep Learning Algorithm System	38	5.2	核心技術：AI深度學習算法體系
5.3	Academic Achievements	40	5.3	學術成果
5.4	Progress of Key R&D Projects	43	5.4	重點研發項目進展
5.5	Intellectual Property Management	45	5.5	知識產權管理
06	RESPONSIBLE OPERATIONS	54	06	負責任運營
6.1	Information Security and Privacy Protection	54	6.1	信息安全與隱私保護
6.2	Product Quality and Customer Service	60	6.2	產品質量與客戶服務
6.3	Sustainable Supply Chain	67	6.3	可持續供應鏈
6.4	Integrity and Compliance Operation	72	6.4	誠信合規運營
6.5	AI Algorithm Governance and Medical Ethics	78	6.5	AI演算法治理與醫療倫理
07	INCLUSIVE AI MEDICAL ECOSYSTEM DEVELOPMENT	81	07	AI醫療普惠生態
7.1	Technology Empowering Inclusive Scenarios	82	7.1	技術賦能普惠場景
7.2	Public Health Value Output	87	7.2	公共健康價值輸出
7.3	AI Medical Low-Carbon Operation	90	7.3	AI醫療低碳運營
08	TALENT TRAINING AND DEVELOPMENT	92	08	人才培養與發展
8.1	Safeguarding Employees' Rights and Interests	92	8.1	維護員工權益
8.2	Employee Care and Welfare	100	8.2	員工關愛及福利
8.3	Employee Health and Safety	102	8.3	員工健康與安全
8.4	Employee Development and Training	103	8.4	員工發展與培訓

CONTENTS 目錄

09	GREEN SUSTAINABLE DEVELOPMENT AND CLIMATE RESPONSE	109	09 綠色可持續發展與氣候應對
9.1	Resource Consumption and Emission Management	111	9.1 資源消耗與排放管理
9.2	Greenhouse Gas Emission Data Disclosure	114	9.2 溫室氣體排放數據披露
9.3	Governance of Addressing Climate Change	120	9.3 應對氣候變化的治理
9.4	Strategies for Addressing Climate Change	125	9.4 應對氣候變化的策略
9.5	Climate Scenario Analysis and Strategic Impact	134	9.5 氣候情景分析與策略影響
9.6	Participation in the BRICS Green Cooperation International Platform	145	9.6 參與金磚國家綠色合作國際平台
APPENDIX: INDEX OF CONTENT IN THE ESG REPORTING CODE		147	附錄：香港聯交所ESG報告守則內容索引

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

MESSAGE FROM MANAGEMENT

Chairman & Chief Executive Officer

Our mission is “Accessible and Affordable to Everyone” (讓健康無處不在). Our vision is to ensure that quality healthcare services are as ubiquitous and readily accessible as air, anytime and anywhere. These two statements not only define Airdoc’s strategic direction but also embody our core values that guide every business decision, every technical iteration, and every public-interest initiative.

We build on our proprietary “WanYu” (萬語) medical large language model as our technological foundation to continuously advance the broad, equitable deployment of AI retinal screening and youth myopia prevention and control. Through this approach, we have identified a path by which technological innovation and social responsibility can create mutual value. Guided by our initial aspiration to safeguard human life and health, we respond to expectations with steadfast commitments to quality and sustainable development.

I. Technology Foundation: The “Wanyu” Large Language Model — Enabling AI Healthcare to Be Implemented, Scaled and Sustained

In the global AI healthcare industry, there are few enterprises that can transition from the laboratory to real clinical settings and achieve large-scale commercial deployment. Our proprietary “WanYu” medical large language model is based on over 30 million real-world clinical diagnosis and treatment data and evidence-based medical knowledge graph entities covering more than 90 clinical application scenarios, serving as the unified technological platform across all our AI product lines.

管理層致辭

董事長兼行政總裁

我們的使命，是「讓健康無處不在」；我們的願景，是讓優質的醫療健康服務像空氣一樣，隨時隨地，觸手可及。這兩句話，既是鷹瞳科技的方向，也是我們在每一個業務決策、每一次技術迭代、每一項公益行動背後，始終堅守的價值初心。

我們以自主研發的「萬語」醫療垂直大模型為技術底座，持續推動AI眼底篩查與青少年近視防控的普惠化落地，在技術創新與社會責任之間找到了彼此成就的路徑。我們以初心守護生命健康，以高質量和可持續發展的堅定步伐，回應每一份期待。

一、技術底座：「萬語」大模型，讓AI醫療可落地、可推廣、可持續

在全球AI醫療賽道上，能夠從實驗室真正走入臨床場景、實現規模化商業落地的企業寥寥無幾。「萬語」醫療垂直大模型，以逾3,000萬份真實世界臨床數據為訓練基礎，融合多模態算法與醫學知識圖譜，覆蓋90餘個臨床應用場景，是我們所有AI產品線的統一技術平台。

In FY2025, the token consumption of our "WanYu" large language model token consumption by our customers was approximately 799.2 billion with over 77% of computing resources allocated to core commercialisable medical business. We served 478 hospitals and 1,633 primary healthcare institutions. We continued to publish high-quality research in leading journals, including Nature Medicine and Nature Communications Medicine. We steadily translated cutting-edge advances, such as atrial fibrillation detection, eclampsia prediction, and early screening for cognitive impairment, into clinical tools that reach primary healthcare settings. The goal of technology ultimately remains focused on those populations that are often the most difficult to reach.

2025年度，我們的「萬語」大模型客戶調用Token消耗量約7,992億，逾77%算力資源聚焦可商業化核心醫療業務，服務478家等級醫院及1,633家基層醫療機構。我們在《Nature Medicine》《Nature Communications Medicine》等頂刊持續發表高水平論文，將房顫檢測、子癇預測、認知障礙早篩等前沿成果不斷轉化為觸達基層的臨床工具 — 技術的終點，始終指向那些最難被照見的人群。

II. Protecting Vision: AI Fundus Screening — Bringing Chronic Disease Early Detection to Everyone Who Needs It

二、守護視界：AI眼底篩查，讓慢病早篩觸達每一個需要的人

"One fundus photograph, one step ahead of chronic disease" — this is not just a technical tagline but a promise we have made to hundreds of millions of individuals at high risk of chronic conditions. Historically, three barriers have kept fundus examination out of reach for the vast majority of patients at the primary care level: the need for specialist ophthalmologists, pupil dilation procedures and expensive equipment. It is precisely these barriers that Airdoc's AI is designed to dismantle.

「眼底一張照，慢病早知道」— 這不僅是一句技術口號，更是我們對數億慢病高風險人群許下的承諾。過去，規範眼底檢查的三重門檻 — 專業醫生、散瞳操作、昂貴設備 — 將廣大基層患者拒之門外。鷹瞳科技的AI，正是要打破這道無形的牆。

In 2025, our Retina-AI platform detected a cumulative total of 7.12 million cases, identified 37,210 significant positive cases and supported the identification of 55 categories of health risk. Our AI devices have extended their reach from leading tertiary hospitals in Beijing, Shanghai and Guangzhou to the "Rural Artificial Intelligence Laboratory" in Miyun District, and across county, township and village-level medical institutions in Sanming City — delivering reports within three minutes and replacing the cumbersome multi-hour referral journeys previously required. In December 2025, we published the *Health Blue Book of Six Million Physical Examination Subjects Based on Retinal AI Assessment* for the seventh consecutive year, with cumulative research samples surpassing 6 million, providing a scientifically grounded evidence base for public health policy.

2025年，我們的Retina-AI累計完成712萬例篩查，識別重大陽性案例37,210例，支持55種健康風險識別。AI設備從北上廣三甲醫院延伸至密雲農村「鄉村人工智慧實驗室」、三明市縣鄉三級醫療機構，以3分鐘快速出報告替代傳統繁瑣就醫流程。2025年12月，我們連續第七年發布《六百萬體檢人群健康藍皮書》，累計研究樣本突破600萬，以真實世界大數據為公共衛生政策提供科學依據。

III. Safeguarding the Next Generation: Taking Responsibility for Adolescent Myopia Prevention as a National Imperative

三、護航未來：在青少年近視防控中，擔當國家責任

Youth myopia has emerged as a major public health challenge in China with myopia prevalence exceeding 80% among senior high school students and the age of onset continuing to fall. A child's eyesight is bound up with a family's future — and with the quality of the nation's human capital.

中國青少年近視問題已成為重大公共衛生挑戰，高中生近視率逾80%，近視低齡化趨勢令人憂慮。一個孩子的視力，關係到一個家庭的未來，更關係到國家人才儲備的質量。

Our myopia prevention AI, PBM-AI, is centred on photobiomodulation (PBM) therapy and integrates the precision fitting and myopia risk prediction capabilities of the "Wanyu" model to provide personalised, full-cycle vision management programmes for each young patient. The core product has obtained a medical device registration certificate from the National Medical Products Administration (NMPA). In 2025, we entered Zhongguancun No. 3 Primary School in Haidian District, Beijing and implemented a "hospital and school" linkage model in Sanming City. Under a programme led by the Nanchang Municipal Government, our Neuro-AI stress resilience monitoring system served 1.5 million primary and secondary school students and teachers, measuring stress indicators through a 90-second, contactless process to safeguard the physical and mental wellbeing of the younger generation. We firmly believe that protecting every child's vision and mental health is the most meaningful social investment an enterprise can make.

我們的近視防控AI（PBM-AI），以光生物調節療法為核心，融合「萬語」大模型的精準驗配與近視風險預測能力，為每位青少年建立個性化全周期視力管理方案，核心產品已取得國家藥監局醫療器械注冊證。2025年，我們走進北京海淀中關村三小、落地三明「醫院+學校」聯動模式；在南昌市政府主導下，Neuro-AI抗壓能力監測惠及150萬中小學生及教師，以90秒非接觸式測量守護青少年身心健康。我們深信，保護每一雙孩子的眼睛和身心健康，是企業最有溫度的社會投資。

IV. Embracing Responsibility: ESG is Our DNA, Not a Compliance Obligation

四、責任擔當：ESG不是義務，是我們的基因

For Airdoc, ESG has never been a regulatory obligation of a listed company — it is encoded in our corporate DNA. Every AI fundus screening case completed represents a positive contribution to the public health system. Every piece of equipment donated to a primary healthcare institution is a concrete response to the inequitable distribution of medical resources. Every high-risk case detected early by AI may spare a family from poverty caused by illness.

對鷹瞳科技而言，ESG從來不是上市公司的合規義務，而是流淌在企業血脈中的基因。每完成一次眼底AI篩查，是對公共衛生體系的正向貢獻；每向基層醫療機構捐贈設備，是對醫療資源不均的切實回應；每一個被AI提前發現的陽性病例，都可能讓一個家庭免於因病致貧。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

This report is our fourth annual ESG Report, prepared in accordance with the Environmental, Social and Governance Reporting Code set out in Appendix C2 of the Hong Kong Listing Rules. The Board has established an Environmental, Social and Governance Committee which holds quarterly meetings to ensure that our sustainability objectives are deeply integrated with our core business activities. In 2025, the Company was honoured with a number of prestigious recognitions, including the "Indigenous Innovation Globalisation Award" at the World Artificial Intelligence Conference (WAIC), the Bethune Foundation "Sparks of Dedication Cup", and the "Most Socially Responsible Enterprise in China's Digital Intelligence Industry" award. These accolades affirm our past endeavours and serve as a further impetus for the journey ahead.

本報告為我們發布的第四份ESG年度報告，依據香港上市規則附錄C2《環境，社會及管治報告守則》編製。董事會下設環境、社會及管治委員會，每季度召開專項會議，確保可持續發展目標與核心業務深度融合。2025年，公司榮獲世界人工智慧大會「本土創新全球化獎」、白求恩公益基金會「薪火•奉獻杯」、「中國數智產業最具社會責任感企業」等殊榮，既是對過去努力的肯定，更是繼續前行的動力。

The retina is the only tissue in the human body through which the nervous system can be directly observed non-invasively — a window into life itself. Airdoc is striving to become that window for an ever-greater number of people. Making quality healthcare as pervasive and accessible as air is our mission, and the promise we make to the future.

視網膜，是人體唯一可無創直接觀察神經系統的窗口；鷹瞳科技，正努力成為更多人健康生命的那扇窗。讓優質醫療健康服務像空氣一樣觸手可及 — 這是我們的使命，也是我們向未來許下的承諾。

Beijing Airdoc Technology Co., Ltd.
Chairman and Chief Executive Officer
Zhang Dalei
2026

北京鷹瞳科技發展股份有限公司
董事長兼行政總裁
張大磊
2026年

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

01 ABOUT THIS REPORT

This is the fourth Environmental, Social and Governance ("**ESG**") Report (hereinafter referred to as "**this Report**") released by Beijing Airdoc Technology Co., Ltd. (hereinafter referred to as "**we**" or "**the Company**" or the "**Group**"). Adhering to the principles of materiality, quantification, balance and consistency, this Report systematically summarizes our management concepts and practical achievements in the ESG field during the period from January 1, 2025 to December 31, 2025 (hereinafter referred to as the "**Reporting Period**"), focuses on the core concerns of internal and external stakeholders, and comprehensively demonstrates our efforts and results in promoting the sustainable development of the economy, environment and society.

Unless otherwise specified, all information in this Report is the data and achievements for the year 2025, covering the Company and its subsidiaries, with a scope consistent with the Annual Report. The data disclosed in this Report is sourced from internal statistical systems and relevant business records, and has been verified through internal review.

Report Preparation Principles

This Report is prepared in accordance with the following reporting principles:

- **Materiality:** We identify our main ESG issues through materiality assessment and disclose them in this Report;
- **Quantification:** Quantitative data is presented in environmental and social aspects, with relevant explanations to clarify its purpose and impact. Future ESG Reports will gradually provide comparative data to demonstrate continuous improvement;

01 關於本報告

本報告是北京鷹瞳科技發展股份有限公司(以下簡稱「**我們**」、「**公司**」或「**集團**」)發布的第四份環境、社會及管治(「**ESG**」)報告。本報告秉承重要性、量化、平衡性及一致性原則，系統總結我們於2025年1月1日至2025年12月31日期間(以下簡稱「**報告期**」)在ESG領域的管理理念與實踐成果，聚焦內外部利益相關方核心關注點，全面展現我們在推動經濟、環境及社會可持續發展方面的努力與成效。

除特別說明外，報告信息均為2025年度數據成果，涵蓋北京鷹瞳科技發展股份有限公司及其附屬公司，範圍與年報保持一致。本報告所披露數據來源於內部統計系統及相關業務記錄，經內部審核確認。

報告編製原則

本報告依據以下呈報原則編製：

1. **重要性**：通過重要性評估確定我們主要ESG議題，並在本報告中予以披露；
2. **量化**：在環境及社會方面列示量化數據，並附相關說明以闡釋其目的與影響。未來的ESG報告將逐步提供對比數據，以展現持續改進；

- **Balance:** This Report provides an unbiased picture of the Company's performance. This Report avoids selections, omissions, or presentation formats that may inappropriately influence a decision or judgment by the reader of this Report;

- **Consistency:** As the fourth ESG Report we have released, we commit to continuing a consistent information disclosure method in the future to ensure that year-on-year comparisons are meaningful and coherent.

Report Preparation Basis

This Report is prepared in accordance with the requirements of the Environmental, Social and Governance Reporting Code of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (hereinafter referred to as "**Stock Exchange**") (hereinafter referred to as "**ESG Reporting Code**"), with reference to the latest climate-related disclosure requirements, and optimizes the information presentation in combination with the attributes of the AI medical industry.

Obtaining and Responding to This Report

This Report is published in both Chinese and English. In case of any discrepancy in the understanding of the two versions, the Chinese version shall prevail. You can download the Chinese and English versions of this Report from the website of the Stock Exchange (http://www.hkexnews.hk) and our official website (http://www.airdoc.com). If you have any comments or suggestions on our ESG performance, please feel free to send an email to ir@airdoc.com.

3. **平衡性**：本報告呈現公司表現之客觀中立資訊，避免選取、遺漏或採用可能不當影響報告使用者決策或判斷之資訊呈現方式；

4. **一致性**：作為我們發布的第四份ESG報告，我們承諾未來延續一致的信息披露方法，確保逐年比較具有意義和連貫性。

報告編製依據

本報告依據香港聯合交易所有限公司(簡稱「聯交所」)《環境、社會及管治報告守則》(簡稱「**ESG報告守則**」)的要求編製，並參考最新氣候相關披露要求，結合AI醫療行業屬性優化信息呈現。

獲取及回應本報告

本報告以中英文兩種文字出版，在對兩種版本理解發生歧義時，以中文版本為準。您可於聯交所網站(http://www.hkexnews.hk)及我們官網(http://www.airdoc.com)下載本報告的中英文版本。如對我們ESG表現有任何意見或建議，歡迎發送郵件至ir@airdoc.com。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Disclaimer

Some contents of this Report are forward-looking and subject to uncertainties, which may lead to significant differences between actual results and forward-looking statements. We do not assume any obligation to update any forward-looking statements in this Report.

免責聲明

本報告部分內容具有前瞻性，易受不確定因素影響，可能導致實際結果與前瞻性陳述存在重大差異。我們不承擔更新本報告中任何前瞻性陳述的義務。

02 ABOUT US

We are an artificial intelligence healthcare company specialising in the medical and healthcare sector, with our proprietary vertical medical large language model “WanYu” serving as the core technological foundation. Built upon this foundation, we have established three core AI product lines, forming an overall business architecture featuring “One Large Language Model Foundation, Three Core AI Products, Multi-Scenario Implementation”. Under this architecture, each product line features homologous technology, complementary scenarios, and clear commercialization paths, achieving a complete closed-loop for vertical domain large language models from technology R&D to commercial monetization. As a vertical large language model enterprise that has achieved large-scale commercial landing in real-world medical scenarios, our relevant AI products and solutions have been widely applied in various real-world medical healthcare scenarios, including medical institutions, optometry centers, primary healthcare institutions, and health management settings, responding to the core needs of public health through technological innovation and earnestly fulfilling corporate social responsibility.

02 關於我們

我們是一家專注於醫療健康領域的人工智慧醫療企業，以自主研發的醫療垂直大模型「萬語」作為核心技術底座，並以此為支撐構建三大核心AI產品線，形成「一個大模型底座、三大AI產品、多場景落地」的整體業務架構。該架構下各產品線技術同源、場景互補、商業化路徑明確，實現了垂直領域大模型從技術研發到商業化變現的完整閉環。作為在真實醫療場景實現規模化商業化落地的垂直領域大模型企業，相關AI產品及解決方案已廣泛應用於醫療機構、視光中心、基層醫療及健康管理等多類真實醫療健康場景，以技術創新回應公共健康核心需求，切實踐行企業社會責任。

2.1 *"WanYu" Large Language Model: The Unified Technological Foundation*

Our self-developed "WanYu" vertical medical large language model is an exclusive AI technology base developed for the healthcare field and oriented to the needs of inclusive medical care. Differentiating itself from general-purpose large language models, it is deeply trained based on vast medical professional knowledge base, integrates core technologies such as multimodal algorithms and medical knowledge graphs, strictly adheres to medical compliance requirements and diagnostic protocols, and can be deeply adapted to meet the demands of various scenarios, including clinical testing, health assessment, primary chronic disease screening, etc. As a unified technological foundation for all our AI product lines, the "WanYu" large language model adopts a virtuous cycle of "Models Empowering Business, Business Iterating Models", deeply penetrating technical capabilities into various healthcare scenarios. It not only continuously reduces the technical threshold of AI application in primary medical care through algorithm iteration, but also continuously optimizes model capabilities relying on real data accumulated in business, making advanced medical AI technology implementable, reusable and promotable. It provides a solid technical guarantee for promoting the equality of medical resources and realizing the popularization of AI medical care, and helps solve the social public health pain points such as insufficient primary medical resources and low coverage of chronic disease screening through technological innovation.

2.1 *「萬語」大模型：醫療AI普惠化的核心技術底座*

我們自主研發的「萬語」醫療垂直大模型，是深耕醫療健康領域、面向普惠醫療需求打造的專屬AI技術底座，區別於通用大模型，其依託海量醫療專業數據完成深度訓練，融合多模態演算法、醫學知識圖譜等核心技術，嚴循醫療合規與診療規範，可精准適配臨床檢測、健康評估、基層慢病篩查等全場景需求。作為我們所有AI產品線的統一技術平台，「萬語」大模型以「模型賦能業務、業務迭代模型」的正向迴圈模式，將技術能力深度滲透到各類醫療健康場景，既通過演算法迭代持續降低基層醫療AI應用的技術門檻，又依託業務積累的真實數據不斷優化模型能力，讓先進的醫療AI技術可落地、可複用、可推廣，為推動醫療資源均等化、實現AI醫療普惠化提供了堅實的技術保障，以技術創新助力解決基層醫療資源不足、慢病篩查覆蓋率低等社會公共衛生痛點。

2.2 Three Core AI Product Lines

Myopia Prevention and Control AI (PBM-AI)

Focusing on the major public health needs of the younger age and high incidence of myopia among adolescents in China, with PBM (photobiomodulation) therapy as the core, it deeply integrates the precise fitting, myopia risk prediction and full-cycle intelligent management capabilities of the "WanYu" AI large language model, creating a full-process digital closed-loop solution from AI assessment of adolescents' myopia risk, AI adaptation of personalized phototherapy plans, to dynamic monitoring of treatment effects and prediction of myopia development trends, realizing the scientization, personalization and systematization of myopia prevention and control.

- **Application Scenarios:** Medical scenarios (myopia treatment), optometry centers (myopia prevention and eye axis control)
- **Core Value:** AI+ PBM to provide personalized and precise myopia intervention; the core product has obtained medical device registration certification from the National Medical Products Administration, becoming an important scientific and technological product to support the national strategy for myopia prevention and control in adolescents, and earnestly protecting the visual health of the next generation.

2.2 三大核心AI產品線

近視防控AI（PBM-AI）

聚焦我國青少年近視低齡化、高發化的重大公共衛生需求，以PBM光生物調節療法為核心，深度融合「萬語」AI大模型的精準驗配、近視風險預測及全週期智能管理能力，打造從青少年近視風險AI評估、個性化光療方案AI適配，到治療效果動態監測、近視發展趨勢預判的全流程數字化閉環解決方案，實現近視防控的科學化、個性化與體系化。

- **應用場景**：醫療場景（近視治療）、視光中心（近視預防與眼軸控制）
- **核心價值**：AI+PBM光生物調節，提供個性化精準近視干預；核心產品已獲國家藥監局醫療器械註冊證，成為助力國家青少年近視防控戰略的重要科技產品，切實守護下一代視力健康。

Retinal Detection AI (Retina-AI)

Centering on the core strategy of "Retina AI + Early Chronic Disease Screening", relying on the multimodal algorithm and clinical logical reasoning capabilities of the "WanYu" AI large language model, it breaks through the limitations of traditional fundus detection, realizing the technical extension from fundus disease screening to early screening of systemic chronic diseases, and becoming a core AI tool for chronic disease prevention and control and clinical auxiliary diagnosis in primary medical care.

- **Application Scenarios:** Auxiliary diagnosis medical scenarios, risk assessment general health scenarios
- **Core Value:** Accurately screening fundus diseases such as diabetic retinopathy and retinal vein occlusion, and making progress in cross-departmental high social value scenarios such as atrial fibrillation detection and preeclampsia prediction; in 2025, a total of 7.12 million cases were detected, with 37,210 significant positive cases identified, which has realized the identification of 55 types of health risks, effectively alleviating the social pain points of insufficient primary medical resources and low coverage of chronic disease early screening, and the product compliance layout covers domestic and overseas emerging markets.

視網膜檢測AI（Retina-AI）

圍繞「視網膜AI＋慢病早篩」核心戰略，依託「萬語」AI大模型的多模態算法與臨床邏輯推理能力，突破傳統眼底檢測侷限，實現從眼底疾病篩查到全身慢病早篩的技術延伸，成為基層醫療慢病防控與臨床輔助診斷的核心AI工具。

- **應用場景**：輔助診斷醫療場景、風險評估大健康場景
- **核心價值**：精準篩查糖尿病視網膜病變、視網膜靜脈阻塞等眼底疾病，同時在房顫檢測、子癇預測等跨科室高社會價值場景取得進展；2025年累計檢測712萬病例，識別重大陽性案例37,210例，已實現55種健康風險識別，有效緩解基層醫療資源不足、慢病早篩覆蓋率低的社會痛點，產品合規佈局覆蓋國內及海外新興市場。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Stress Resilience Monitoring AI (Neuro-AI)

Targeting the essential need for stress management in the physical and mental health market, especially the stress management needs of key groups such as adolescents, workplace groups and new employment groups, it fills the gap in intelligent stress management in the consumer health market.

- **Application Scenarios:** School scenarios, general health scenarios, medical scenarios
- **Core Value:** Realizing accurate monitoring and quantitative assessment of stress resistance and stress status through AI technology, supporting personalized intervention plans, and creating a full-link physical and mental health service; adopting 90-second non-contact measurement, which greatly reduces the threshold for large-scale census, provides efficient scientific and technological support for schools, enterprises and communities, and helps improve the national physical and mental health management level.

抗壓能力監測AI（Neuro-AI）

瞄準國民身心健康保障的社會剛需，尤其針對青少年、職場人群、新就業群體等重點人群的壓力管理需求，填補消費健康市場智能化壓力管理的空白。

- **應用場景**：學校場景、大健康場景、醫療場景
- **核心價值**：通過AI技術實現抗壓能力與壓力狀態的精準監測、量化評估，配套個性化干預方案，打造全鏈路身心健康服務；採用90秒非接觸式測量，大幅降低大規模普查門檻，為學校、企業、社區提供高效科技支撐，助力提升全民身心健康管理水平。

As a technology enterprise deeply engaged in the field of AI medical care, we always adhere to the parallel development of technological innovation and social responsibility, solve the problems in the field of public health with independent core technologies, narrow the gap in the distribution of medical resources with inclusive AI medical products, and deeply bind the enterprise's commercial value with social value. In the future, we will continue to rely on the technological advantages of the "WanYu" vertical medical large language model, continuously deepen product R&D and scenario landing, fully promote the process of AI medical popularization, earnestly fulfill the commitment of sustainable development, and continuously contribute to protecting national health and promoting the high-quality development of the medical industry.

作為深耕醫療AI領域的科技企業，我們始終堅持技術創新與社會責任並行，以自主核心技術破解公共健康領域難題，以普惠化AI醫療產品縮小醫療資源分配差距，將企業商業價值與社會價值深度綁定。未來，我們將繼續基於「萬語」醫療垂直大模型技術優勢，不斷深化產品研發與場景落地，全力推動AI醫療普惠化進程，切實踐行可持續發展承諾，為守護國民健康、推動醫療行業高質量發展持續貢獻力量。

2.3 External Recognition Obtained in 2025

During the Reporting Period, we continued to strengthen our presence in the AI healthcare sector, maintaining a dual focus on independent R&D and the practice of inclusive medical care, and through innovations in our core technologies and sustainable development practices, we received strong recognition from the national level, leading media and top industry platforms. These recognitions and honors have further reinforced our brand credibility, and highlighted our core competitiveness and social value within the AI healthcare domain.

2.3 2025年我們獲得的外部認可情況

報告期內，我們深耕AI醫療領域，堅持自主研發與普惠醫療踐行並重，憑藉核心技術創新成果與可持續發展實踐，收穫國家層面、權威媒體及頂級行業平台的高度認可，各項認可與榮譽進一步築牢品牌公信力，彰顯我們在AI醫療垂直領域的核心競爭力與社會價值。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

At the 2025 World AI Conference (WAIC) and the High-Level Meeting on Global AI Governance, relying on a number of original medical AI technologies and commercialization achievements, we became a key focus enterprise in the medical sector, won the "Local Innovation Globalization Award" (「本土創新全球化獎」), and was successfully listed on WAIC's 2025 Recommended List of Sustainable Innovation Cases in Healthcare. As a model representative of local technology enterprises' innovative overseas expansion, it fully demonstrated the international competitiveness and global development potential of AI medical technology, laying a solid foundation for the layout of domestic and foreign businesses and ecological cooperation.

在2025世界人工智慧大會(WAIC)暨人工智慧全球治理高級別會議現場，我們憑藉多項醫療AI原創技術與商業化落地成果，成為醫療板塊重點關注企業，榮獲「本土創新全球化獎」，同時成功入選WAIC《2025醫健可持續創新案例推薦榜》，作為本土科技企業創新出海的典型代表，充分展現AI醫療技術的國際競爭力與全球化發展潛力，為海內外業務佈局與生態合作奠定堅實基礎。

In addition, we also won a number of prestigious industry awards in the fields of social responsibility practice, intellectual property innovation, and digital medical landing, covering public welfare dedication, corporate social responsibility, intellectual property, digital health and other dimensions, comprehensively reflecting the market and industry's high recognition of our adherence to the original intention of technology and the mission of inclusive medical care. The honors and recognitions we have received represent both encouragement and responsibility. Moving forward, we will continue to advance our business driven by our core technologies, deepen scenario-based application and international deployment, apply AI-driven solutions to enhance the accessibility of healthcare resources, and support the high-quality and sustainable development of the healthcare industry.

此外，我們在社會責任踐行、知識產權創新、數智醫療落地等領域同步斬獲多項行業重磅獎項，覆蓋公益奉獻、企業社會責任、知識產權、數字健康等多個維度，全方位體現市場與行業對我們堅守技術初心、踐行普惠醫療使命的高度肯定。各項榮譽與認可既是鼓勵，更是責任，未來我們將持續以核心技術為驅動，深化場景應用與全球化佈局，以AI科技賦能醫療資源普惠，助力醫療健康行業高質量可持續發展。

Award Name 獎項名稱	Awarding Institution 主辦方
2025 “Xinhuo • Dedication” Cup 2025「薪火 • 奉獻」杯	Beijing Bethune Public Welfare Foundation 北京白求恩公益基金會
2025 China Digital Intelligence Industry Most Socially Responsible Enterprise 2025中國數智產業最具社會責任感企業	Data Ape/Shanghai Big Data Alliance 數據猿／上海大數據聯盟
Intellectual Property “Innovation Model” Enterprise 知識產權「創新典範」企業	Beijing Intellectual Property Protection Association 北京知識產權保護協會
Friendly Service Partner for New Employment Groups 新就業群體友好服務夥伴	Relevant departments such as the Social Work Department of Haidian District Committee 海淀區委社會工作部等相關部門
2025 Local Innovation Internationalization Case 2025本土創新國際化案例	China Business News/Jianwen Consulting 第一財經／健聞諮詢
2025 Bund Conference Thank-You Letter 2025外灘大會感謝信	Bund Conference Organizing Committee/ People’s Government of Huangpu District, Shanghai 外灘大會組委會／上海市黃浦區人民政府
2025 Global Ophthalmology User Experience Award 2025全球眼科用戶體驗獎	Zhongguancun Lianxin Biomedical Industry Alliance 中關村聯新生物醫藥產業聯盟
2025 AI Healthcare Innovation Case (2025年度AI醫療創新案例) 2025年度AI醫療創新案例	China Times 華夏時報
2025 Digital Health Innovative Application Case (2025數字健康創新應用案例) 2025數字健康創新應用案例	VBData.cn 動脈網

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Award Name 獎項名稱	Awarding Institution 主辦方
2025 “Golden Wisdom Award” Outstanding Frontier Technology Enterprise (2025“金智獎”傑出前沿科技企業) 2025「金智獎」傑出前沿科技企業	JRJ.com 金融界
2025 Outstanding Medical Technology Innovation Award (2025傑出醫療科技創新獎) 2025傑出醫療科技創新獎	The 14th China Finance Summit CFS第十四屆財經峰會
2025 Outstanding Product Innovation Leadership Award (2025傑出產品創新引領獎) 2025傑出產品創新引領獎	The 14th China Finance Summit CFS第十四屆財經峰會











03 BOARD STATEMENT

The Board of Directors assumes full responsibility for the Company's ESG strategies and reporting. The Board of Directors confirms that this Report is prepared in accordance with the requirements of the ESG Reporting Code (2024 Revision), and the content is true, accurate and complete, without any false records, misleading statements or material omissions.

As the highest responsible body for our ESG work, the Board of Directors is responsible for the formulation, approval and progress review of ESG goals, ensuring that ESG goals are deeply integrated with the Company's core AI medical business. The specific mechanisms are as follows:

- **ESG Goal Progress Review Mechanism:** The Board of Directors has established an Environmental, Social and Governance Committee (hereinafter referred to as the "**ESG Committee**"), chaired by the Chairman of the Board. The ESG Committee holds special ESG meetings on a quarterly basis to review the progress in advancing ESG goals (including mandatory environmental KPI goals); at the annual Board of Directors meeting each year, it reviews the annual completion of ESG goals, the reasons for any uncompleted goals and the optimization and adjustment plans, and formulates the "ESG Goal Progress Review Report", which serves as an important basis for the Board's decision-making and the optimization of ESG work. Meanwhile, the ESG Committee regularly reports major issues arising in the process of advancing the goals to the Board of Directors to ensure the implementation of the goals.

03 董事會聲明

董事會對本公司環境、社會及管治策略及匯報承擔全部責任。董事會確認，本報告按照ESG報告守則(2024年修訂版)的要求編製，內容真實、準確、完整，不存在任何虛假記載、誤導性陳述或重大遺漏。

董事會作為我們ESG工作的最高責任主體，負責ESG目標的制定、審批及進度檢討，確保ESG目標與公司AI醫療核心業務深度融合，具體機制如下：

- **ESG目標進度檢討機制**：董事會下設環境、社會及管治委員會(以下簡稱「**環境、社會及管治委員會**」)，由董事長擔任主席，每季度召開ESG專項會議，檢討ESG目標(含環境類強制KPI目標)的推進進度；每年年度董事會會議，審議ESG目標年度完成情況、未完成原因及優化調整方案，形成《ESG目標進度檢討報告》，作為董事會決策及ESG工作優化的重要依據。同時，環境、社會及管治委員會定期向董事會匯報目標推進過程中的重大問題，確保目標落地執行。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

- **Relevance between ESG Goals and Core Business:** Our ESG goals are formulated in close alignment with the development philosophy of "Inclusiveness, Compliance and Green Development" of AI medical care, and are deeply bound to the core business: Environmental goals (energy conservation and waste reduction) are in line with the characteristics of the Company's light-asset operation. Through green office and low-carbon supply chain collaboration, the Company reduces operating costs while practicing the concept of "Green Medical Care", helping to promote the coordinated development of public health and the ecological environment; goals related to the inclusiveness of AI medical care are consistent with the Company's mission of making health "Accessible and Affordable to Everyone" (讓健康無處不在). Through technology sinking and public welfare services, the Company integrates ESG value into product implementation and market expansion, achieving a win-win situation of commercial value and social value, which complies with the disclosure requirements of the Stock Exchange regarding the relevance between ESG goals and business.

- **ESG目標與核心業務的關聯性：**我們ESG目標設定緊密圍繞AI醫療「普惠、合規、綠色」的發展理念，與核心業務深度綁定：環境類目標（節能、減廢）貼合公司輕資產運營特點，通過綠色辦公、低碳供應鏈協同，降低運營成本的同時，踐行「綠色醫療」理念，助力公共健康與生態環境協同發展；AI醫療普惠相關目標，與公司「讓健康無處不在」的使命一致，通過技術下沉、公益服務，將ESG價值融入產品落地與市場拓展，實現商業價值與社會價值雙贏，符合聯交所ESG目標與業務關聯性的披露要求。

Taking into account the external socio-economic macro-environment as well as our development strategy, the management team conducts dynamic assessments of the materiality of ESG issues to identify and analyze the risks and opportunities in the environment, society and our governance, incorporates the management and improvement of key issues into our annual sustainable development strategy, formulates ESG work goals, and supervises the performance of ESG work. The 2025 materiality assessment identified that R&D innovation and intellectual property protection, information security and privacy protection, product quality and after-sales service support, the development of an inclusive AI medical ecosystem, employee care and welfare, and employee development and training are still the core ESG issues of concern to internal and external stakeholders.

結合外部社會經濟宏觀環境與我們發展戰略，管理團隊動態評估ESG議題重要性，識別並分析環境、社會及我們治理方面的風險與機遇，將重點議題管理與提升納入可持續發展年度戰略計劃，制定ESG工作目標，監督ESG工作績效表現。2025年度重要性評估顯示，研發創新與知識產權保護、信息安全與隱私保護、產品質量與售後服務支持、AI醫療普惠生態建設、員工關愛與福利及員工發展與培訓等，仍是內外部利益相關方關注的核心ESG議題。

We strictly safeguard user privacy and remain driven by user needs and market orientation, encourage innovation, implement rigorous product quality control, and prize customer service management. Guided by the principle of mutual benefit, we actively integrate and share industry resources, foster a cooperative ecosystem with all stakeholders, create value for shareholders, provide high-quality services for customers, share the achievements of our growth and development with employees, and actively give back to society.

我們嚴格保護用戶隱私，堅持以用戶需求為驅動力、以市場為導向，鼓勵創新，對產品質量實施嚴格把控，注重客戶服務管理。秉承互利共贏原則，我們積極整合並分享行業優勢資源，與各利益相關方共同打造合作生態圈，為股東謀取價值，為客戶提供優質服務，與員工共享企業發展成果，同時積極回饋社會。

As an AI medical enterprise, we deeply recognize the dual nature of technology — algorithm bias, data privacy protection and AI interpretability are also core ESG risks that require active management. Alongside our continued pursuit of technological innovation, we have integrated “Responsible AI Development and Deployment” into our ESG governance framework to ensure the use of technology for good, data security, and model credibility, creating sustainable health value for patients, medical institutions and all sectors of society.

作為一家AI醫療企業，我們深刻認識到技術的雙面性 — 算法偏差、數據隱私保護及AI可解釋性同樣是需要主動管理的ESG核心風險。我們在持續推動技術創新的同時，將「負責任的AI開發與部署」納入ESG治理框架，確保技術向善、數據安全、模型可信，為患者、醫療機構及社會各方創造可持續的健康價值。

In the face of increasingly strict regulatory requirements and the growing emphasis on green, safe and sustainable development, we are both seizing new development opportunities and addressing emerging challenges. Looking ahead, we will continue to flexibly adapt our sustainable development management strategy and implementation approaches in line with stakeholder expectations and our operational realities, and continuously enhance our performance across the economic, environmental and social aspects of sustainable development.

面對日益嚴格的監管要求及綠色、安全、可持續發展趨勢，我們既把握發展機遇，也應對全新挑戰。展望未來，我們將繼續根據利益相關方期望及我們實際運營情況，靈活調整可持續發展管理策略與推進方式，不斷提升我們在經濟、環境與社會方面的可持續發展水平。

04 SUSTAINABLE DEVELOPMENT MANAGEMENT SYSTEM

04 可持續發展管理體系

Since the United Nations World Commission on Environment and Development first proposed the concept of “sustainable development” in 1987, sustainable development has become an important issue closely related to every enterprise and individual. Since establishment, we have remained committed to the integrated development of the economy, society, and environment, advancing sustainable business practices and upholding our corporate social responsibilities to better capture the opportunities arising from the growth of the AI healthcare industry.

自1987年聯合國環境與發展世界委員會首次提出「可持續發展」概念，可持續發展便成為與每個企業及個人息息相關的重要議題。我們自成立以來，始終遵循經濟、社會及環境共同發展的經營理念，推進可持續性業務實踐並履行企業社會責任，以更好地把握AI醫療行業發展帶來的機遇。

4.1 Actions Corresponding to the United Nations Sustainable Development Goals (SDGs)

4.1 聯合國可持續發展目標(SDGs)對應行動

United Nations Sustainable Development Goals 聯合國可持續發展目標	Our Core Actions 我們核心行動
SDG 1/3/11 No Poverty • Good Health and Well-being • Sustainable Cities and Communities	Guided by our mission of "Accessible and Affordable to Everyone (讓健康無處不在)", we actively carry out inclusive healthcare services such as eye health programs for adolescents and national chronic disease screening services, and strive for our corporate vision of "A Health Check In One Minute For One Yuan (一分鐘一塊錢做一次體檢)". We donate AI screening equipment free of charge to primary medical institutions in underdeveloped areas to narrow the urban-rural medical gap. At the same time, we attach great importance to the physical and mental health of our employees, provide free health checks, and foster a caring and supportive working environment.
SDG 1/3/11消除貧困 • 良好的健康與福祉 • 可持續城市與社區	以「讓健康無處不在」為使命，廣泛開展青少年眼健康和國民慢性病篩查普惠服務，致力於「一分鐘一塊錢做一次體檢」的企業願景。向欠發達地區基層醫療機構無償捐贈AI篩查設備，縮小城鄉醫療差距。同時，高度關注員工身心健康，提供免費健康體檢，營造關懷與支持的工作環境。
SDG 8 Decent Work and Economic Growth	Upholding a people-oriented management philosophy, we create a safe and comfortable working environment for our employees, improve our employee welfare system, promote workplace equality and inclusion, and foster an open and democratic corporate culture. We continue to carry out campus recruitment, create high-quality employment opportunities in the AI healthcare sector, and help talent training and career development.
SDG 8體面工作與經濟增長	秉持以人為本的管理理念，為員工營造安全舒適的工作環境，完善福利體系，推動職場平等與包容，構建民主開放的企業文化。持續開展校園招聘，創造AI醫療領域高質量就業崗位，助力人才培養與職業發展。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

United Nations Sustainable Development Goals 聯合國可持續發展目標	Our Core Actions 我們核心行動
SDG 9 Industry, Innovation and Infrastructure	With the "WanYu" large language model as the core foundation, we continue to increase R&D investment, have applied for 468 patents in China, published more than 60 papers in top journals such as Nature Medicine and The Lancet, promoted the formation of AI medical technology standards, and supported the construction of industrial infrastructure.
SDG 9產業 • 創新 • 基礎設施	以「萬語」大模型為底座，持續加大研發投入，累計在中國申請468項專利，在《Nature Medicine》《Lancet》等頂刊發表60+篇論文，推動AI醫療技術標準形成，支持產業基礎設施建設。
SDG 13 Climate Action	We practice the concept of green office, implement the 26°C air conditioning temperature standard, and adopt energy-saving LED lamps; the Changsha factory gives priority to low-power chips and degradable materials; we incorporate environmental management requirements into the supplier evaluation system, encourage suppliers to obtain ISO14001 certification, and promote low-carbon transformation of the upstream and downstream.
SDG 13氣候行動	踐行綠色辦公理念，執行26°C空調溫度標準，採用節能LED燈具；長沙工廠優先選用低功耗芯片和可降解材料；將環境管理要求納入供應商評估體系，鼓勵供應商取得ISO14001認證，推動上下游低碳轉型。
SDG 17 Partnerships for the Goals	We actively listen to the opinions and needs of stakeholders and establish and improve a continuous communication mechanism. We deeply integrate ESG standards into supplier management and daily operations, and ensure that the concepts and requirements of supply chain management are effectively transmitted through capacity building and resource sharing, so as to jointly promote the achievement of sustainable development goals.
SDG 17全球夥伴關係	積極傾聽利益相關方意見與需求，建立並完善持續溝通機制。將ESG標準深度融入供應商管理及日常運營，通過能力建設和資源共享，確保供應鏈管理理念與要求得到有效傳遞，共同推動可持續發展目標實現。

4.2 Stakeholder Engagement

The Group attaches great importance to communication and interaction with various stakeholders. We have identified governments and regulatory authorities, shareholders and investors, medical institutions and customers, employees, suppliers and partners, and communities and the public as our main stakeholders. We maintain daily contact with them through diversified channels, continuously understand their expectations and concerns, and incorporate stakeholder feedback into the Group's ESG management decisions and report disclosure considerations.

4.2 持份者參與

本集團高度重視與各持份者之間的溝通與互動。我們識別出政府及監管機構、股東及投資者、醫療機構及客戶、員工、供應商及合作夥伴、社區與公眾為主要持份者，並通過多元化渠道與其保持日常聯繫，持續了解各方的期望與關切，將持份者反饋納入本集團ESG管理決策及報告披露的考量之中。

Stakeholders 持份者	Key Concerns 主要關注事項	Communication Channels 溝通渠道	Engagement Outcomes and Responses 參與成果及回應
Governments and Regulatory Authorities	Regulatory Compliance, Medical Device Regulation, Data Security, AI Ethics and Accountability	Regulatory Filings and Regular Reports, Policy Seminars and Industry Consultations, Routine Inspections by Regulatory Authorities, Correspondence	Continuously update the compliance system in accordance with the requirements of the National Medical Products Administration (NMPA) and relevant Hong Kong regulations; actively participate in discussions on the regulatory framework for AI medical devices.
政府及監管機構	法規合規 醫療器械監管 數據安全 AI倫理與問責	監管申報及定期報告 政策研討及行業諮詢 監管機構例行審查 往來函件	按國家藥監局(NMPA)及香港相關法規要求持續更新合規體系；積極參與AI醫療器械監管框架討論

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Stakeholders 持份者	Key Concerns 主要關注事項	Communication Channels 溝通渠道	Engagement Outcomes and Responses 參與成果及回應
Shareholders and Investors	Financial Performance, Corporate Governance, ESG Information Disclosure, Sustainability of Business Model	Annual General Meeting, Annual Report and Results Announcements, Results Presentations and Roadshows, Reverse Roadshows and One-on-One Meetings, Company Official Website	Hold regular investor meetings; enhance the depth of information disclosure on ESG issues; improve the diversity of the Board of Directors and the risk governance framework.
股東及投資者	財務表現 公司管治 ESG信息披露 商業模式可持續性	股東週年大會 年報及業績公告 業績發佈會及路演 反向路演及一對一會議 公司官方網站	定期舉行投資者會議；加強ESG議題的信息披露深度；完善董事會多元化及風險管治架構
Medical Institutions and Customers	Product Accuracy and Safety, After-Sales Support Services, Data Privacy Protection, Patient Medical Convenience	Customer Satisfaction Surveys, Academic Cooperation and Industry Conferences, Customer Service Hotline and Email, On-Site Visits and Operation Training	Continuously iterate product algorithms to improve diagnostic accuracy; optimize after-sales training processes; strengthen encryption management and access control of patient data.
醫療機構及客戶	產品準確性與安全 售後支持服務 數據隱私保護 患者就醫便利性	客戶滿意度調查 學術合作及行業會議 客戶服務熱線及電郵 實地拜訪及操作培訓	持續迭代產品算法，提升診斷準確率；優化售後培訓流程；加強患者數據的加密管理及訪問控制

Stakeholders 持份者	Key Concerns 主要關注事項	Communication Channels 溝通渠道	Engagement Outcomes and Responses 參與成果及回應
Employees	Remuneration and Benefits, Career Development, Occupational Health and Safety, Working Environment	Regular Performance Evaluation and Feedback, All-Staff Communication Meetings with Management, Internal Training and Workshops, Employee Activities and Team Building, Email, Notices and Internal Systems	Optimize the remuneration and benefits system; establish clear promotion channels; continuously enrich technical training courses to support employees in adapting to the rapid iteration of the AI industry.
員工	薪酬福利 職業發展 職業健康與安全 工作環境	定期績效評估及反饋 管理層全員溝通會議 內部培訓及工作坊 員工活動及團建 電郵、通知及內部系統	優化薪酬福利體系；搭建清晰晉升通道；持續豐富技術培訓課程，支持員工應對AI行業快速迭代
Suppliers and Partners	Fair Procurement, Intellectual Property Protection, Supply Chain Compliance	Public Bidding and Contract Negotiations, Annual Supplier Evaluation, On-Site Audits and Investigations, Regular Meetings and Telephone Communication	Establish supplier ESG evaluation standards; work with strategic partners to promote the implementation and application of AI ophthalmic imaging technology.
供應商及合作夥伴	公平採購 知識產權保護 供應鏈合規	公開招標及合同洽談 年度供應商評估 實地審核及調研 定期會議及電話溝通	建立供應商ESG評估標準；與戰略合作夥伴共同推進AI眼科影像技術的落地應用
Communities and the Public	Accessibility of Primary Medical Care, Public Welfare for Eye Health, Popularization of AI Medical Knowledge	Public Welfare Screening Activities, Media Releases and Interviews, Official Website and Social Media, Academic and Public Education Cooperation	Carry out free fundus screening in grass-roots and rural areas; enhance public awareness and trust in AI-assisted diagnosis through media and popular science activities.
社區與公眾	基層醫療可及性 眼健康公益 AI醫療科普	公益篩查活動 媒體發佈及採訪 官方網站及社交媒體 學術及公眾教育合作	開展基層及農村地區免費眼底篩查；通過媒體及科普活動提升公眾對AI輔助診斷的認知與信任

4.3 Materiality Assessment

In accordance with the requirements of the ESG Reporting Code, with reference to the Global Reporting Initiative (GRI) Standards and industry best practices, the Group conducted a systematic materiality assessment during the Reporting Period to identify and prioritize ESG issues that have the most significant impact on the Group's business development and various stakeholders. The assessment results were reviewed by the management and submitted to the Board of Directors for review and confirmation, ensuring that the disclosed issues truly reflect the Group's core risk exposure and long-term value drivers in the AI medical imaging industry.

Materiality Assessment Process:

- **Identification** Identify potential ESG issues highly relevant to the Group's business, with reference to the ESG Reporting Code, GRI Standards, NMPA regulatory requirements for medical devices, mainstream ESG rating frameworks and disclosures by peers in the AI medical industry.
- **Assessment** Invite internal and external stakeholders to assess the importance of the identified issues. Internal stakeholders judge from the perspectives of long-term strategy, management enhancement and competitive advantages; external stakeholders consider the impact on their decision-making and their own interests. A draft materiality matrix is formed after integration.

4.3 重要性評估

本集團依照聯交所ESG報告守則要求，並參考全球報告倡議組織(GRI)準則及同業最佳實踐，於本報告期內開展系統性重要性評估，識別並排序對本集團業務發展及各持份者最具影響力的ESG議題。評估結果經管理層審核後提交董事會審議確認，確保所披露議題真實反映本集團在AI醫療影像行業的核心風險敞口與長期價值驅動因素。

重要性評估流程：

- **識別** 結合聯交所ESG報告守則、GRI準則、NMPA醫療器械監管要求、主流ESG評級框架及AI醫療同業披露，識別與本集團業務高度相關的潛在ESG議題
- **評估** 邀請內外部持份者就所識別議題的重要性進行評估。內部持份者從長遠戰略、管理提升及競爭優勢角度判斷；外部持份者從其決策影響及自身利益角度考量，整合後形成重要性矩陣初稿

- **Verification** The management reviews the prioritisation of issues, aligning with the Group's core strategy and actual operations, and submits the same to the Board for review and confirmation, ensuring the assessment results objectively reflect the material risks and opportunities faced by the Group.

- **Review** After the Reporting Period, collect feedback from internal and external stakeholders on the content of the current report as a basis for optimising the assessment mechanism for the next reporting period, and continuously improve the ESG issue identification and disclosure system.

- **驗證** 管理層對議題重要性排序進行復核，結合本集團核心戰略與實際營運，提交董事會審議確認，確保評估結果客觀反映本集團面臨的實質風險與機遇

- **審查** 報告期後，收集內外部持份者對本期報告內容的反饋意見，作為優化下一報告期評估機制的依據，持續完善ESG議題識別與披露體系

4.4 Material Issues Matrix

The Group has identified a total of 22 ESG topics, which are assessed against two dimensions — financial materiality (vertical axis) and impact materiality (horizontal axis) — and classified into three tiers:

Tier 1 (High Materiality)

Greenhouse Gas Emissions, R&D Innovation and Intellectual Property Protection, Information Security Management, Product Quality and After-Sales Service Support, Data Privacy and Patient Information Protection, Construction of Inclusive AI Healthcare Ecosystem, Business Ethics and Anti-Corruption

4.4 重要性議題矩陣

本集團共識別22項ESG議題，按財務重要性（縱軸）及影響重要性（橫軸）兩個維度進行評估，劃分為三個級別：

第一級（高度重要性）

溫室氣體排放、研發創新與知識產權保護、信息安全管理、產品質量與售後服務支持、數據隱私與患者信息保護、AI醫療普惠生態建設、商業道德與反腐敗

Tier 2 (Medium Materiality)

Employee Development and Training, Employee Care and Benefits, Supply Chain Management, Occupational Health and Safety, Compliance Management, ESG Governance Framework, Energy Management

第二級(中度重要性)

員工發展與培訓、員工關愛與福利、供應鏈管理、職業健康與安全、合規管理、ESG管治架構、能源管理

Tier 3 (General Materiality)


Waste Management, Diversity and Inclusion, Community Public Welfare, Water Resource Management, Packaging Materials, Compliance of Promotion and Publicity, Detailed Management of Intellectual Property

第三級(一般重要性)

廢棄物管理、多元包容、社區公益、水資源管理、包裝材料、宣傳推廣合規、知識產權細項管理

4.5 Material Issues List

4.5 重要性議題清單



No. 序號	ESG Issues ESG議題	Tier 級別	Category 類別	Basis for Materiality Judgment 重要性判斷依據	Corresponding Report Chapter 對應報告章節
1	Greenhouse Gas Emissions	Tier 1	Environment	Regulators and investors have increasingly stringent requirements for carbon emission disclosure, and the Stock Exchange has mandated such disclosure.	Chapter 09 Green Sustainable Development and Climate Response
1	溫室氣體排放	第一級	環境	監管機構及投資者對碳排放披露要求趨嚴，聯交所已強制要求披露	第09章綠色可持續發展與氣候應對
3	R&D Innovation and Intellectual Property Protection	Tier 1	Operations	Technological R&D capability is the core competitive barrier, and IP protection directly affects long-term commercial value.	Chapter 05 Core Technology and R&D Innovation
3	研發創新與知識產權保護	第一級	營運	技術研發能力為核心競爭壁壘，IP保護直接影響長期商業價值	第05章核心技術與研發創新
4	Information Security Management	Tier 1	Operations	AI healthcare involves a large amount of patients' health data, and regulatory and compliance requirements are continuously rising.	Chapter 06 Responsible Operations
4	信息安全管理	第一級	營運	AI醫療涉及大量患者健康數據，監管與合規要求持續提升	第06章負責任運營
5	Product Quality and After-Sales Service Support	Tier 1	Operations	Medical devices directly affect the accuracy of clinical diagnosis and patient safety, which is a core regulatory compliance requirement.	Chapter 06 Responsible Operations
5	產品質量與售後服務支持	第一級	營運	醫療器械直接影響臨床診斷準確性及患者安全，為核心監管合規要求	第06章負責任運營
6	Data Privacy and Patient Information Protection	Tier 1	Operations	Patients' personal health data is strictly regulated by the Personal Information Protection Law and other regulations, and the risk of data leakage has significant impacts.	Chapter 06 Responsible Operations
6	數據隱私與患者信息保護	第一級	營運	患者個人健康數據受《個人信息保護法》等嚴格監管，數據洩露風險影響重大	第06章負責任運營
7	Construction of Inclusive AI Healthcare Ecosystem	Tier 1	Social	It reflects the mission-driven business model and serves as the core carrier for technology enterprises to fulfill their social responsibilities.	Chapter 07 Inclusive AI Medical Ecosystem Development
7	AI醫療普惠生態建設	第一級	社會	體現使命驅動型業務模式，為科技企業履行社會責任的核心載體	第07章AI醫療普惠生態

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

No. 序號	ESG Issues ESG議題	Tier 級別	Category 類別	Basis for Materiality Judgment 重要性判斷依據	Corresponding Report Chapter 對應報告章節
8	Business Ethics and Anti-Corruption	Tier 1	Governance	The medical industry has high requirements for integrity and compliance, and business ethics is a core concern of regulators and investors.	Chapter 06 Responsible Operations
8	商業道德與反腐敗	第一級	管治	醫療行業廉潔合規要求高，商業道德是監管機構及投資者核心關切	第06章負責任運營
9	Employee Development and Training	Tier 2	Social	The AI industry has rapid technological iteration, and continuous learning ability is the talent foundation for maintaining competitive advantages.	Chapter 08 Talent Training and Development
9	員工發展與培訓	第二級	社會	AI行業技術迭代迅速，持續學習能力是保持競爭優勢的人才基礎	第08章人才培養與發展
10	Employee Care and Benefits	Tier 2	Social	Talent is the core production factor of AI R&D, and employee care directly affects the stability of the core team and innovation momentum.	Chapter 08 Talent Training and Development
10	員工關愛與福利	第二級	社會	人才為AI研發核心生產要素，員工關愛直接影響核心團隊穩定性與創新動能	第08章人才培養與發展
11	Supply Chain Management	Tier 2	Operations	The medical device supply chain has strict compliance requirements, and supplier management affects product quality and reputation risks.	Chapter 06 Responsible Operations
11	供應鏈管理	第二級	營運	醫療器械供應鏈合規要求嚴格，供應商管理影響產品質量及聲譽風險	第06章負責任運營
12	Occupational Health and Safety	Tier 2	Social	Ensuring employees' work safety is a basic legal requirement and an important embodiment of employers' responsibilities.	Chapter 08 Talent Training and Development
12	職業健康與安全	第二級	社會	保障員工工作安全為法規基本要求，亦是僱主責任的重要體現	第08章人才培養與發展
13	Compliance Management	Tier 2	Governance	Under the multi-regulatory environment for medical devices, the improvement of the compliance system directly affects business licenses and market access.	Chapter 06 Responsible Operations
13	合規管理	第二級	管治	醫療器械多重監管環境下，合規體系完善程度直接影響業務許可及市場准入	第06章負責任運營

No. 序號	ESG Issues ESG議題	Tier 級別	Category 類別	Basis for Materiality Judgment 重要性判斷依據	Corresponding Report Chapter 對應報告章節
14	ESG Governance Framework	Tier 2	Governance	Institutional investors have increasingly higher requirements for the ESG governance framework, which directly affects valuation and rating.	Chapter 06 Responsible Operations
14	ESG管治架構	第二級	管治	機構投資者對ESG管治架構的要求日益提升，直接影響估值評級	第06章負責任運營
15	Energy Management	Tier 2	Environment	AI computing power consumes a large amount of energy, and energy use efficiency is an important environmental management issue.	Chapter 09 Green Sustainable Development and Climate Response
15	能源管理	第二級	環境	AI算力運算耗能較大，能源使用效率為重要的環境管理議題	第09章綠色可持續發展與氣候應對
16–22	Waste Management, Diversity and Inclusion, Community Public Welfare, Water Resources, Packaging Materials, Promotion and Publicity, Intellectual Property (in detail)	Tier 3	–	These issues have relatively low impacts on the Group's business, are classified as general materiality issues, and will be continuously monitored.	Relevant Chapters
16–22	廢棄物管理、多元包容、社區公益、水資源、包裝材料、宣傳推廣、知識產權（細項）	第三級	–	對本集團業務影響相對較低，列為一般重要性議題，持續監察	各相關章節

Regarding Stakeholder Engagement Methods: The Group's stakeholder engagement mainly takes the form of daily business communication, including regular service docking with healthcare institution customers, compliance communication with regulatory authorities, performance and training interactions with employees, procurement and audit collaboration with suppliers, and continuous communication with investors through performance conferences and roadshows. The stakeholder opinions obtained from the above daily communications have been systematically incorporated into the materiality assessment process of this Reporting Period and responded to in the management measures of each chapter.

關於持份者參與形式：本集團的持份者參與以日常業務溝通為主要形式，包括與醫療機構客戶的定期服務對接、與監管部門的合規溝通、與員工的績效及培訓互動、與供應商的採購及審核協作，以及通過業績發佈會及路演與投資者持續交流。上述日常溝通所獲取的持份者意見，已系統性地納入本報告期的重要性評估過程，並於各章節的管理舉措中予以回應。

05 CORE TECHNOLOGY AND R&D INNOVATION

We have always regarded scientific research and innovation as an important pillar of our core competitiveness, with the "WanYu" medical large language model as the unified technological foundation, and continuously deepened the scenario-based and industrial application of AI medical technology. We firmly believe that the ultimate value of technological innovation lies in promoting health inclusion, and we are committed to using AI technology to solve social pain points such as the uneven distribution of medical resources and insufficient coverage of chronic disease screening, and effectively reducing the technical threshold of primary medical care. The "WanYu" large language model is built on the basis of more than 30 million real-world clinical diagnosis and treatment data and more than 800 evidence-based medical knowledge graphs, and has developed a deep learning algorithm system covering more than 90 clinical application scenarios. It has established cooperative relations with more than 100 top-tier research institutions, forming a complete research ecosystem covering basic research to clinical validation, forming our core technological barrier, which is difficult to replicate.

05 核心技術與研發創新

我們始終將科研創新作為核心競爭力的重要支柱，以「萬語」醫療大模型為統一技術底座，持續深化AI醫療技術的場景化與產業化應用。我們深信技術創新的終極價值在於推動健康普惠，致力於以AI技術破解醫療資源分配不均、慢病篩查覆蓋不足等社會痛點，切實降低基層醫療的技術門檻。「萬語」大模型以逾3,000萬份真實世界臨床診療數據及800餘項循證醫學知識圖譜為基礎構建，已開發覆蓋90餘個臨床應用場景的深度學習算法體系，並與逾100家頂尖科研機構建立合作關係，形成覆蓋基礎研究至臨床驗證的完整科研生態，構成我們難以複製的核心技術壁壘。

Leveraging such technological strengths, we focus on the health needs of vulnerable groups of high social concern and relatively inadequate medical resources, and continuously promote the implementation of high-value R&D projects. Guided by our core philosophy of "One Fundus Image, Early Insight into Chronic Diseases", our solutions support the identification of 55 types of health risks. In 2025, our R&D expenditure amounted to RMB58.1 million, representing a year-on-year decrease of 42.9% from RMB101.7 million in 2024.This is primarily attributable to the empowerment of our "WanYu" large language model. Our R&D strategy has shifted from "scale input-driven" to "efficiency optimization-driven", enabling an AI-Native transformation of the R&D team. Through the large-scale application of AI-assisted R&D tools and the optimization of the R&D team structure, we have significantly enhanced R&D efficiency and resource utilization effectiveness, achieving a more efficient allocation of R&D resources.

基於這一技術優勢，我們聚焦社會關注度高、醫療資源相對薄弱的弱勢群體健康需求，持續推進高價值研發專案落地。我們以「眼底一張照，慢病早知道」為核心理念，支持55種健康風險識別。2025年，我們的研發開支為人民幣5,810萬元，較2024年度人民幣10,170萬元同比下降42.9%，主要因為基於「萬語」大模型技術賦能，我們的研發策略從「規模投入驅動」轉向「效率優化驅動」，實現研發團隊AI-Native變革，通過AI輔助研發工具大規模應用與研發團隊結構優化，顯著提升研發效率與資源使用效益，實現研發資源更高效配置。

For the year, the total token consumption of our "WanYu" large language model by customers reached approximately 799.2 billion, of which 35.6 billion tokens were consumed by Pediatric Myopia Control AI (PBM-AI) and 32.0 billion tokens by Retinal Detection AI (Retina-AI). Over 77% of computing power resources were deployed to our core commercializable healthcare businesses, fully demonstrating the status of the "WanYu" large language model as an irreplaceable technological foundation and core driving engine for the Group's AI healthcare business.

我們的「萬語」大模型年度客戶調用Token消耗量約7,992億（其中，近視防控AI（PBM-AI）消耗356億Token,視網膜檢測AI（Retina-AI）消耗320億Token），逾77%算力資源用於可商業化核心醫療業務，充分彰顯「萬語」大模型作為集團AI醫療業務不可替代的技術根基與核心驅動引擎地位。

5.1 Technology Platform and Competitive Advantages

Our independently developed "WanYu" exclusive medical large language model is a vertical large language model deeply optimized for the healthcare field. Relying on the training of vast medical knowledge bases and real clinical data, it integrates core technologies such as RAG retrieval enhancement, multi-modal understanding, medical knowledge graphs and AI Agent, with precise reasoning, standardized generation and intelligent recommendation capabilities, and strictly abides by compliance guidelines, and can be deeply adapted to the full-scenario medical needs such as detection, assessment, intervention and management.

Leveraging the "WanYu" technological foundation, we have built it into an intelligent engine that bridges data and clinical decisions, providing comprehensive support for our three core product lines; and leveraging this foundation, we have established six core technical barriers, realizing the end-to-end transformation of value from algorithm R&D to clinical application, driving continuous expansion of our business reach and enhancement of service efficiency:

5.1.1 One-stop Integrated Solution to Achieve Full-scenario Clinical Application

Create an integrated solution integrating hardware, software, algorithms and services, provide full-process support from deployment, docking to operation, significantly reduce the threshold for intelligent screening in primary medical institutions, and ensure that AI technology is implementable, promotable and sustainable.

5.1 技術平台與競爭優勢

我們自主研發的「萬語」醫療專屬大語言模型，是面向醫療健康領域深度優化的垂直大模型。依託海量醫療知識庫與真實臨床數據訓練，融合RAG檢索增強、多模態理解、醫學知識圖譜及AI Agent等核心技術，具備精准推理、規範生成與智能推薦能力，嚴格恪守合規準則，可深度適配檢測、評估、干預與管理等全場景醫療需求。

基於「萬語」技術底座，我們將其打造成了連接數據與臨床決策的智能大腦，全面賦能三大核心產品線；並以此構築六大核心技術壁壘，實現從演算法研發到臨床落地的全鏈條價值轉化，業務覆蓋與服務效能持續提升：

5.1.1 一站式整合方案，實現全場景臨床落地

打造融合硬體、軟體、演算法與服務的一體化解決方案，提供從部署、對接到運營的全流程支持，顯著降低基層醫療機構智慧篩查門檻，確保AI技術可落地、可推廣、可持續。

5.1.2 Full-scenario Algorithm System to Drive Clinical Outcome Transformation

Build an independently developed algorithm system covering more than 90 clinical scenarios, and enhance model robustness relying on core technologies such as open-domain generalization and self-supervised pre-training. We focus on clinical value transformation, and our business has reached 478 hospitals and 1,633 primary healthcare institutions (including community hospitals), promoting the in-depth empowerment of scientific research achievements in the whole process of clinical diagnosis and treatment.

5.1.2 全場景算法體系，驅動臨床成果轉化

搭建覆蓋90餘個臨床場景的自主研發演算法體系，依託開放域泛化、自監督預訓練等核心技術增強模型魯棒性。我們聚焦臨床價值轉化，業務已觸達478家等級醫院及1633家基層醫療機構（含社區醫院），推動科研成果深度賦能臨床診療全流程。

5.1.3 High-quality Data Assets to Support High-precision Model Training

Establish a retinal image database cross-annotated by hundreds of medical experts, combined with a private data lake and AI training infrastructure, supporting parallel computing of more than 300 deep learning models, providing solid data support for high-robustness and high-generalization clinical AI models.

5.1.3 高質量數據資產，支撐高精度模型訓練

建立由數百名醫學專家交叉標注的視網膜圖像資料庫，搭配私有數據湖與AI訓練基礎設施，支持300 +深度學習模型並行計算，為高魯棒性、高泛化性的臨床AI模型提供堅實數據支撐。

5.1.4 Multidisciplinary Interdisciplinary Team to Break the Barrier Between Technology and Clinical Practice

We have a comprehensive innovation team covering optics, mechanics, electronics and system science, equipped with senior clinical experts and top algorithm engineers, ensuring that technological R&D is closely linked to clinical needs and realizing a closed loop of "Engineering Implementation — Clinical Verification — Regulatory Landing".

5.1.4 多學科交叉團隊，打通技術與臨床壁壘

擁有覆蓋光學、機械、電子、系統科學的綜合性創新團隊，並配備資深臨床專家與頂尖演算法工程師，確保技術研發緊扣臨床需求，實現「工程實現 — 臨床驗證 — 監管落地」閉環。

5.1.5 Top-level Scientific Research Ecosystem to Accelerate Large-scale Application of Achievements

In-depth cooperation with many domestic Grade 3A hospitals and academic leaders has formed a complete scientific research ecosystem from basic research to real-world application. Academic papers and core algorithms are no longer confined to laboratories, but transformed into clinically scalable tools, which effectively change doctors' diagnosis and treatment behaviors and optimize diagnosis and treatment paths.

5.1.5 頂級科研生態，加速成果規模化應用

與國內多家三甲醫院及學科帶頭人深度合作，形成從基礎研究到真實世界應用的完整科研生態。學術論文與核心演算法不再停留於實驗室，而是轉化為可規模化推廣的臨床工具，切實改變醫生診療行為、優化診療路徑。

5.1.6 Independent Production and Strict Compliance to Ensure Stable Business Development

We have independent factories and large-scale production capacity, which can quickly respond to the needs of the national and global markets; we strictly align with medical device regulatory requirements, ensuring that the entire process of products from R&D, production to clinical application is compliant, providing a reliable guarantee for the large-scale promotion of technology.

5.1.6 自主生產與嚴格合規，保障業務穩健發展

具備獨立工廠與規模化生產能力，可快速回應全國以及全球市場需求；嚴格對標醫療器械監管要求，確保產品從研發、生產到臨床應用全流程合規，為技術大規模推廣提供可靠保障。

Based on the above technical barriers, the industry-leading "WanYu" large language model is deeply integrated into the three core product lines, realizing the intelligent upgrading of the whole diagnosis and treatment chain, further amplifying the technical value and improving the patient experience:

基於上述技術壁壘，行業領先的「萬語」大模型深度融入三大核心產品線，實現診療全鏈條智能化升級，進一步放大技術價值、提升患者體驗：

- **Auxiliary Diagnosis and Report Generation:** Automatically generate structured and standardized diagnosis suggestions based on images and clinical information, reduce the repetitive work of doctors, and improve the consistency and efficiency of image reading;

- **輔助診斷與報告生成**：基於影像與臨床信息自動生成結構化、規範化診斷建議，減少醫生重複勞動，提升閱片一致性與效率；

- **Patient Report Interpretation:** Convert professional medical conclusions into easy-to-understand language, clearly inform the risk level, follow-up suggestions and intervention points, and significantly improve patient understanding and treatment compliance;

- **患者報告解讀**：將專業醫學結論轉化為通俗易懂的語言，清晰告知風險等級、隨訪建議與干預要點，顯著提升患者理解度與治療依從性；

- **Primary Medical Care and Health Management:** Support functions such as intelligent consultation, risk stratification and follow-up reminders, help community doctors efficiently carry out chronic disease management and health screening, and further amplify the inclusive value of AI medical care.

- **基層醫療與健康管理**：支持智能問診、風險分層、隨訪提醒等功能，幫助社區醫生高效開展慢病管理與健康篩查，進一步放大AI醫療的普惠價值。

5.2 Core Technology: AI Deep Learning Algorithm System

Our algorithm system is driven by the in-depth understanding of disease pathological mechanisms, committed to building a high-precision and high-generalization AI deep learning technology base, fully empowering the full-cycle management of chronic diseases and the integrated intelligent diagnosis and treatment solution. The main technical features are as follows:

- We have built a composite algorithm matrix covering intelligent disease classification, precise lesion detection, quantitative segmentation and risk stratification assessment, with more than 90 clinical application scenarios implemented; we focus on overcoming key technologies such as ultra-wide-angle fundus image intelligent analysis, accurate cataract grading, and quantitative assessment of dry eye syndrome, and rely on large language models to realize automatic interpretation of medical reports and multi-round intelligent interactive consultation, greatly improving the efficiency of clinical decision-making.

5.2 核心技術：AI深度學習算法體系

我們的算法體系以疾病病理機制深度認知為核心驅動，致力於構建高精度、高泛化性的AI深度學習技術底座，全面賦能慢病全週期管理與智能診療一體化解決方案。主要技術特色如下：

- 我們已搭建覆蓋疾病智能分型、病灶精准檢測、量化分割與風險分層評估的複合型演算法矩陣，落地臨床應用場景超90項；重點攻克超廣角眼底影像智能解析、白內障精准分級、幹眼症量化評估等關鍵技術，並基於大語言模型實現醫學報告自動化解讀與多輪智能交互問診，大幅提升臨床決策效率。

- Strengthen the model's adaptability to cross-dataset and cross-device distribution based on open-domain generalization learning, realize the efficient use of high-value medical data through semi-supervised learning, and build a self-supervised pre-training basic framework; innovatively develop multi-modal alignment and fusion technology, realize the collaborative modeling and in-depth analysis of multi-dimensional data such as images, texts and clinical data, and comprehensively improve the robustness and diagnostic consistency of algorithms in real and complex medical scenarios.

- 通過開放域泛化技術增強模型、跨分佈適配能力，通過半監督學習實現高價值醫療數據高效利用，搭建自監督預訓練基礎框架；創新研發多模態對齊融合技術，實現影像、文本、臨床多維度數據的協同建模與深度分析，全面提升演算法在真實複雜醫療場景中的魯棒性與診斷一致性。

- The coordinated intelligence of software and hardware is the core technical advantage. The self-developed intelligent fundus imaging terminal is equipped with a lightweight neural network architecture with independent intellectual property rights, natively deploying the AI diagnostic reasoning module on the built-in high-performance computing chip, realizing millisecond-level on-edge real-time reasoning, and building an end-to-end Edge AI closed-loop solution; on the premise of strictly ensuring the privacy and security of medical data, it significantly improves the timeliness of diagnosis and clinical accessibility.

- 軟硬一體協同智能為核心技術優勢。自研智能眼底影像終端搭載自主知識產權的輕量化神經網路架構，將AI診斷推理模組原生部署於內置高性能計算晶片，實現毫秒級端側即時推理，構建端到端邊緣智能(Edge AI)閉環方案；在嚴格保障醫療數據隱私安全的前提下，顯著提升診斷時效性與臨床可及性。

- With a forward-looking strategy toward next-generation breakthrough technologies, focus on long-term health risk prediction models, temporal cross-modal medical image registration and dynamic analysis systems, and focus on cutting-edge directions such as early warning of diabetic retinopathy progression and early screening of cognitive dysfunction, providing core technical support for building a full-life-cycle health management ecology.

In 2025, the Company carried out a full-stack iterative upgrade covering hardware carrier, core algorithms, software systems, and overall solutions: while optimizing equipment costs, it comprehensively improved hardware stability, automation integration and intelligent interaction level; and through multi-dimensional technological innovation, expanded the multi-modal data collection dimension and in-depth health risk analysis capabilities of equipment, further consolidating the core competitiveness of our products.

5.3 Academic Achievements

We actively promote industry-university-research collaborative innovation, serving public health through academic research. To date, we have published more than 60 high-quality academic papers in prestigious peer-reviewed journals such as The Lancet series, Nature series, British Journal of Ophthalmology, and international top-tier academic conferences such as MICCAI, undertaken more than ten national, provincial and municipal-level scientific research projects, and established cooperative relations with more than 100 top-tier scientific research institutions, forming a complete scientific research ecosystem covering basic research to clinical validation.

- 前瞻佈局下一代突破性技術體系，聚焦長期健康風險預測模型、時序跨模態醫學影像配准與動態分析系統，重點深耕糖尿病視網膜病變進展預警、認知功能障礙早期篩查等前沿方向，為構建全生命週期健康管理生態提供核心技術支撐。

2025年，公司從硬件載體、核心算法、軟件系統至整體解決方案進行全棧式迭代升級：在實現設備成本優化的同時，全面提升硬件穩定性、自動化集成度與智能交互水平；並通過多維度技術創新，拓展設備多模態數據採集維度與深度健康風險解析能力，進一步夯實產品核心競爭力。

5.3 學術成果

我們積極推進產學研協同創新，以學術研究服務公共健康。迄今已在《柳葉刀》系列、《自然》系列、《英國眼科學雜志》等權威同行評審期刊及MICCAI等國際頂級學術會議累計發表逾60篇高水平學術論文，承擔十餘項國家級、省市級科研課題，與逾100家頂尖科研機構建立合作關係，形成覆蓋基礎研究至臨床驗證的完整科研生態。

In 2025, our joint research team published 15 new high-quality academic papers, many of which were accepted by international top academic conferences such as MICCAI 2025, CVPR 2025 (Oral), ICCV 2025, AAAI 2025 and ACL 2025. The key achievements are as follows:

Nature Medicine

Research Direction: Research on multimodal visual foundation models in clinical dermatology

Research Value: Build a large-scale multi-modal skin image foundation model, significantly improve the accuracy and generalization ability of diagnosis of skin tumors and common skin diseases, provide an internationally leading AI auxiliary tool for primary medical care and telemedicine, and promote early screening and treatment of malignant skin diseases.

Nature Communications Medicine

Research Direction: Research on predicting the progression of diabetic retinopathy based on GAN models

Research Value: Realize non-invasive quantitative prediction of the future development risk of diabetic retinopathy, make up for the lack of long-term prediction methods in clinical practice, and help protect the vision of diabetic patients and the whole-process management of chronic diseases.

2025年，我們聯合研究團隊共新增發表15篇高水平學術論文，多篇獲MICCAI 2025、CVPR 2025(Oral)、ICCV 2025、AAAI 2025及ACL 2025等國際頂級學術會議接收。重點成果如下：

Nature Medicine

研究方向：多模態視覺基礎模型在臨床皮膚病方向的研究

研究價值：構建大規模多模態皮膚影像基礎模型，顯著提升皮膚腫瘤與常見皮膚病診斷準確性與泛化能力，為基層醫療、遠程診斷提供國際領先的AI輔助工具，推動皮膚惡性疾病早篩早治。

Nature Communications Medicine

研究方向：基於GAN模型預測糖尿病視網膜病變進展的研究

研究價值：實現糖尿病視網膜病變未來發展風險的無創量化預測，彌補臨床缺少長期預測手段的短板，助力糖尿病患者視力保護與慢病全程管理。

Heart

Research Direction: Research on the application of fundus imaging in the detection of cardiovascular diseases

Research Value: Verify the correlation between fundus imaging and cardiovascular diseases, establish a non-invasive, fast and low-cost screening model, reduce the threshold for large-scale cardiovascular risk screening in primary medical care, and help primary prevention of chronic diseases.

International Journal of General Medicine

Research Direction: Research on the application of fundus imaging in the detection of cognitive diseases

Research Value: Realize early identification of cognitive impairment based on retinal micro-characteristics, provide a large-scale and low-cost screening method for cognitive impairment in an aging society, and support the construction of the public health system.

IEEE Journal of Biomedical and Health Informatics

Research Direction: Research on intelligent analysis of biomedical information

Research Value: Establish a multi-modal medical data fusion analysis framework, improve the efficiency of medical data processing and algorithm robustness, and provide core technical support for product compliant landing, clinical quality control and standardization.

Heart

研究方向：眼底影像應用於心血管疾病檢測研究

研究價值：驗證眼底影像與心血管疾病的關聯性，建立無創、快速、低成本的篩查模型，降低基層大規模心血管風險篩查門檻，助力慢病一級預防。

International Journal of General Medicine

研究方向：眼底影像應用於認知疾病檢測研究

研究價值：基於視網膜微觀特徵實現認知功能損傷早期識別，為老齡化社會提供大規模、低成本認知障礙篩查手段，支撐公共衛生體系建設。

IEEE Journal of Biomedical and Health Informatics

研究方向：生物醫學資訊智能分析研究

研究價值：建立多模態醫療數據融合分析框架，提升醫學數據處理效率與演算法穩健性，為產品合規落地、臨床質控與標準化提供核心技術支撐。

MICCAI 2025/CVPR 2025 (Oral)/AAAI 2025

Research Direction: Cutting-edge applications of AI medical image analysis and intelligent diagnosis

Research Value: A number of original algorithm achievements have been selected into top international conferences on medical imaging and artificial intelligence, covering core scenarios such as lesion detection, image segmentation and risk prediction, reaching the international advanced (SOTA) level, fully reflecting our original R&D strength and global competitiveness in the field of medical AI.

5.4 Progress of Key R&D Projects

In 2025, the key R&D projects we focused on are all directed at the health issues of vulnerable groups with high social attention and relatively scarce medical resources. With the core concept of "One Fundus Image, Early Insight into Chronic Diseases", we now support the identification of 55 types of health risks:

1. **Atrial Fibrillation Detection:** Reached in-depth scientific research collaboration with Beijing Anzhen Hospital affiliated to Capital Medical University, jointly advancing the national key R&D plan, used fundus images for non-invasive screening of atrial fibrillation, helped early screening and treatment of cardiovascular diseases, and reduced the social burden of chronic diseases;

MICCAI 2025 / CVPR 2025 (Oral)/ AAAI 2025

研究方向：AI醫療影像分析及智能診斷前沿應用

研究價值：多項原創演算法成果入選醫學影像與人工智能頂級會議，覆蓋病灶檢測、圖像分割、風險預測等核心場景，達到國際先進(SOTA)水準，充分體現我們在醫療AI領域的原創研發實力與全球競爭力。

5.4 重點研發項目進展

2025年，我們重點佈局的研發項目，均指向社會關注度高、醫療資源相對匱乏的弱勢群體健康議題。我們以「眼底一張照，慢病早知道」為核心理念，現已支持55種健康風險識別：

1. **房顫檢測**：與首都醫科大學附屬北京安貞醫院達成深度科研合作，共同推進國家重點研發計劃，利用視網膜影像無創篩查房顫，助力心血管疾病早篩早治，減輕社會慢病負擔；

2. **Eclampsia Prediction:** Completed the construction of a dedicated dataset, significantly improving model prediction accuracy, and reached preliminary commercial collaboration with multiple medical institutions, which will soon fill the market gap in AI-powered early screening for pre=eclampsia during pregnancy and contribute scientific and technological support to safeguarding maternal health and;

3. **Deepening of Myopia Prevention and Control AI:** Actively respond to the major public health challenge of the earlier-onset adolescent myopia, continue to promote R&D and landing around functions such as axial growth trend prediction and personalized prevention and control approach recommendations, introduce voice interaction and intelligent reminder capabilities, help adolescents and parents establish scientific eye use management habits, and protect the visual health of the next generation.

2. **子癇預測**：專屬數據集構建完成，模型預測精確度顯著提升，並與多家醫療機構達成初步商業化合作意向，即將填補孕期子癇前期早期AI篩查的市場空白，為保障孕產婦生命安全貢獻科技力量；

3. **近視防控AI深化**：積極回應青少年近視低齡化這一重大公共衛生挑戰，圍繞眼軸發育趨勢預測、個性化防控方案建議等功能持續推進研發落地，引入語音交互與智能提醒功能，幫助青少年及家長建立科學用眼管理習慣，守護下一代視力健康。

5.5 Intellectual Property Management

We attach great importance to intellectual property management. In accordance with the Patent Law of the People's Republic of China, the Trademark Law of the People's Republic of China and the Copyright Law of the People's Republic of China, we have specially set up an Intellectual Property Department and formulated the Measures for the Administration of Intellectual Property Rights (Trial), clarifying the standards and processes for the creation, application, management and protection of intellectual property rights, encouraging independent innovation, and rewarding employees who have made substantial contributions to service inventions after filing patent applications.

Management System Development

We has established a systematic intellectual property management system. Key practices include:

(i) **Application and registration**: All research and development outputs are promptly protected through patent applications, software copyright registrations and trademark registrations in accordance with applicable laws;

(ii) **Confidentiality and compliance management:** Confidentiality agreements are entered into with employees, business partners and suppliers, setting out clearly the ownership of intellectual property and confidentiality obligations;

5.5 知識產權管理

我們高度重視知識產權管理，依據《中華人民共和國專利法》、《中華人民共和國商標法》及《中華人民共和國著作權法》，專門設置知識產權部，制定《知識產權管理辦法》(試行)，明確知識產權創造、運用、管理和保護的標準及流程，鼓勵自主創新，對職務發明作出實質性貢獻的員工在提出專利申請後予以獎勵。

管理體系建設

我們已建立系統化的知識產權管理體系，主要慣例包括：

(一) **知識產權申請與登記**：所有研發成果均依法及時申請專利、軟體著作權及商標註冊保護；

(二) **保密與合規管理**：與員工、合作夥伴及供應商簽訂保密協議，明確知識產權歸屬及保密義務；

(iii) **Infringement monitoring:** Regular market surveillance is conducted in respect of the Company's core technology patents, and legal measures are taken promptly upon identification of potential infringement.

（三）**侵權監察**：定期對公司核心技術專利進行市場監察，發現潛在侵權行為及時採取法律措施；

(iv) **Training and awareness:** Regular intellectual property protection training sessions are provided to research and development and business personnel to strengthen intellectual property awareness across the organisation.

（四）**培訓教育**：定期對研發及商務人員開展知識產權保護培訓，強化全員知識產權保護意識。

In 2025, the Intellectual Property Department carried out the following key work:

2025年，知識產權部主要開展了以下工作：

- Took responsibility for regularly collating the intellectual property needs of all departments, formulated our intellectual property strategy and management plan and drove their implementation;
- 負責定期收集各部門知識產權需求，制定我們知識產權戰略及管理計劃並推動實施；
- Carried out intellectual property training for relevant personnel including R&D personnel and marketing personnel, improved employees' awareness of intellectual property rights, and incorporated the intellectual property module into the new employee induction assessment system;
- 對包括研發人員、營銷人員在內的相關人員開展知識產權培訓，提高員工知識產權意識，並將知識產權模塊納入新員工入職考核體系；
- Carried out intellectual property mining and layout, and improved our competitiveness through the deployment of high-quality intellectual property rights;
- 開展知識產權挖掘和佈局，通過佈局高質量知識產權提升我們競爭力；
- In collaboration with the R&D Team, carried out patent analysis, conducted third-party infringement risk assessments before project initiation, proactively carried out design-around measures, and reduced infringement risks;
- 聯合研發團隊開展專利分析工作，從項目立項前開始進行第三方侵權風險排查，主動進行規避設計，降低侵權風險；

- We have signed confidentiality, non-competition and intellectual property ownership agreements with all employees to ensure the safety of intellectual property rights at the institutional level;

In 2025, our wholly-owned subsidiary Shanghai Airdoc Medical Technology Co., Ltd. obtained certification of the national standard "Requirements for Enterprise Intellectual Property Compliance Management System" (GB/T 29490–2023). This standard officially came into effect on 1 January 2024 and strengthened compliance on the basis of the original management framework and works in synergy with international standards such as ISO 56005. The completion of the certification indicates that we have achieved standardized and normalized operations across the whole process of intellectual property creation, application, protection and management, which helps to improve our compliance credibility in international cooperation and commercial promotion.

- 我們已與所有員工簽訂保密、不競爭及知識產權所有權協議，從制度層面確保知識產權安全。

2025年，全資子公司上海鷹瞳醫療科技有限公司完成《企業知識產權合規管理體系要求》國家標準(GB/T 29490–2023)貫標認證。該標準於2024年1月1日正式實施，在原有管理框架基礎上強化了合規屬性，與ISO 56005等國際標準形成協同。貫標認證的完成，標誌著我們在知識產權創造、運用、保護及管理全流程中已實現標準化、規範化運作，有助於提升我們在國際合作及商業化推廣中的合規可信度。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Intellectual Property Accumulation

In 2025, we added 25 patents, including 14 invention patents, 6 utility model patents and 5 design patents, with invention patents accounting for more than 50%. These patents cover key technological fields such as fundus retinal image recognition and detection, health risk assessment, and adolescent myopia prevention and control. We also added 5 software copyrights and 3 Patent Cooperation Treaty (PCT) applications.

As of 31 December 2025, we owned a total of 295 patents in China (including 142 invention patents, 70 utility model patents and 83 design patents), 104 software copyrights and 25 PCT applications, further expanding the scope of our global patent protection.


知識產權積累

2025年，我們新增25項專利，其中發明專利14項、實用新型專利6項及外觀設計專利5項，發明專利佔比超50%，涵蓋眼底視網膜影像識別檢測、健康風險評估及青少年近視防控等關鍵技術領域；新增軟件著作權5項，PCT（專利合作條約）申請3項。

截至2025年12月31日，我們在中國累計擁有295項專利（其中發明專利142項、實用新型專利70項及外觀設計專利83項），軟件著作權共計104項，及25項PCT（專利合作條約）申請，進一步擴大全球專利保護範圍。

Year	年份	Accumulated patent applications 累計專利申請量	Patent applications in that year 當年專利申請量	Total patent authorizations 總專利授權量	Number of patent authorizations in that year 當年專利授權量
2013–2017	2013–2017年	6	6	1	1
2018	2018年	27	21	1	0
2019	2019年	74	47	6	5
2020	2020年	127	53	14	8
2021	2021年	202	75	40	26
2022	2022年	339	137	143	103
2023	2023年	418	79	230	87
2024	2024年	452	34	270	40
2025	2025年	468	16	295	25

Trend of patent applications and authorizations of Airdoc Technology over the years (2013-2015)
鷹瞳科技歷年專利申請與授權趨勢(2013-2015)



Establishment of National Intellectual Property Demonstration Enterprise

In terms of comprehensive intellectual property capability building, in 2025, we were recognized by the China National Intellectual Property Administration (CNIPA) as a candidate National Intellectual Property Demonstration Enterprise (2025–2027) (Document No.: Guozhifa Yunhanzi [2026] No. 25). We have completed the full progression from National Intellectual Property Pilot Enterprise, to an Advantageous Enterprise, and now to Demonstration Enterprise, enabling us to maintain a leading position among peer AI medical enterprises.

國家知識產權示範企業創建

在知識產權綜合能力建設方面，2025年我們榮獲國家知識產權局認定為2025–2027年國家知識產權示範企業創建對象（國知發運函字〔2026〕25號），完成了從國家知識產權試點企業、優勢企業到示範企業的完整跨越，在同類AI醫療企業中保持領先地位。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

The National Intellectual Property Demonstration Enterprise is the highest-level certification comprehensively evaluated by CNIPA in terms of the intellectual property creation quality, application efficiency, protection effectiveness, and management capabilities of enterprises. A total of 1,495 enterprises nationwide were selected. Our inclusion fully demonstrates the substantial achievements we have made in the establishment of a comprehensive intellectual property management system, and also reflects the high recognition of regulatory authorities for the quality of our intellectual property work.

國家知識產權示範企業為國家知識產權局就企業知識產權創造質量、運用效益、保護效果及管理能力等維度綜合評定的最高級別認定，全國入選企業共1,495家。我們能夠躋身其列，充分彰顯了我們在知識產權綜合管理體系建設方面所取得的實質性成就，亦體現了監管機構對我們知識產權工作質量的高度認可。

Intellectual Property Qualifications

In 2025, our wholly-owned subsidiary, Shanghai Airdoc Medical Technology Co., Ltd., achieved dual breakthroughs in special intellectual property qualifications: first, it was successfully recognized as “Shanghai Pilot Unit for Patent Work of Enterprises and Institutions”, indicating formal recognition by the Shanghai intellectual property authorities for our standardized approach to patent management; second, it completed acceptance for inclusion as “Shanghai Science and Technology Little Giant (Cultivation)” in August 2025, further demonstrating our sustained growth strength as a scientific and technological innovation enterprise.

知識產權資質

2025年，我們的全資子公司上海鷹瞳醫療科技有限公司在知識產權專項資質方面取得雙重突破：一是順利通過「上海市企事業專利工作試點單位」認定，這表明我們在專利工作規範化推進方面獲得上海市知識產權主管部門的正式認可；二是於2025年8月完成「上海市科技小巨人(培育)」驗收，進一步印證我們作為科技型創新主體的持續成長實力。

Trademark and Brand Protection

In 2025, our "Yingtong (Airdoc)" (鷹瞳) trademark was included in the Beijing Key Trademark Protection List. The Beijing Key Trademark Protection List is annually assessed by Beijing's intellectual property authorities, aiming to provide an enhanced protection mechanism for trademarks with strong brand influence and market recognition, helping to prevent the risks of trademark infringement and counterfeiting. Being included in this list is not only an external recognition of the market value of the "Yingtong (Airdoc)" (鷹瞳) brand, but also will further strengthen our resource access and proactive protection capabilities in trademark rights protection.

商標品牌保護

2025年，我們的「鷹瞳」商標入選北京市重點商標保護名錄。北京市重點商標保護名錄由北京市知識產權主管部門按年度評定，旨在為具有較強品牌影響力及市場認知度的商標提供重點保護機制，有助於防範商標侵權與仿冒風險。入選這一名錄，既是對「鷹瞳」品牌市場價值的外部認可，亦將進一步強化我們在商標維權方面的資源獲取與主動保護能力。

Patent-Intensive Products

In 2025, we successfully completed the filing of 4 national patent-intensive products, covering our two core product lines: fundus screening and PBM. We achieved full coverage of patent-intensive products in our core business areas, built solid technical support for the development of main businesses with high-value independent patents, and fully demonstrated our deep integration capability of technology R&D and product transformation.

The filing of patent-intensive products is a key intellectual property initiative promoted by CNIPA with stringent criteria. Products must be supported by the enterprise's valid independent patents as core technologies, and such patents must be directly linked to the product's core functions and technical innovations. It is an authoritative recognition of an enterprise's technological innovation capacity, patent achievement transformation capability, and commercialization capability.

專利密集型產品

2025年，我們成功完成4件國家專利密集型產品備案，備案產品覆蓋眼底篩查與PBM（光生物調節）兩大核心產品線，實現核心業務領域專利密集型產品全覆蓋，以高價值自主專利為主要業務發展築牢技術支撐，充分彰顯我們技術研發與產品轉化的深度融合能力。

專利密集型產品備案系國家知識產權局推行的重點知識產權工作機制，備案認定標準嚴苛，要求產品必須以企業自主有效專利為核心技術支撐，且相關專利需與產品核心功能、技術創新點直接關聯，是對企業技術創新能力、專利成果轉化能力及商業落地能力的權威認可。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

The 4 core commercialized products filed this year are all equipped with exclusive independent patents, with patent layout precisely matching product functions, achieving deep integration of technology and patents:

- **Automatic Fundus Camera:** Targeting the core needs of fundus screening hardware, it is supported by multi-dimensional independent patents covering fundus imaging, image restoration, disease risk assessment, and intelligent equipment control, forming a full technical chain patent support for basic fundus screening hardware.
- **Fundus Camera:** Focused on the optimization and functional upgrading of fundus camera equipment, it is equipped with exclusive patents for fundus image synthesis, focal length adjustment, refractive adjustment, and usage status detection, further improving the patent layout of fundus screening hardware.
- **Artificial Intelligence Fundus Image Analysis Software:** Centered on the core technology of AI recognition of fundus images, it is supported by multiple patents for machine learning, fundus image detection, model training, and fundus identity recognition, consolidating the technical empowerment of AI algorithms for fundus screening.

本次備案的4件核心商業化產品均配套專屬自主專利，專利佈局與產品功能精准匹配，實現技術與專利的深度綁定：

- **全自動眼底照相機**：錨定眼底篩查硬件核心需求，關聯眼底拍攝、圖像修復、疾病風險評估、設備智能化控制等多維度自主專利，形成對眼底篩查基礎硬件的全技術鏈專利支撐；
- **眼底照相機**：聚焦眼底相機設備優化與功能升級，配套眼底圖像合成、焦距調整、屈光調節、使用狀態檢測等專屬專利，進一步完善眼底篩查硬件的專利佈局；
- **人工智能眼底圖像分析軟件**：聚焦眼底影像AI識別核心技術，配套機器學習、眼底圖像檢測、模型訓練、眼底身份識別等多項專利，夯實AI算法對眼底篩查的技術賦能；

- **Airdoc PBM-LED® Vision Rehabilitation Device:** As the core PBM-LED® myopia prevention and control product, it is supported by exclusive patents for myopia lighting systems, optical path design, R&D and control, and adjustable fixing devices, forming comprehensive patent coverage for myopia prevention and control hardware.

- **鷹瞳PBM-LED®視力康復儀：**作為PBM-LED®近視防控核心產品，關聯近視光照系統、光路設計、研發與控制、可調式固定裝置等專屬專利，形成對近視防控硬件產品的全方位專利覆蓋。

The patents associated with the above filed products are highly consistent with the products' core functions and technical cores, enabling full-life-cycle empowerment by patented technologies. The successful filing of these 4 core products not only confirms that our core technological achievements have formed an efficient transformation path from R&D innovation to product launch, but also reflects that our patent assets have clear and mature commercialization capabilities, with patent layout highly coordinated with core business development.

以上備案產品的關聯專利均與產品核心功能、技術內核高度契合，實現專利技術對產品全生命週期的全方位賦能。此次4件核心產品成功通過國家專利密集型產品備案，不僅印證了我們核心技術成果已形成從研發創新到產品落地的高效轉化路徑，更體現我們專利資產具備清晰、成熟的商業化落地能力，專利佈局與核心業務發展高度協同。

In the future, we will continue to take the R&D and filing of patent-intensive products as a starting point, deepen the integration of intellectual property with product R&D and commercial application, build a solid technological moat with high-value intellectual property rights, provide strong intellectual property protection for the continuous innovation of our products and market expansion, and at the same time fulfill corporate innovation responsibility through technological innovation and patent transformation to support the high-quality development of intellectual property in the AI medical industry.

未來，我們將持續以專利密集型產品研發與備案為抓手，深化知識產權與產品研發、商業化應用的深度融合，以高價值知識產權築牢技術護城河，為我們的產品的持續創新與市場拓展提供堅實的知識產權保障，同時以技術創新與專利轉化踐行企業創新責任，助力AI醫療行業知識產權高質量發展。

06 RESPONSIBLE OPERATIONS

6.1 Information Security and Privacy Protection

As an AI medical enterprise processing massive patient retinal image data, information security and privacy protection are among our most important responsibilities. We attach great importance to information security management, have formulated and implemented nearly 40 policies and systems including the General Outline of Information Security Management System, Measures for the Management of Security Risk Assessment, Data Backup Management System, Measures for the Management of Data Confidentiality, and Measures for the Management of the Use of Communication Tools, and strictly implement the above policies and systems.

Principles of Data Collection and Use

When providing artificial intelligence solutions, we obtain explicit consent and authorization from users before directly collecting or using users' personal data (primarily retinal images) through business partners. We have signed agreements with business partners to clarify their obligation to obtain authorization from individual users. Regarding the collected user information, we commit:

- Having obtained explicit authorization and consent before collecting users' personal data;
- Using users' personal data in a manner consistent with the granted authorization and consent;

06 負責任運營

6.1 信息安全與隱私保護

作為一家處理海量患者視網膜影像數據的AI醫療企業，信息安全與隱私保護是我們最重要的責任之一。我們高度重視信息安全管理，制定並實施《信息安全管理體系總綱》、《安全風險評估管理辦法》、《數據備份管理制度》、《數據保密管理辦法》及《通訊工具使用管理辦法》等近40項政策及制度，並嚴格按照上述政策及制度執行。

數據收集與使用原則

在提供人工智慧解決方案期間，我們直接收集或通過業務合作夥伴收集、使用用戶個人資料(主要為視網膜影像)時，均事前獲取用戶明示同意授權。我們已與業務合作夥伴簽訂協議，明確其負責從用戶個人處獲得授權的義務。就收集的用戶信息，我們承諾：

- 於收集用戶個人資料前已獲得明示授權同意；
- 使用用戶個人資料的方式與所獲得的授權同意相一致；

- Having adopted multiple measures to protect relevant data from abuse, leakage, and attacks, ensuring compliance with applicable Chinese data privacy and protection laws and regulations and current industry practices.

Data Storage and Access Control

In terms of data storage, retinal images in our databases have no lifecycle and will not be deleted; retinal images in temporary data storage systems are typically assigned a lifecycle of one day to one year by business partners and deleted as required. We have developed systems and a "Data Secure Room" structure to ensure data is only used under limited conditions specified by internal policies.

Large Language Model Compliance and Technical Protection System

We strictly align with the latest regulatory requirements such as the Interim Measures for the Administration of Generative Artificial Intelligence Services, and establish a full-chain compliance mechanism around the "WanYu" technological foundation: training data are sourced from legally authorized channels, explicit consent is obtained for all personal information involved, and unauthorized data collection and use are prohibited; a training data content review mechanism is established to safeguard intellectual property rights and data authenticity and compliance, ensuring full compliance of large language model services.

- 已採取多種措施保護相關數據免遭濫用、泄露及攻擊，確保符合中國適用的數據隱私和保護法律法規及現行行業慣例。

數據存儲與訪問管控

在數據存儲方面，我們數據庫中視網膜影像無生命周期且不會被刪除；臨時數據存儲系統中的視網膜影像通常由業務合作夥伴設定生命周期，並根據其要求適時刪除。我們已開發系統及「數據安全屋」結構，確保數據僅在內部政策限定的有限情況下使用。

大模型合規與技術防護體系

我們嚴格對標《生成式人工智慧服務管理暫行辦法》等最新監管要求，圍繞「萬語」技術底座建立全鏈條合規機制：訓練數據均來自合法授權來源，涉及個人資訊均取得明示同意，杜絕未經授權數據採集與使用；建立訓練數據內容審核機制，保障知識產權與數據真實合規，確保大模型服務全流程符合監管規定。

On the technical protection front, we have passed the Class III Filing and Assessment of Information System Security Level Protection, and recertified multiple management systems including ISO27001, ISO20000, ISO45001, ISO14001, and ISO9001. Meanwhile, we have introduced a privacy-preserving computing framework based on federated learning, conducting distributed model training in the mode of "Data Stays Local, Models Move". Original medical data does not leave local sites or under central aggregation, thereby eliminating sensitive data leakage risks at the source and balancing model performance with data privacy and security.

在技術防護層面，我們通過資訊系統安全等級保護三級備案與測評，以及ISO27001、ISO20000、ISO45001、ISO14001、ISO9001等多項管理體系復審。同時引入基於聯邦學習的隱私計算框架，以「數據不動模型動」模式開展分佈式模型訓練，原始醫療數據不出本地、不集中彙聚，從源頭杜絕敏感數據洩露風險，兼顧模型性能與數據隱私安全。

Key Information Security Initiatives *信息安全重點舉措*

Initiatives **舉措**	**Details** **具體內容**
Data Security Governance Structure	Established a dedicated Data Security Internal Audit Committee composed of the head of R&D for the data team, the Company's legal person in charge, and the Company's human resources person in charge to centrally coordinate data security compliance work.
數據安全治理架構	成立由數據組研發負責人、我們法務負責人及我們HR負責人組成的專門數據安全內審委員會，統籌數據安全合規工作。
System Improvement	Further improved information security systems in line with national information security and data regulations, formulated the Measures for the Management of Data Confidentiality and Measures for the Management of the Use of Communication Tools, issued company-wide email notices, and conducted regular training and examinations.
制度完善	根據國家頒布的信息安全和數據方面的法規政策，進一步完善信息安全制度，制定《數據保密管理辦法》、《通訊工具使用管理辦法》，發布全員郵件通知並舉辦定期培訓及考試。

Initiatives 舉措	Details 具體內容
Security Review Mechanism 安全評審機制	Held monthly security review meetings covering hardware R&D, edge intelligence algorithms, cloud service development, database management, operation and maintenance services, discussed security upgrades and fixes, and assigned dedicated personnel for implementation. 每月組織一次安全評審會議，涵蓋硬件研發、邊緣智能算法、雲服務開發、數據庫管理、運維服務等多個方面，討論安全升級和修復方案，並指定專人落實。
External Security Audit 外部安全審計	Engaged security experts to conduct overall security checks on office networks, data centers, and cloud services, continuously monitoring industry security incidents for timely detection and remediation. 聘用安全專家，對辦公網絡、數據中心和雲服務進行整體安全排查，持續關注業界安全事件，做到及時發現及時修復。

Overseas Compliance and Cross-border Privacy Protection

海外業務合規與跨境隱私保護

Amid the rapid expansion of our overseas business, the Group strictly fulfils its ESG compliance responsibilities for cross-border operations. We have established a full-process management and control system covering data privacy compliance, employee rights protection, and supply chain ESG management, ensuring that business development advances in tandem with local regulations and social responsibility.

伴隨海外業務快速拓展，本集團嚴格落實跨國運營ESG合規責任，建立覆蓋數據隱私合規、員工權益保護、供應鏈ESG管理的全流程管控體系，確保業務發展與當地法規、社會責任同步推進。

The Group's overseas operations strictly comply with the data protection and personal information laws and regulations of the host jurisdictions. We have completed compliance adaptation for major markets including Southeast Asia, Europe, the United States, the Middle East and South America, covering the Personal Data Protection Acts (PDPA) of various Southeast Asian countries, the EU General Data Protection Regulation (GDPR), relevant US data privacy regulations and local cybersecurity requirements. For countries where commercialisation has been implemented, such as Vietnam, Thailand, Malaysia, Indonesia, Saudi Arabia, Brazil and Mexico, we have established a full-process privacy protection mechanism covering data classification and grading, security assessment of cross-border data transfer, user informed consent, and data retention and destruction. Regular compliance reviews and risk assessments are conducted on overseas business systems, partners and service processes to effectively safeguard the security of medical data and personal information of overseas users.

本集團境外業務嚴格遵守經營所在地數據保護與個人資訊相關法律法規，已完成對東南亞、歐美、中東、南美等主要市場的合規適配，包括東南亞各國個人數據保護法(PDPA)、歐盟GDPR、美國相關數據隱私法規及當地網路安全要求。針對越南、泰國、馬來西亞、印尼、沙特、巴西、墨西哥等已實現商業化落地的國家，建立數據分類分級、跨境數據傳輸安全評估、用戶知情同意、數據留存與銷毀等全流程隱私保護機制，並定期對境外業務系統、合作方與服務流程開展合規審查與風險評估，切實保障境外用戶醫療數據與個人資訊安全。

The Group strictly abides by the labour laws and regulations and local employment standards of overseas countries. We have established a unified employee rights protection system compatible with local practices, standardising the management of employment contracts, remuneration and benefits, occupational health and safety, working hours and rest and leave. We adhere to fair employment and prohibit all forms of discrimination, protect the legitimate rights and career development opportunities of overseas employees, and promote an inclusive and diverse cross-border team culture.

本集團嚴格遵守海外各國勞動法律法規與當地用工規範，建立統一且相容當地習慣的員工權益保障制度，規範勞動合同、薪酬福利、職業健康安全、工作時長與休息休假管理，堅持公平就業、禁止任何形式歧視，保障海外員工合法權益與職業發展機會，推動多元共融的跨國團隊文化。

The Group incorporates ESG requirements into the entire process of overseas supplier onboarding, evaluation and continuous monitoring. ESG risk due diligence and daily management are carried out for overseas production, logistics and service partners, with a focus on environmental protection, labour rights, occupational safety, business ethics and compliant operations, so as to drive a stable, responsible and sustainable development of the global supply chain.

本集團將環境、社會與治理(ESG)要求納入海外供應商准入、評價與持續監督全流程，對海外生產、物流、服務合作方開展ESG風險盡職調查與日常管理，重點關注環境保護、勞工權益、職業安全、商業道義與合規經營，推動全球供應鏈穩定、負責任、可持續發展。

In the future, we will continue to strictly implement various security management systems, closely monitor the legislative and regulatory developments related to data security and generative AI, timely conduct compliance training and program updates to ensure business always meets the latest regulatory requirements. Supported by a comprehensive security framework, we will provide solid safeguards for full-life-cycle health management and AI medical services.

未來，我們將持續嚴格執行各項安全管理制度，密切跟進數據安全、生成式AI相關立法與監管動態，及時開展合規培訓與方案更新，確保業務始終匹配最新監管要求。以完善的安全體系為支撐，為全生命周期健康管理與AI醫療服務提供堅實安全保障。

Benefiting from the above robust information security management system, we did not experience any data leakage incidents in 2025.

得益於上述完善的信息安全管理體系，2025年我們未發生任何數據泄露事件。

6.2 Product Quality and Customer Service

Product Quality Assurance and Recall

In terms of product and service quality, we strictly comply with laws, regulations and standards including the Product Quality Law of the People's Republic of China and YY/T 0287–2017 idt ISO13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes. Meanwhile, we have internally formulated a series of quality management systems including the Beijing Airdoc Quality Manual, Management System for Quality Documents, Management System for Procurement and Acceptance, Regulations for the Quality Management of Medical Devices, Management System for Sales and After-sales Service, Management System for Non-conforming Products, Management System for Medical Device Recall, Regulations for Quality Management Training and Assessment, and Management System for Handling Quality Accidents and Complaints to ensure product and service quality and continuously improve customer satisfaction.

Our core products are AI medical devices that have obtained medical device registration certificates from the National Medical Products Administration (NMPA), and product quality management strictly complies with medical device regulatory requirements. The quality assurance process mainly includes:

(i) **Research and development stage:** Algorithm models undergo rigorous internal validation and multi-centre clinical data retrospective analysis to ensure diagnostic accuracy, specificity and sensitivity meet the standards required for market launch.

6.2 產品質量與客戶服務

產品質量保障與召回

我們在產品及服務質量方面嚴格遵照《中華人民共和國產品質量法》、YY/T0287–2017 idt ISO13485：2016《醫療器械質量管理體系用於法規的要求》等法律法規及標準。同時，我們內部制定了《北京鷹瞳質量手冊》、《質量文件的管理制度》、《採購驗收的管理制度》、《醫療器械質量管理的規定》、《銷售及售後服務的管理制度》、《不合格產品管理制度》、《醫療器械召回管理制度》、《質量管理培訓及考核的規定》及《質量事故和投訴處理的管理制度》等一系列質量管理制度，保障產品及服務質量，持續提升客戶滿意度。

我們的核心產品為已獲國家藥品監督管理局（NMPA）醫療器械註冊證的AI醫療器械，產品品質管理嚴格遵循醫療器械監管法規。品質保證流程主要包括：

（一）**研發階段**：演算法模型經嚴格的內部驗證及多中心臨床數據回溯分析，確保診斷準確性、特異性及敏感性達到上市標準；

(ii) **Production stage:** The Changsha factory implements production quality management in accordance with the Good Manufacturing Practice (GMP) for medical devices, and incoming inspections are conducted for key components procured.

（二）**生產階段**：長沙工廠依據醫療器械生產品質管理規範(GMP)實施生產品質管控，關鍵器件採購實施來料檢驗；

(iii) **Post-market surveillance:** An active surveillance mechanism for adverse events involving medical devices has been established, with regular compilation and trend analysis of product complaints and adverse events.

（三）**上市後監測**：建立醫療器械不良事件主動監測機制，定期匯總產品投訴及不良事件資訊並分析趨勢；

(iv) **Recall procedures:** In accordance with the Administrative Measures for Medical Device Recalls, a three-tier recall system has been established (Class I recall: serious risk to life; Class II recall: potential harm to health but at a lower risk level; Class III recall: non-conforming products with no material harm to health). Initiation of a recall requires approval from the Quality Management Committee and must be completed within prescribed time limits, covering notification, retrieval and disposal.

（四）**召回程式**：依據《醫療器械召回管理辦法》，建立三級召回制度（一級召回：存在危及生命嚴重風險；二級召回：可能危害健康但風險較低；三級召回：不合格但對健康無實質危害），召回啟動須經品質管理委員會審批並在規定期限內完成通知、回收及處置。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

We assigned professional personnel to manage the monitoring and management of adverse events of products and services. Adverse event information is received through our official website and customer channels, and reported to monitoring agencies in a timely manner through the National Medical Device Adverse Event Monitoring Information System within the specified time. In the event of an adverse event, we will handle it in accordance with the provisions of the product adverse event monitoring and control procedures, conduct safety research, risk analysis and assessment, and take measures such as suspending production and sales, and product recalls to minimize risks. Relevant medical device adverse event monitoring records will also be systematically and completely retained. No product recall events of any classification occurred during the reporting period.

我們安排專業人員負責產品及服務的不良事件監測和管理工作，通過我們官網、客戶渠道等接收不良事件信息，並在規定時間內通過國家醫療器械不良事件監測信息系統及時向監測機構報告。若發生不良事件，我們將按照產品不良事件監測控制程序的規定予以處理，開展安全研究、風險分析及評估，並採取暫停生產及銷售、產品召回等措施將風險降至最低。相關醫療器械不良事件監測記錄文件亦將系統完整予以保存。本報告期內，我們發生任何級別的產品召回事件。

In 2025, the specific measures we took to strengthen product quality management are as follows:

2025年，我們加強產品質量管理的具體措施如下：

- Organized production and full-process product quality control in strict accordance with the Good Manufacturing Practice for Medical Devices, and provided training on medical device product quality-related regulations for all departments and positions.

- 嚴格依據《醫療器械生產質量管理規范》組織生產及全過程產品質量控制，對各部門和崗位進行醫療器械產品質量相關法規的培訓；

- Established quality management system documents including quality manuals, procedural documents, and management systems in accordance with YY/T 0287–2017 idt ISO13485:2016. The quality management system operated normally and effectively, met regulatory requirements, and continuously improved through internal audits and management reviews; we successfully passed on-site system assessments and routine supervision inspections by the Medical Products Administration and other relevant authorities.

- 依據YY/T0287–2017 idt ISO13485：2016建立質量手冊、程序文件及管理制度等質量管理體系文件。質量管理體系運行正常有效，滿足法規要求，並通過內審和管評等持續改進；我們順利通過藥品監督管理局等相關部門的體系現場考核、例行監督審查；

- In accordance with relevant laws and regulations and the Guidelines for Supplier Audit of Medical Device Manufacturers, formulated the procedural document SMP-05 Supplier Audit System to control the processes of supplier audit and evaluation, conducted annual evaluations of existing suppliers, all of which met the requirements of qualified suppliers.

- 依據相關法律法規及《醫療器械生產企業供應商審核指南》，制定程序文件《SMP-05供應商審核制度》，對供應商審核、評價等過程進行控制，對現有供應商開展年度評價，均滿足合格供應商要求；

- Formulated QCP-17 Traceability Control Procedure and established a traceability system covering the entire procurement, production, inspection, and sales process to ensure quality traceability for each device.

- 制定《QCP-17可追溯性控制程序》，建立可追溯性系統，覆蓋採購、生產、檢驗及銷售全過程，確保每一台設備的質量可回溯；

- Formulated QCP-23 Quality Control Procedure and Finished Product Inspection Specifications to clarify quality control requirements and acceptance criteria; full-time quality inspectors conducted finished product inspections in accordance with regulations, non-conforming products were handled in accordance with QCP-25 Non-conforming Product Control Procedure, and qualified products were released only after authorized release personnel signed release instructions.

- 制定《QCP-23質量控制程序》及《成品檢驗規程》，明確質量控制要求及接收準則；由專職質檢人員依規執行成品檢驗，不合格品依據《QCP-25不合格品控制程序》處置，合格品經授權放行人簽署放行指令後方可出廠。

In 2025, no major violations related to product quality occurred, and no large-scale product returns were reported. The quality management system operated normally and effectively overall. In the future, we will continue to improve the level of product and service quality management in the following aspects: strengthen quality awareness, enhance inspection skills, improve suppliers' quality assurance capabilities, standardize workshop on-site and production process quality control, improve system implementation, regularly carry out quality month activities, and promote product design improvement.

2025年，我們未發生與產品質量相關的重大違法違規事件，亦未出現客戶大量退回產品的情況，質量管理體系整體運行正常有效。未來，我們將從以下方面持續提升產品及服務質量管理水平：強化質量意識、提升質檢技能、加強供應商質量保障能力、規範車間現場和生產過程質量控制、完善制度執行、定期開展質量月活動、推進產品設計改良。

Customer Service Management

We have established a market- and customer-oriented management system including customer classification, customer relationship management, customer loyalty management, and customer maintenance, and continuously improved relevant mechanisms and various business operation processes in line with business development and changes in the internal and external environment. This enables the effective utilization of customer resources, reduces operating costs, improves service quality, builds long-term friendly and stable customer relationships, and continuously enhances our reputation.

客戶服務管理

我們建立了以市場和客戶為導向的管理體系，包括客戶分類、客戶關係管理、客戶忠誠度管理和客戶維護等，並根據業務發展及內外部環境變化不斷完善相關機制及各項業務操作流程，從而實現客戶資源的有效利用，降低運營成本，提升服務質量，以構建長期友好穩定的客戶關係，不斷提升我們商譽。

After-sales Service Support

In terms of after-sales service, we provide a comprehensive after-sales service system including customer service and technical support:

- Customers can contact, file complaints, and obtain support through the customer service hotline; 24/7 online service, 400 toll-free consultation hotline, and official website appeal email services are available to ensure year-round service accessibility.
- Sales and marketing personnel must pass 31 internal examinations (including product operation steps and technical support) before providing after-sales service to ensure service quality.
- When launching new products, we provide extensive training for sales and marketing personnel to ensure they can provide high-quality after-sales service; the sales and marketing personnel responsible for training have an average of more than 10 years of work experience and extensive industry knowledge.
- AI algorithm models are continuously updated online; customers can continuously obtain improved algorithm performance without replacing hardware devices, effectively reducing customers' full-cycle ownership costs.

For self-developed hardware devices, the warranty period is generally no less than one year from the date of product delivery. Free repair or replacement services are provided during this period (except for man-made damage or damage caused by force majeure). In 2025, no major customer complaints occurred.

售後服務支持

在售後服務方面，我們提供包含客戶服務與技術支持的全面售後服務體系：

- 客戶可通過客戶服務熱線聯絡、投訴並獲得支持；提供24小時在線服務、400電話免費諮詢熱線及官網訴求郵件服務，確保全年無休的服務可及性；
- 銷售及營銷人員須通過31項內部考試（含產品使用步驟及技術支持等）方可開展售後服務工作，確保服務質量；
- 我們發布新產品時，對銷售及營銷人員進行廣泛培訓，確保其可提供高質量的售後服務；負責培訓的銷售及營銷人員平均擁有超過十年工作經驗及豐富行業知識；
- AI算法模型持續在線迭代更新，客戶無需更換硬件設備即可持續獲得算法性能提升，有效降低客戶全周期持有成本。

對於自主研發的硬件設備，保修期一般不少於一年，自產品交付之日起計算。在此期間提供免費維修或更換服務（人為損壞或因不可抗力造成的損壞除外）。2025年，我們未發生任何重大客戶投訴。

Algorithm Performance Monitoring and Responsible AI Mechanism

In view of the characteristics of AI medical products, we have established a risk monitoring system covering the full algorithm lifecycle. Software algorithm performance deviations, diagnostic consistency fluctuations, scenario adaptability differences, etc., are included in the scope of suspected adverse events and risk early warning, realizing continuous monitoring and closed-loop management of the real-world performance of AI models. Through real-world data (RWD), we continuously track core indicators such as algorithm accuracy, sensitivity, and specificity, compare model stability across different devices, populations, and clinical scenarios, and promptly identify potential performance degradation and bias risks.

We have established an algorithm iteration, update, and exit mechanism: when monitoring reveals that algorithms deviate from expected performance, clinical applicability declines, or potential diagnostic risks exist, we immediately initiate risk assessment and expert review, and implement control measures such as online model iteration, parameter optimization, and scenario-restricted use as needed; for algorithm models no longer suitable for clinical scenarios or with irreparable defects, we implement procedures for delisting, version exit, and clinical discontinuation, and simultaneously issue risk prompts to cooperative medical institutions to ensure that AI diagnosis and treatment services are always in a safe, effective, and controllable state.

算法性能監控與負責任AI機制

針對AI醫療產品特點，我們建立覆蓋演算法全生命週期的風險監控體系，將軟體演算法性能偏差、診斷一致性波動、場景適配性差異等納入擬似不良事件與風險預警範圍，實現對AI模型真實世界表現的持續監測與閉環管理。通過真實世界數據(RWD)持續跟蹤演算法準確率、靈敏度、特異度等核心指標，對比不同設備、不同人群、不同臨床場景下的模型穩定性，及時識別潛在性能衰減與偏差風險。

我們已建立演算法迭代更新與退出機制：當監測發現演算法偏離預期性能、臨床適用性下降或存在潛在診斷風險時，立即啟動風險評估與專家評審，按需實施模型線上迭代、參數優化、場景限定使用等管控措施；對不再適用於臨床場景或存在難以修復缺陷的演算法模型，執行程式下架、版本退出與臨床停用流程，並同步向合作醫療機構發佈風險提示，確保AI診療服務始終處於安全、有效、可控狀態。

In the future, the Company will continue to improve the medical device adverse event monitoring and AI algorithm risk control system, strictly implement various internal control processes and information disclosure requirements, and while ensuring the safety and reliability of hardware devices, strengthen the full-life-cycle compliance management of algorithms, and effectively safeguard public life and health.

未來，公司將持續完善醫療器械不良事件監測與AI演算法風險管控體系，嚴格執行各項內控流程與資訊披露要求，在保障硬體設備安全可靠的同時，強化演算法全生命週期合規管理，切實維護公眾生命健康安全。

6.3 Sustainable Supply Chain

6.3 可持續供應鏈

Sincere cooperation with suppliers is an important guarantee for us to achieve our strategic goals and an enduring driving force for our development. We value communication with suppliers, actively build cooperation platforms, strive to establish long-term, close and win-win cooperative relationships, and work together to provide high-quality products and services for customers and promote the sustainable and stable development of the industry. In 2025, the number of our supplier partners was optimized from 147 in 2024 to 126.

與供應商的精誠合作是我們實現戰略目標的重要保障，亦是我們發展的不竭動力。我們重視與供應商的交流，積極搭建合作平台，力求建立長期緊密互惠共贏的合作關係，攜手為客戶提供優質產品和服務，推動行業持續穩定發展。2025年，我們供應商合作夥伴數量由2024年的147家調優至126家。

In accordance with YY/T 0287-2017 idt ISO13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes, ISO14001 environmental management system standards, and the Guidelines for Supplier Audit of Medical Device Manufacturers, we formulated the procedural document SMP-05 Supplier Audit System to manage and control risks of suppliers.

我們依據YY/T0287-2017 idt ISO13485：2016《醫療器械質量管理體系用於法規的要求》、ISO14001環境管理體系標準和《醫療器械生產企業供應商審核指南》，制定程序文件《SMP-05供應商審核制度》對供應商進行管理和風險管控。

Supplier Classification Management Mechanism

Our suppliers are divided into types such as complete machine suppliers, optical component suppliers, electronic component suppliers, mechanical structure component suppliers, and packaging auxiliary material suppliers according to the materials supplied, and into three levels according to importance:

- **Level A (Strategic Cooperation Suppliers):** Relatively strict access requirements, including the collection of qualification documents, on-site inspections, personnel allocation, and understanding of upstream and downstream data chains. After being reviewed and confirmed by the technical team, sample verification is conducted, and they can be formally introduced only after passing the verification and added to the list of qualified suppliers;
- **Level B (Key Suppliers):** Access requirements are similar to Level A, requiring complete qualification review and on-site inspection processes;
- **Level C (General Cooperation Suppliers):** On-site inspection is optional, and the access process is relatively flexible.

On-site inspections for supplier access include inspections of the safe working environment of personnel and reviews of labor contracts, and the use of child labor is strictly prohibited; suppliers holding ISO14001 and other environmental management system certifications will be given appropriate extra points in the audit score.

供應商分級管理機制

我們的供應商按所供物料分為整機供應商、光學件供應商、電子件供應商、機械結構件供應商、包裝輔料供應商等種類，並根據重要性分為三個等級：

1. **A級（戰略合作供應商）**：准入相對嚴苛，包括資質文件收集、現場審查、人員配置及上下游數據鏈了解等。通過技術小組評審確認後，進行打樣驗證，驗證無問題方可正式引入，加入合格供應商清單；
2. **B級（重要供應商）**：准入要求類同A級，需通過完整的資質審核和現場審查流程；
3. **C級（一般合作供應商）**：現場審核可作為可選項，准入流程相對靈活。

供應商准入的現場審核涵蓋人員安全工作環境考察，並審查勞動合同，嚴禁使用童工；持有ISO14001等環境管理體系認證的供應商在審核評分中適當加分。

We conduct a three-party review of suppliers' annual delivery quality, price conditions, and service quality, issue annual evaluation reports, and the score results affect the distribution of cooperation shares in the coming year. During the performance of suppliers, we conduct strict inspections and supervision, and the inspection results on social responsibility and environmental protection are also included in the scoring system; once child labor is found, rectification is ordered and points are deducted in the annual evaluation, and those with excessively low scores will be eliminated.

我們對供應商的年交貨質量、價格情況、服務質量進行三方評審，出具年度評價報告，評分結果影響來年合作份額分配。在供應商履約過程中，我們嚴格進行檢查和監督，對社會責任及環境保護方面的考察結果亦納入評分體系；一旦發現使用童工現象，責令整改並在年度評價中扣減分值，分值過低者將被淘汰。

Regional Distribution of Suppliers in 2025

2025年供應商地區分佈

Region **地區**	**Number of Suppliers in 2025 (units)** **2025年供應商數量（個）**
North China (Beijing, Tianjin, Shanxi Province, Hebei Province, Inner Mongolia Autonomous Region) 華北地區（北京市、天津市、山西省、河北省、內蒙古自治區）	21
Northeast China (Heilongjiang Province, Jilin Province, Liaoning Province) 東北地區（黑龍江省、吉林省、遼寧省）	0
East China (Shanghai, Jiangsu Province, Zhejiang Province, Anhui Province, Fujian Province, Jiangxi Province, Shandong Province) 華東地區（上海市、江蘇省、浙江省、安徽省、福建省、江西省、山東省）	22
Central China (Henan Province, Hubei Province, Hunan Province) 華中地區（河南省、湖北省、湖南省）	15
South China (Guangdong Province, Guangxi Zhuang Autonomous Region, Hainan Province) 華南地區（廣東省、廣西壯族自治區、海南省）	65
Southwest China (Sichuan Province, Guizhou Province, Yunnan Province, Chongqing, Tibet Autonomous Region)	3

Region 地區	Number of Suppliers in 2025 (units) 2025年供應商數量（個）
西南地區（四川省、貴州省、雲南省、重慶市、西藏自治區）	
Northwest Region (Shaanxi Province, Gansu Province, Qinghai Province, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region) 西北地區（陝西省、甘肅省、青海省、寧夏回族自治區、新疆維吾爾自治區）	0
Total 合計	126

In the future, we will continue to strictly review suppliers at the access stage, never accept suppliers that use child labor or have environmental pollution, and encourage suppliers to recommend environmentally friendly products such as low-power chips, degradable materials, and reusable materials. In terms of supplier management, we will continuously strengthen standardization and timeliness, enhance random inspections of key materials and quality assurance, and tend to cooperate with well-known brand manufacturers based on social responsibility considerations.

未來，我們將在供應商准入環節繼續從嚴審核，絕不接受使用童工和存在環境污染現象的供應商，並鼓勵供應商推薦低功耗芯片、可降解材質、重複利用材料等環保產品。在供應商管理上，持續加強規範性和及時性，強化重點物料抽查和質量保障，並基於社會責任考量傾向於與知名品牌廠家合作。

ESG Risk Identification and Management in the Supply Chain

供應鏈ESG風險識別與管理

The Company has identified the main ESG risks in the supply chain as follows:

公司識別供應鏈主要ESG風險如下：

Risk Category 風險類別	Main Risks 主要風險	Mitigation Measures 緩解措施
Environmental Risks 環境風險	Energy consumption and waste emissions during suppliers' production 供應商生產過程中的能耗及廢棄物排放	In the supplier audit scoring system, the possession of ISO14001 certification is included as an extra point item; suppliers are encouraged to provide degradable materials and low-power components 供應商審核評分體系中，ISO14001認證持有情況納入加分項；鼓勵供應商提供可降解材料及低功耗元器件
Social Risks 社會風險	Suppliers' use of child labor or forced labor 供應商使用童工或強制勞工	On-site inspections must check labor contracts and employees' age certificates; once violations are found, immediate rectification is required and points are deducted in the annual score, and cooperation is terminated for serious cases 現場審核必須查驗勞動合同及員工年齡證明；一旦發現違規立即整改並在年度評分中扣減，情節嚴重者終止合作
Compliance Risks 合規風險	Suppliers failing to meet medical device regulatory requirements 供應商不符合醫療器械法規要求	Strictly conduct supplier qualification audits and annual three-party reviews in accordance with ISO13485 standards 嚴格按ISO13485標準進行供應商資質審核及年度三方評審
Concentration Risks 集中度風險	Concentration of suppliers in South China (accounting for 53%) 華南地區供應商集中（佔53%）	Continuously evaluate the regional distribution of suppliers and optimize the procurement diversification strategy 持續評估供應商地域分佈，優化採購多元化策略

In 2025, the Company completed annual reviews of all 126 qualified suppliers, and no major ESG violations were found.

2025年，公司對全部126家合格供應商完成年度評審，未發現重大ESG違犯事件。

6.4 Integrity and Compliance Operation

Compliance Governance Structure

As an AI medical enterprise, based on our traditional anti-corruption and compliance practices, we have incorporated AI ethics and compliance into our overall integrity operation system, and comprehensively integrated emerging risks such as AI algorithm bias, misdiagnosis in clinical decision-making, and impacts on medical fairness into our corporate risk identification, assessment and prevention and control system, ensuring that our technological applications and commercial activities abide by the compliance principles of fairness, responsibility and transparency.

We have built a dual-track governance system covering integrity (Trinity System) governance and AI ethics governance, with special governance mechanisms established respectively:

Integrity Governance — "Prevention-Monitoring-Response"

Formed a three-level governance structure of "Strategic Decision-Making Level (Board of Directors) — Independent Supervision Level (Audit Committee) — Implementation Level (Internal Audit Department)"

- **Strategic Decision-Making Level (Board of Directors):** As the highest governance body for anti-fraud work, it undertakes the following core functions: serving as the primary advocate for anti-fraud culture construction, reviewing internal audit reports quarterly; directly leading the handling of major fraud cases; approving the annual anti-fraud budget and internal control system upgrade plan;

6.4 誠信合規運營

合規治理架構

作為AI醫療企業，我們在傳統廉潔合規基礎上，將AI倫理與合規納入整體誠信運營體系，把AI算法偏差、診療誤判風險及醫療公平性影響等新型風險，全面納入公司風險識別、評估與防控體系，確保技術應用與商業行為均恪守公平、負責、透明的合規原則。

我們構建了覆蓋廉潔治理與AI倫理治理的雙軌治理體系（三位一體體系），分別設立專項治理機制：

廉潔治理 —「預防 — 監控 — 回應」

形成「戰略決策層（董事會）— 獨立監督層（審計委員會）— 執行落地層（內審部）」三級治理架構

- **戰略決策層（董事會）：**作為反舞弊工作的最高治理主體，承擔以下核心職能：擔任反舞弊文化建設的首要倡導者，每季度審議內部審計報告；直接領導重大舞弊案件處置；審批年度反舞弊預算及內控體系升級方案；

- **Independent Supervision Level (Audit Committee):** As a supervisory body directly under the Board of Directors, it undertakes key checks and balances functions, establishes an anti-fraud KPI assessment system, and conducts annual competency evaluations on the person in charge of the Audit Department;

- **獨立監督層(審計委員會)**:作為董事會直屬監督機構,承擔關鍵制衡職能,建立反舞弊KPI考核體系,對審計部負責人實施年度勝任力評估;

- **Implementation Level (Internal Audit Department):** As a permanent anti-fraud functional department, it is responsible for coordinating and implementing cross-departmental and company-wide anti-fraud actions, including receiving reports, recording and registering, organizing case investigations, issuing investigation reports and handling suggestions, and regularly compiling the Anti-Fraud Supervision Briefing to report to the management.

- **執行落地層(內審部)**:作為常設反舞弊職能部門,負責統籌執行跨部門全公司範圍反舞弊行動,包括受理舉報、記錄登記、組織案件調查、出具調查報告及處理建議,並定期編撰《反舞弊監察簡報》,匯報予管理層。

AI Ethics Governance: Special Mechanism of the AI Ethics Committee

As the core governance mechanism for the Company's AI medical strategy, the AI Ethics Committee is composed of experts in technology, medicine, legal affairs and compliance, and reports directly to the Board of Directors. Its main responsibilities include:

- **Algorithm Fairness Review:** Regularly conduct fairness assessments on core AI algorithms to ensure that there is no systematic bias or discrimination in the performance of algorithms among different genders, ages, regions and population subgroups.

AI倫理治理:AI倫理委員會專項機制

AI倫理委員會作為公司AI醫療戰略的核心治理機制,由技術、醫學、法務及合規領域專家組成,直接向董事會匯報。其主要職責包括:

- **演算法公平性審查**:定期對核心AI演算法進行公平性評估,確保演算法在不同性別、年齡、地域及人群亞組中的表現不存在系統性偏差或歧視。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

- **Transparency Management:** Establish algorithm interpretability standards to ensure that key medical decision paths are traceable and auditable; provide clear product performance descriptions and risk prompts to users and medical institutions.

- **Ethical Risk Assessment:** Conduct pre-ethical risk assessments before new product approval, algorithm iteration and commercial deployment, focusing on privacy protection, data security and medical fairness issues.

- **External Supervision and Feedback:** Establish an independent complaint and feedback channel to accept ethical opinions from patients, doctors and the public, and regularly issue AI ethics governance reports.

- **透明度管理**：建立演算法可解釋性標準，確保關鍵醫療決策路徑可追溯、可審計；向用戶及醫療機構提供清晰的產品性能說明與風險提示。

- **倫理風險評估**：在新產品立項、演算法迭代及商業化部署前進行倫理風險前置評估，重點關注隱私保護、數據安全及醫療公平性議題。

- **外部監督與回饋**：建立獨立的投訴與回饋通道，接受來自患者、醫生及社會公眾的倫理相關意見，並定期發佈AI倫理治理報告。

Compliance and Whistleblowing

We are committed to fostering an honest and clean operating environment and has established a comprehensive anti-corruption and compliance management system covering policy formulation, risk prevention, training, incentive and disciplinary mechanisms, as well as whistleblowing administration to ensure the effective implementation and continuous improvement of all integrity requirements.

- **System Construction:** Continuously standardized and improved codes of conduct and requirements related to business ethics, covered anti-fraud, anti-money laundering, anti-bribery and other requirements to all employees and partners, standardized employee behaviors from multiple perspectives such as gifts, entertainment, and presents, and put forward clear anti-corruption and anti-bribery requirements;

- **Risk Prevention and Control:** Regularly updated prevention and control plans for high-risk areas, actively carried out internal audits and risk assessments related to business ethics and anti-corruption, covering all financial and material-related processes such as sales and accounts receivable, expenses, funds, payables and procurement, R&D, and conducted departure audits for important positions or key personnel;

合規建設與舉報

我們致力構建誠信廉潔的營運環境，已建立涵蓋制度規範、風險防控、培訓教育、獎懲機制及舉報管理的全面反貪污與合規管理體系，確保各項廉潔從業要求有效落實並持續優化。

- **制度建設**：持續規範和完善商業道德相關行為準則及要求，將反舞弊、反洗錢、反賄賂等要求覆蓋至全體員工及合作夥伴，從禮物、招待、贈送等多個角度規範員工行為，提出明確的反腐敗及反賄賂要求；

- **風險防控**：定期更新高風險領域防控方案，積極開展商業道德及反腐敗相關內部審計與風險評估，覆蓋銷售與應收、費用、資金、應付與採購、研發等所有涉財、涉物流程，並對重要崗位或關鍵人員開展離任審計；

- **Continuous Training:** Established an inter-departmental joint investigation team, equipped with professional anti-fraud investigation tools, carried out anti-corruption, anti-bribery and business ethics training for all employees, and fostered an anti-corruption culture within the Company through daily work exchanges and promotion of the latest domestic and foreign policy trends, comprehensively building a line of defense for compliance and business ethics;

- **持續培訓**：組建跨部門聯合調查組，配置專業反舞弊調查工具，對全員開展反腐敗、反賄賂與商業道德培訓，通過日常工作交流及國內外最新政策動向宣傳，在我們內部形成反腐文化，全方位築牢合規與商業道德防線；

- **Clear Rewards and Punishments:** Improved the Employee Code of Professional Ethics and Major Violations (Version 2.0), including to reward employees who made significant contributions to reporting corruption incidents; strictly handle corruption incidents such as bribery, embezzlement, and extortion; for suppliers/customers who violate anti-corruption regulations, take measures such as terminating commercial contracts and listing them on the blacklist according to the severity of the incident.

- **明確獎懲**：完善《員工職業道德準則與重大違規行為2.0版》，對舉報腐敗事件有重大貢獻的員工予以獎勵；對賄賂、貪污、勒索等腐敗事件嚴肅處理；對違反反腐敗規定的供應商／客戶，按照事件嚴重程度採取終止商業合同、列入黑名單等措施。

We has established a comprehensive whistleblowing mechanism to provide employees, business partners and relevant parties with safe and accessible reporting channels, with a view to effectively preventing and detecting violations. Major arrangements are as follows:

我們建立了完善的舉報機制，為員工、合作夥伴及相關方提供安全、便捷的舉報管道，以有效防範和發現違規行為。主要安排如下：

- **Reporting channels:** The Company has set up a dedicated compliance reporting email address (ray@10000.life). Employees may use this channel to report suspected corruption, bribery, conflicts of interest, financial fraud, professional misconduct and other violations. Concerns may also be raised directly with independent non-executive directors through the Audit Committee.

- **舉報管道**：公司設立專用合規舉報郵箱（ray@10000.life），員工可通過上述管道就涉嫌貪污、行賄、利益衝突、財務舞弊、違反職業操守及其他違規行為進行舉報；亦可通過審計委員會向獨立非執行董事直接反映相關問題。

- **Anonymity protection:** Whistleblowers may submit reports anonymously. The Company strictly prohibits any form of retaliation against whistleblowers who report in good faith. Such prohibitions are explicitly set out in the Employee Code of Professional Ethics and the Major Violations Handling Procedures.

- **匿名保護**：舉報人可選擇匿名方式提交舉報。公司嚴格禁止對善意舉報人實施任何形式的打擊報復，相關禁止性規定已明確載入《員工職業道德行為準則》及重大違規處理辦法。

- **Handling process:** Reports are received in confidence by the compliance team. Following a preliminary review, a determination is made as to whether to initiate a formal investigation. Investigation conclusions are submitted to management and, in cases of serious misconduct, to the Audit Committee for deliberation. Confirmed violations are dealt with in accordance with relevant regulations, and the outcome is communicated to the whistleblower in an appropriate manner (subject to the requirement to preserve the confidentiality of the investigation).

- **處理流程**：舉報信息由合規部門進行保密受理，經初步審查後確認是否啟動正式調查；調查結論須提交管理層及（如情節嚴重）審計委員會審議；對查證屬實的違規行為依規處理，處理結果以適當方式回饋至舉報人（在不影響調查保密性的前提下）。

- **Monitoring mechanism:** The Human Resources Department and compliance team are responsible for ensuring that the reporting channel remains accessible and confidential on a day-to-day basis. The Audit Committee reviews the operation of the whistleblowing mechanism and annual reporting statistics at least once a year, and reports to the Board.

- **監察機制**：人力資源部門及合規團隊負責日常維護舉報管道的暢通與保密，審計委員會每年至少審閱一次舉報機制的運行情況及年度舉報案件統計，並向董事會報告。

In 2025, the above integrity governance system achieved remarkable results. We found no major risks involving embezzlement, no confirmed whistleblowing and embezzlement incidents, or public legal lawsuits related to embezzlement against us or our employees. In the future, we will continue to attach importance to anti-corruption work, strengthen the functions of the anti-corruption supervision agency, expand the field of external supervision, improve the internal audit mechanism, and build a solid compliance guarantee for the healthy and sustainable development of the enterprise.

2025年度，上述廉潔治理體系運作成效顯著。我們未發現涉及舉報和貪污的重大風險，亦未出現已確認的貪污事件或公開針對我們及其員工的貪污相關法律訴訟。未來，我們將持續重視反腐倡廉工作，強化反腐監察機構的職能，拓寬外部監督領域，完善內部審計機制，為企業健康持續發展構築堅實的合規保障。

6.5 AI Algorithm Governance and Medical Ethics

6.5 AI演算法治理與醫療倫理

As an AI medical enterprise, algorithm bias, data privacy protection and AI interpretability are core ESG issues that the Company needs to actively manage. The Company has incorporated "Responsible AI Development and Deployment" into the overall ESG governance framework, and built a comprehensive artificial intelligence governance system from four dimensions: ethical principles, algorithm auditing, clinical responsibility and data governance. The Board of Directors is the highest responsible body for "AI ethics and data security" affairs, overseeing the relevant governance and supervision work.

作為一家AI醫療企業，算法偏差、數據隱私保護及AI可解釋性係公司需主動管理的核心ESG議題。公司將「負責任的AI開發與部署」納入整體ESG治理框架，以倫理原則、算法審計、臨床責任及數據治理四個維度，構建完備的人工智慧治理體系。董事會為「AI倫理與數據安全」事務的最高責任機構，統籌相關治理與監督工作。

AI Ethical Principles

AI倫理原則

Accuracy and Reliability: All AI diagnostic algorithms must complete strict multi-center clinical verification before listing and obtain NMPA medical device registration certificates (our core products have been approved) to ensure that algorithm performance meets clinically reliable standards.

準確性與可靠性：所有AI診斷算法須在上市前完成嚴格多中心臨床驗證，並取得NMPA醫療器械註冊證(核心產品已獲批)，確保算法性能達到臨床可靠標準。

Interpretability: We continue to promote the application of large language model technology in automatic report interpretation and intelligent Q&A, so that AI diagnostic results are presented in language understandable to doctors and patients, avoiding "black box" decisions.

可解釋性：我們持續推進大語言模型技術在報告自動解讀和智能問答中的應用，使AI診斷結果以醫生和患者可理解的語言呈現，避免「黑箱」決策。

Fairness and Representativeness: The retinal image database is cross-annotated by hundreds of medical experts, covering patient groups of different ages, genders and disease severity, and continuously monitors the diagnostic accuracy of algorithms in different populations to prevent systematic bias.

公平性與代表性：視網膜影像數據庫由數百名醫學專家交叉標注，覆蓋不同年齡、性別及疾病嚴重程度的患者群體，持續監測算法在不同人群中的診斷準確率，防範系統性偏差。

Patient Safety First: AI-assisted diagnosis results are positioned as clinical "auxiliary tools" rather than replacing doctors' judgments, and the final diagnostic responsibility is borne by qualified medical professionals.

患者安全優先：AI輔助診斷結果定位為臨床「輔助工具」而非替代醫生判斷，最終診斷責任由具備資質的醫療專業人員承擔。

Algorithm Auditing and Model Monitoring

算法審計與模型監測

- **Regular Model Performance Evaluation:** Conduct regular real-world data retrospective analysis on major algorithm models to monitor core indicators such as accuracy, specificity and sensitivity;
- **定期模型性能評估**：對各主要算法模型定期開展真實世界數據回溯分析，監測準確率、特異性及敏感性等核心指標；
- **Bias Detection Procedures:** For major algorithm version updates, conduct subgroup analysis across devices, regions and populations to identify and correct potential diagnostic biases;
- **偏見檢測程序**：針對重大算法版本更新，開展跨設備、跨地域、跨人群的子組分析，識別並修正可能存在的診斷偏差；
- **SaMD Continuous Monitoring:** In accordance with NMPA and IEC 62304 standards, conduct post-market monitoring on listed SaMD products, and timely collect, analyze and report adverse events;
- **SaMD持續監測**：依照NMPA及IEC 62304標準，對已上市SaMD產品開展上市後監測，及時收集、分析並報告不良事件；

- **Version Control and Traceability:** Establish a strict AI model version control system to ensure that each algorithm update has complete training data records and verification results to support regulatory audits.

- **版本管控與可追溯性：**建立嚴格的AI模型版本管控體系，確保每次算法更新均有完整的訓練數據記錄和驗證結果，支持監管審計。

Clinical Responsibility Mechanism

臨床責任機制

- All AI diagnostic reports clearly indicate the "auxiliary diagnosis" attribute, prompting medical professionals to make independent judgments and not be used as the basis for independent diagnosis;

- 所有AI診斷報告明確標注「輔助診斷」屬性，提示醫療專業人員進行獨立判斷，不作為獨立診斷依據；

- Contracts with medical institutions clearly specify the norms for the use of AI diagnostic results and the attribution of clinical responsibilities;

- 與醫療機構的合同中明確規定AI診斷結果使用規範及臨床責任歸屬；

- Sales and technical personnel can provide services only after passing internal assessments, and the training covers the usage norms and limitations of AI-assisted diagnosis.

- 銷售及技術人員通過內部考核方可開展服務，培訓涵蓋AI輔助診斷的使用規範及局限性說明。

Data Governance Structure

數據治理架構

- A Data Security Internal Audit Committee has been established to coordinate the compliant use of personal medical data;

- 已成立數據安全內審委員會，統籌個人醫療數據的合規使用；

- Patient retinal image data are strictly used within the scope of informed consent and authorization, and expired data cannot be recovered, effectively protecting patients' data rights and interests;

- 患者視網膜影像數據嚴格按照知情同意授權範圍使用，過期數據不可恢復，切實保障患者數據權益；

- Metadata that can identify personal identity are anonymized or desensitized in algorithm training;

- 在算法訓練中對能識別個人身份的元數據進行匿名化或脱敏處理；

- Overseas business strictly complies with local data protection laws and regulations to ensure that cross-border data flow meets local regulatory requirements.

In 2025, no major complaints or regulatory penalties occurred due to AI algorithm issues. In the future, we will actively follow the latest requirements of regulatory authorities such as the Cyberspace Administration of China, the National Health Commission of the People's Republic of China, and NMPA in terms of AI medical devices and algorithm governance, and continuously improve AI governance capabilities.

- 境外業務嚴格遵守所在地數據保護法規，確保跨境數據流轉符合當地監管要求。

2025年，我們未因AI算法問題引發任何重大投訴或監管處罰。未來，我們將積極跟進國家互聯網信息辦公室、國家衛生健康委員會及NMPA等監管機構在AI醫療器械及算法治理方面的最新要求，持續提升AI治理能力。

07 INCLUSIVE AI MEDICAL ECOSYSTEM DEVELOPMENT

With the mission of making health "Accessible and Affordable to Everyone" (讓健康無處不在), we give full play to the unique advantages of AI technology in lowering the threshold of health services, build a trinity AI medical inclusive ecosystem of "technical capability — operational responsibility — social value", emphasising being "ecosystem-oriented, full-lifecycle and inclusive", transforming our technological strengths into public health value, and actively advancing the United Nations Sustainable Development Goals.

In 2025, our AI has accumulated 7.12 million screened cases and identified 37,210 significant positive cases. Through continuous iteration of algorithms and hardware, we have extended the chronic disease screening services that were previously only available in tertiary hospitals in large cities to rural areas, communities and campuses. At the same time, AI-assisted diagnosis and treatment effectively reduce unnecessary offline consultations and repeated inspections caused by misdiagnosis, and while improving diagnosis and treatment efficiency and medical resource utilization, significantly reduce energy consumption and carbon emissions in medical scenarios, helping social low-carbon sustainable development with a new "green medical" model.

07 AI醫療普惠生態

我們以「讓健康無處不在」為使命，充分發揮AI技術在降低健康服務門檻上的獨特優勢，構建「技術能力 — 運營責任 — 社會價值」三位一體的AI醫療普惠生態，突出「生態化、全週期、普惠性」，將技術優勢轉化為公共健康價值，積極踐行聯合國可持續發展目標。

2025年，我們AI累計篩查712萬病例，識別重大陽性案例37,210例。通過演算法與硬體持續迭代，將以往僅大城市三甲醫院可提供的慢病篩查服務延伸至鄉村、社區與校園。同時，AI輔助診療有效減少不必要的線下就診與因誤診導致的重複檢查，在提升診療效率與醫療資源利用率的同時，顯著降低醫療場景能耗與碳排放，以「綠色醫療」新模式助力社會低碳可持續發展。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

7.1 Technology Empowering Inclusive Scenarios

Friendly Services for New Employment Groups

After the summer of 2025, Beijing experienced continuous high temperatures. In response to the health challenges of new employment groups such as food delivery workers and couriers working outdoors, as a friendly service partner for new employment groups in Haidian District, we actively responded to the "One City, Refreshing" summer care campaign launched by the Social Work Department of the Beijing Municipal Party Committee and the district-level arrangements. In July, we provided free AI fundus detection public welfare services for new employment groups and business district workers in the Wukesong Business District of Wanshou Road Street. Compared with the cumbersome process of traditional ophthalmic screening that requires mydriasis and waiting, our AI equipment can complete the detection and output reports in 1–3 minutes, helping long-term outdoor workers quickly grasp their eye and physical health status, which has been widely recognized by new employment groups.

7.1 技術賦能普惠場景

新就業群體友好服務

2025年入夏後北京持續高溫，針對外賣員、快遞員等新就業群體戶外工作的健康挑戰，我們作為海淀區新就業群體友好服務夥伴，積極響應北京市委社會工作部「一城清爽」夏季關懷行動及區級部署，於7月在萬壽路街道五棵松商圈，為新就業群體及商圈工作者免費提供AI眼底檢測公益服務。相較於傳統眼科篩查需要散瞳、等候的繁瑣流程，我們AI設備1–3分鐘即可完成檢測並輸出報告，幫助長期戶外從業者快速掌握眼部及身體健康狀況，獲新就業群體廣泛認可。







Entering Communities and Malls

In 2025, we organized an inclusive team to enter surrounding communities and malls to carry out public welfare activities and provide AI fundus screening services for residents. Relying on advanced AI technology, we achieved rapid detection in 1–3 minutes, and provided professional and detailed report interpretation services for residents, focusing on protecting the eye health and chronic disease health of the middle-aged and elderly groups. During the year, we successively participated in the Dragon Boat Festival "Zong Xiang An Kang" community health public welfare activity in May and the "Safe Use of Drugs and Medical Devices to Protect Healthy Life" themed activity organized by the Haidian District Administration for Market Regulation in September, empowering people's livelihood services with technology, and relevant public welfare initiatives have been widely recognized by community residents.

走進社區商場

2025年，我們組織普惠小隊走進周邊社區、商場開展公益活動，為居民提供AI眼底篩查服務。依托先進的AI技術實現1–3分鐘快速檢測，並為居民提供專業細緻的報告解讀服務，重點守護中老年群體眼健康與慢病健康。年內，我們先後參與5月端午「粽享安康」社區健康公益活動、9月海淀區市場監管局「安全用藥用械守護健康生活」主題活動等，以科技賦能民生服務，相關公益舉措獲得社區居民廣泛認可。





ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Entering Zhongguancun No. 3 Primary School

In September 2025, we were invited to participate in the "Exploration of Education in the Intelligent Era" seminar at Zhongguancun No. 3 Primary School in Haidian District, Beijing, helping AI education move from textbooks to practice with cutting-edge technological achievements. Airdoc Technology's Neuro-AI stress resistance monitoring can help teachers and students understand their own stress resistance, physical and mental stress index and nervous system status through 90-second non-contact measurement; the PBM-LED® vision rehabilitation instrument demonstrated the cutting-edge application of AI in myopia prevention and control, protecting children's vision health and empowering the development of intelligent campus education with technology.

走進中關村第三小學

2025年9月，我們受邀參與北京市海淀區中關村第三小學「面向智能時代的教育探索」研討會，以前沿科技成果助力AI教育從課本走向實踐。鷹瞳科技Neuro-AI抗壓能力監測通過90秒非接觸測量，幫助師生了解自身抗壓能力、身心壓力指數和神經系統狀態；PBM-LED®視力康復儀則展示了AI在近視防控中的前沿應用，守護孩子們的視力健康，以科技為校園智能教育發展賦能。





Entering Rural "Fields and Villages"

In November 2025, we brought the artificial intelligence chronic disease screening system to the "Rural Artificial Intelligence Laboratory" in Xishaoqu Village, Dongshaoqu Town, Miyun District, to carry out AI health assessment public welfare service activities, providing local villagers with professional and convenient retinal image inspection and health science popularization services, allowing villagers to obtain scientific health prompts through fundus screening. This activity was the first time that AI medical services were introduced after the laboratory was established in September. We promoted the in-depth integration of digital technology and rural development through technology sinking, making AI medical care from concept to rural practice, and helping rural health construction.

走進鄉村「田間地頭」

2025年11月，我們攜人工智慧慢病篩查系統走進密雲區東邵渠鎮西邵渠村「鄉村人工智慧實驗室」，開展AI健康評估公益服務活動，為當地村民提供專業便捷的視網膜影像檢查及健康科普服務，讓村民通過眼底篩查獲取科學健康提示。本次活動為該實驗室9月成立後首次引入AI醫療服務，我們以科技下沉推動數字技術與鄉村發展深度融合，讓AI醫療從理念落地鄉村實踐，助力鄉村健康建設。







ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Helping the Iterative Upgrade of Sanming Medical Reform

In December 2025, we officially completed a strategic signing with the Sanming Municipal Health Commission, donating chronic disease screening and fundus auxiliary diagnosis equipment free of charge to the three-level medical system of Sanming City, counties and townships, and carrying out equipment application training to improve the practical operation capacity of primary medical care. At the same time, we explored the "hospital + school" linkage model to launch public welfare special services for adolescent myopia and stress resistance. This cooperation not only helps the iterative upgrade of Sanming medical reform and creates a national "artificial intelligence + medical reform" demonstration benchmark, but also practices the corporate mission of making health "Accessible and Affordable to Everyone" (讓健康無處不在) with practical actions.

助力三明醫改迭代升級

2025年12月，我們正式與三明市衛健委完成戰略簽約，向三明市、縣、鄉三級醫療體系無償捐贈慢病篩查及眼底輔助診斷設備，並開展設備應用培訓，提升基層醫療實操能力。同時，探索「醫院+學校」聯動模式，落地青少年近視與抗壓能力公益專項服務。此次合作既助力三明醫改迭代升級，打造全國「人工智慧+醫改」示範標桿，也以實際行動踐行「讓健康無處不在」的企業使命。



7.2 Public Health Value Output

Release of the "Blue Book on Health of 6 Million Physical Examination Population"

On December 23, 2025, under the guidance of the China Center for Health Economics Research at Peking University, we jointly released the 2025 version of the "Health Blue Book of Six Million Health Checkup Cohort" based on retinal artificial intelligence assessment, together with Beijing Tongren Hospital Affiliated to Capital Medical University, the Key Laboratory of Medical Artificial Intelligence Research and Verification of the Ministry of Industry and Information Technology and other institutions. This version of the Blue Book is the seventh consecutive retinal artificial intelligence assessment-based health blue book of physical examination population released by us, with two major breakthroughs in core data: the cumulative research sample size exceeded 6 million; the number of people undergoing consecutive retinal AI assessments exceeded 1 million people for the first time.



7.2 公共健康價值輸出

《六百萬體檢人群健康藍皮書》發布

2025年12月23日，在北京大學中國衛生經濟研究中心指導下，我們聯合首都醫科大學附屬北京同仁醫院、醫學人工智慧研究與驗證工業和信息化部重點實驗室等多家單位，共同發布2025版基於視網膜人工智慧評估的《六百萬體檢人群健康藍皮書》。本版藍皮書為我們連續第七年發布的視網膜人工智慧評估類體檢人群健康藍皮書，核心數據實現兩大突破：累計研究樣本量突破600萬；連續參與視網膜人工智慧評估的人群首次超100萬。

By dynamically tracking the eye health, overall health status and disease risk distribution characteristics of China's physical examination population, the Blue Book provides real and highly valuable observation basis for public health research relying on desensitized big data, and at the same time enhances the attention of residents and enterprises and institutions to eye health and overall health, helping to establish a national health concept and improve the awareness of health risk prevention and control.

藍皮書通過動態追蹤我國體檢人群眼健康及全身健康狀況、疾病風險分佈特徵，依托脫敏大數據為公共衛生研究提供真實且具高參考價值的觀測依據，同時提升了居民及企事業單位對眼健康及全身健康的重視程度，助力全民健康觀念樹立與健康風險防控意識提升。

Airdoc Neuro-AI Helps Nanchang's 1 Million Teachers and Students Stress Resistance Census

鷹瞳Neuro-AI助力南昌市百萬師生抗壓能力普查

Under the leadership of the Nanchang Municipal Government, Education Bureau and the Education Standards Committee of Beijing Normal University, we fully participated in the campus stress resistance screening project with a scale of 1 million students, relying on our Neuro-AI stress resistance monitoring technology to provide public welfare physical and mental health census services for 1.5 million primary and secondary school students and teachers in the local area, helping schools and teachers establish key attention files and improve intervention efficiency.

在南昌市政府、教育局及北京師範大學教育標準委員會主導下，我們全面參與百萬學生規模校園抗壓能力篩查項目，依托我們的Neuro-AI抗壓能力監測技術，為當地150萬中小學生及教師提供公益性身心健康普查服務，助力學校和老師建立重點關注檔案、提升干預效率。



Special Reports by Authoritative Media

In September 2025, as a core ecological unit of the National Artificial Intelligence Application Pilot Base, we were invited to participate in the 2025 China International Fair for Trade in Services. As an ecological partner of the pilot base, the blinding fundus disease and major chronic disease early warning system jointly developed by us and Tongren Hospital appeared in the exhibition area, and we also displayed the PBM-LED® vision rehabilitation instrument, Neuro-AI stress resistance monitoring and a variety of Airdoc AI fundus cameras. In the same period, our core technology product received a special feature report on CCTV's Focus Report.

權威媒體專題報導

2025年9月，我們作為國家人工智慧應用中試基地核心生態單位，受邀參加2025年中國國際服務貿易交易會。作為中試基地生態夥伴，我們與同仁醫院聯合研發的致盲眼底疾病與重大慢病預警系統亮相展區，同時展示PBM-LED®視力康復儀、Neuro-AI抗壓能力監測及多款鷹瞳AI眼底相機。同期，我們的核心產品獲央視《焦點訪談》專題報導。





7.3 AI Medical Low-Carbon Operation

Compared with traditional medical testing methods, our AI software-driven model itself has significant low-carbon attributes — one AI fundus camera can serve tens of thousands of patients, replacing a large number of repetitive manual operations and the use of consumables; remote AI-assisted diagnosis can also reduce unnecessary travel carbon emissions of patients and medical staff. On this basis, we further integrate the concept of green development into the entire operation process:

1. **Office Scenarios**: Advocate green digital office, promote the use of electronic documents, optimize printing processes, encourage double-sided printing to reduce office paper consumption; implement the 26°C air conditioning temperature standard, adopt energy-saving LED lamps, encourage employees to turn off computers, lamps, air conditioners and other equipment when leaving, reduce standby energy consumption; remind employees to turn off power before holidays, and strengthen awareness of saving electricity and water;

2. **Production Links**: The Changsha factory clearly stipulates that employees should take the pedestrian stairs first to avoid using elevators with high energy consumption; restrict the use of high-power peripheral equipment for non-work needs, optimize production processes to reduce energy consumption; give priority to selecting environmentally friendly accessories such as low-power chips, degradable materials and reusable materials;

7.3 AI醫療低碳運營

相比傳統醫療檢測方式，我們的AI軟件驅動模式本身具有顯著低碳屬性 — 一台AI眼底相機可服務數萬名患者，替代大量重複性人工操作和耗材使用；遠程AI輔助診斷亦可降低患者和醫護人員不必要的出行碳排放。我們在此基礎上將綠色發展理念進一步融入運營全過程：

1. **辦公場景**：倡導綠色數字化辦公，推廣電子文檔使用，優化打印流程、鼓勵雙面打印以減少辦公用紙消耗；執行26°C空調溫度標準，採用節能LED燈具，鼓勵員工離開時關閉電腦、燈具及空調等設備，減少待機能耗；節假日前提醒員工關閉電源，強化節電節水意識；

2. **生產環節**：長沙工廠明確規定員工優先走人行樓梯，避免使用能耗較高的貨梯；限制非工作需要的高功率外圍設備使用，優化生產流程以降低能源消耗；優先選用低功耗芯片、可降解材質及可重複利用材料等環保配件；

3. **Supply Chain Collaboration**: Incorporate environmental management requirements into the supplier evaluation system, suppliers holding ISO14001 and other certifications will be given appropriate extra points in the audit score, encourage suppliers to provide environmentally friendly products, and promote the low-carbon transformation of the upstream and downstream industrial chains.

3. **供應鏈協同**：將環境管理要求納入供應商評估體系，持有ISO14001等認證的供應商在審核評分中適當加分，鼓勵供應商提供環保產品，推動上下游產業鏈低碳轉型。

In 2025, our total electricity consumption was 187,585.64 kWh, the annual electricity consumption per square meter of building area was 28.33 kWh, and the annual per capita electricity consumption was about 880.79 kWh. The above data reflect the positive results of our energy consumption control as an AI medical enterprise with software algorithms as the core, and also provide a benchmark reference for continuous optimization in the future.

2025年，我們電能消耗總量為187,585.64千瓦時，每平米建築面積年耗電量為28.33千瓦時，人均年耗電量約為880.79千瓦時。上述數據反映了我們作為以軟件算法為核心的AI醫療企業在能耗管控方面的積極成效，亦為後續持續優化提供基準參考。

In the future, we will gradually improve our social welfare efforts, with senior management taking turns as public welfare project leaders, encouraging more employees to participate, providing more frequent AI fundus detection services in more scenarios, and reaching more people. Our goal is to regularly and continuously provide retinal vascular and nerve health monitoring services for one-third of the world's population, truly realizing making health "Accessible and Affordable to Everyone" (讓健康無處不在).

未來，我們在社會公益方面將逐步完善，由高管輪值擔任公益項目負責人，發動更多員工參與其中，在更多場景中提供更多頻次的AI眼底檢測服務，觸及更多人群。我們目標是為地球上三分之一的人口定期持續提供視網膜血管神經的健康監測服務，真正實現「讓健康無處不在」。

08 TALENT TRAINING AND DEVELOPMENT

The core competitiveness of the Company is rooted in talent — whether it is AI engineers developing new algorithms, medical consultants ensuring product compliance, or after-sales personnel providing user training, every position directly affects the social value output of AI medical products. We adhere to the people-oriented concept, believe that employees with sufficient skills and experience are the most valuable asset of the enterprise, and under the guidance of the open, unified, innovative and shared corporate culture, continuously improve the talent training system, and take learning as an important part of the enterprise's core competitiveness and corporate culture.

8.1 Safeguarding Employees' Rights and Interests

We strictly comply with relevant laws and regulations such as the Labor Law of the People's Republic of China, the Labor Contract Law of the People's Republic of China, the Social Insurance Law of the People's Republic of China, the Individual Income Tax Law of the People's Republic of China, the Law of the People's Republic of China on the Protection of Women's Rights and Interests, the Regulations on the Labor Protection of Female Employees, and the Measures for Holidays and Memorial Days of the Whole Country.

We mainly recruit employees through recruitment websites, internal recommendations and other channels. In accordance with the Labor Law of the People's Republic of China, we sign individual employment contracts with employees, covering matters such as wages, employee benefits, workplace safety, confidentiality obligations, non-competition and termination reasons.

08 人才培養與發展

鷹瞳科技的核心競爭力根植於人才 — 無論是開發新算法的AI工程師、確保產品合規的醫學顧問，還是為患者提供使用培訓的售後人員，每一個崗位都直接影響AI醫療產品的社會價值輸出。我們堅持「以人為本」的理念，相信具備足夠技能和經驗的員工是企業最寶貴的財富，在開放、統一、創新、共享的企業文化指引下，不斷完善人才培養體系，將學習作為企業核心競爭力和企業文化的重要組成部分。

8.1 維護員工權益

我們嚴格遵守《中華人民共和國勞動法》、《中華人民共和國勞動合同法》、《中華人民共和國社會保險法》、《中華人民共和國個人所得稅法》、《中華人民共和國婦女權益保障法》、《女職工勞動保護規定》及《全國年節及紀念日放假辦法》等相關法律法規。

我們主要通過招聘網站、內部推薦等渠道招聘員工，根據《中華人民共和國勞動法》，與員工簽訂個人僱用合約，涵蓋工資、員工福利、工作場所安全、保密義務、不競爭及終止理由等事項。

We adopt a zero-tolerance stance on the employment of child labor or forced labor under any circumstances. During the recruitment process, candidates must present legal personal identification documents to verify their age, and all employees undergo relevant background checks. Appropriate actions will be taken immediately if fraudulent information is found. In 2025, no child labor or forced labor was employed, and no social insurance violations or arrears occurred, effectively safeguarding the legitimate labor rights and interests of every employee.

我們對在任何情況下僱用童工或強制勞工採取零容忍立場。在招聘過程中，候選人必須出示合法的個人身份證明文件以核實年齡，所有員工接受相關背景調查，一經發現欺詐信息立即採取適當行動。2025年，我們未發生僱用童工或強制勞工現象，亦未出現社會保險違規及欠繳情況，切實保障了每一位員工的合法勞動權益。

Employee Distribution in 2025 *2025年員工分佈*

Classification Dimension 分類維度	Category 類別	2025 Headcount 2025年人數	2024 Headcount 2024年人數	Change 變化幅度
Total Headcount **員工總數**	Total Employees (full-time + part-time) 全體員工（全職+兼職）	213	282	−24.5%
Gender **性別**	Male 男	110	160	−31.3%
Gender **性別**	Female 女	103	122	−15.6%
Employment Type **僱傭類型**	Full-time 全職	181	248	−27.0%
Employment Type **僱傭類型**	Part-time 兼職	32	34	−5.9%
Age Group **年齡層**	Below 30 30歲以下	79	82	−3.7%
Age Group **年齡層**	30–50 30–50歲	122	188	−35.1%

Classification Dimension 分類維度	Category 類別	2025 Headcount 2025年人數	2024 Headcount 2024年人數	Change 變化幅度
Age Group **年齡層**	Above 50 50歲以上	12	12	0.0%
Region **地域**	Beijing, China 中國北京	114	177	−35.6%
Region **地域**	Shanghai, China 中國上海	20	25	−20.0%
Region **地域**	Other Regions 其他	79	80	−1.3%

The Group further optimised its human resource allocation. During the Reporting Period, the total number of employees (full-time + part-time) of the Company was adjusted from 282 in 2024 to 213. Total staff costs decreased from RMB209.7 million in 2024 to RMB103.2 million, representing a year-on-year decrease of 50.8%, which was highly consistent with the optimisation and restructuring of headcount.

- In terms of headcount structure, the scale of the core workforce aged 30–50 and staff in key business regions including Beijing and Shanghai were optimised in tandem. The proportion of non-core positions continued to decline, and the team as a whole became more concentrated on core businesses such as AI research and development and clinical scenario applications.

本集團人力資源配置進一步調優：報告期內，公司員工總數（全職+兼職）由2024年的282人調整為213人，總薪酬成本由2024年的人民幣2.097億元下降至1.032億元，同比降幅達50.8%，與人員規模調優、結構調整高度匹配。

- 人員結構方面，30–50歲核心骨幹群體、北京／上海核心業務區域人員規模同步調優，非核心崗位佔比持續壓降，團隊整體向AI研發、臨床場景等核心業務集中；

- In terms of remuneration efficiency, while headcount decreased by 27%, the Group achieved year-on-year revenue growth and a significant narrowing of losses. Per capita output and per capita revenue increased notably, and the return on human resource investment continued to improve, laying a solid talent foundation for the Group's long-term sustainable development.

- 薪酬效率方面，在人員規模減少27%的同時，公司實現營收同比增長、虧損大幅收窄，人均產出、人均營收顯著提升，人力資源投入產出比持續優化，為公司長期可持續發展奠定堅實人才基礎。

Employee Turnover in 2025 *2025年員工流失情況*

Classification Dimension 分類維度	Category 類別	Number of Attritions 流失人數	Corresponding Headcount 對應在職人數	2025 Attrition Rate 2025年流失率	2024 Attrition Rate 2024年流失率	Change 變化幅度
Gender 性別	Male 男	35	110	31.8%	55.0%	−23.2%
Gender 性別	Female 女	49	103	47.6%	40.2%	7.4%
Age Group 年齡	Below 30 30歲以下	22	79	27.8%	47.6%	−19.8%
Age Group 年齡	30–50 30–50歲	60	122	49.2%	45.7%	3.5%
Age Group 年齡	Above 50 50歲以上	2	12	16.7%	100.0%	−83.3%
Region 地域	Beijing, China 北京	52	114	45.6%	55.4%	−9.8%
Region 地域	Shanghai, China 上海	13	20	65.0%	64.0%	1.0%
Region 地域	Other Regions 其他	19	79	24.1%	28.8%	−4.7%
Total 合計	Total	84	213	39.4%	48.6%	−9.2%

The overall employee attrition rate for 2025 was 39.4%, representing a decrease of 9.2 percentage points from 48.6% in 2024, indicating a significant improvement in overall staff mobility. During the Reporting Period, the Group's total headcount (full-time + part-time) was adjusted from 282 to 213, representing a 27% reduction, primarily driven by the Group's strategic shift to an AI Agent-driven model. On the one hand, AI technologies have replaced certain standardised and repetitive business processes, allowing proactive structural optimisation of non-core positions. On the other hand, the remaining turnover reflected voluntary resignations amid market conditions, with the overall voluntary turnover rate also declining, demonstrating the Group's growing attractiveness as an employer.

2025年員工整體流失率為39.4%，較2024年的48.6%下降9.2個百分點，整體人員流動狀況顯著改善。報告期內，公司員工總人數（全職+兼職）由282人調整至213人，人員規模減少27%，主要源於公司「向AI Agent驅動模式轉型」的戰略調整：一方面，以AI技術替代部分標準化、重複性業務環節，對非核心崗位開展主動結構優化；另一方面，剩餘流失為市場環境下的員工主動離職，整體主動離職率同步下降，體現公司人才吸引力持續提升。

Staff mobility during the year was concentrated mainly among the core workforce aged 30–50 (attrition rate: 49.2%) and female employees (attrition rate: 47.6%). Detailed analysis is as follows:

本年度人員流動主要集中於30–50歲核心骨幹層級（流失率49.2%）及女性員工群體（流失率47.6%），具體分析如下：

Core workforce aged 30–50: Approximately 60% of departures in this group resulted from position optimisation under strategic transformation, covering traditional business and standardised operational roles. The remaining 40% comprised voluntary resignations driven by intensified industry talent competition and adjustments to individual career plans.

30–50歲核心群體：流失中約60%為戰略轉型下的崗位優化，覆蓋傳統業務及標準化運營崗位，剩餘40%為行業人才競爭加劇、個人職業規劃調整導致的主動離職。

Female employees: Around 55% of departures in this group stemmed from structural optimisation of support functions, while the remaining 45% reflected relatively high voluntary turnover influenced by work-life balance needs and the operational nature of the healthcare AI industry.

In response to the above, we will continue to implement a series of measures:

- Align with the AI healthcare strategy to further optimise the staffing structure, focusing on the recruitment and development of core R&D talents.
- Continuously improve the remuneration, benefits and long-term incentive system, establish clear dual career development tracks for technical and management paths, and strengthen the retention of core talents.
- Enhance family-friendly benefits for female employees, optimise maternity leave, parental leave and related support policies to balance work and family needs, improve overall employee satisfaction and sense of belonging, sustainably reduce core talent turnover, and ensure a stable talent supply for the Group's strategic transformation.

女性員工群體：流失中約55%為支持類崗位的結構性優化，剩餘45%受工作與生活平衡需求、行業工作屬性等因素影響，主動離職率相對較高。

針對上述情況，後續我們將持續推進多項舉措：

- 緊扣AI醫療戰略，進一步調優人員結構，聚焦核心研發崗位的引進與培養；
- 持續完善薪酬福利與長期激勵體系，暢通「技術+管理」雙軌職業發展通道，強化核心人才留存；
- 針對女性員工完善生育友好型福利體系，優化產假、育兒假等假期制度，提供相關關懷支持，平衡工作與家庭需求，提升全體員工滿意度與歸屬感，持續降低核心人才流失率，保障公司戰略轉型的人才供給。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

AI Talent Pipeline Development

We have always regarded talent as the core strategic resource. In line with the technological innovation and business development needs of the AI medical sector, we have built a professional and systematic talent pipeline and a full-lifecycle human resource management system to continuously consolidate the Company's core competitiveness. As at the end of 2025, in addition to our original disclosure of employee structure by gender, age and region, we introduced dedicated disclosure on AI talent structure to provide a comprehensive view of our core AI medical talent deployment, as follows:

AI人才梯隊建設

我們始終將人才作為核心戰略資源，圍繞AI醫療賽道的技術創新與業務發展需求，構建了專業化、體系化的人才梯隊與全週期人力資源管理體系，持續夯實公司核心競爭力。截至2025年末，在原有按性別、年齡、地域分類的員工結構披露基礎上，新增AI人才結構專項披露，全面展現AI醫療核心人才佈局，具體如下：

Deployment of Core AI Talents
AI核心人才佈局

Composition of AI R&D Personnel	We have built an appropriately scaled and structurally complete AI R&D team with the ratio of R&D staff to total employees falling within a reasonable and competitive range in the industry. Key roles are clearly specified, covering critical domains including algorithm engineering, large language model training, AI software development, and medical data annotation. This has enabled us to form a full-chain AI R&D capability covering model development → training → engineering → medical data adaptation, providing core support for the iteration of the Company's "WanYu" technology foundation and AI healthcare products.
AI研發人員構成	我們已建立規模適配、結構完備的AI研發團隊，研發人員佔員工總體比例處於行業合理且具競爭力的區間，核心崗位細分明確，覆蓋演算法工程、大模型訓練、AI軟體研發及醫學數據標注等關鍵領域，形成模型研發→訓練→工程化→醫學數據適配的全鏈條AI研發能力，為公司「萬語」技術底座與AI醫療產品迭代提供核心支撐。
Establishment of Human-Machine Collaboration Roles	To ensure the clinical safety, diagnostic accuracy and real-world effectiveness of its AI medical products, the Company has established a comprehensive human-machine collaboration position system, realizing in-depth coordination between AI algorithm output, manual review and clinical needs, and building a quality and safety line of defense for AI medical services.
人機協作崗位設置	為保障AI醫療產品的臨床安全性、診斷準確性與落地效能，公司搭建了完善的人機協作崗位體系，實現AI演算法輸出與人工復核、臨床需求的深度協同，築牢AI醫療服務的品質與安全防線。

Analysis of AI Talent Turnover and Measures for Retaining Core AI Talents
AI人才流失分析與核心人才挽留措施

AI Talent Turnover Rate Situation	In 2025, the turnover rate of the Company's core AI talents was 2%, and the overall employee turnover rate was 39%. The team of core AI R&D and technical talents remained highly stable, providing solid guarantee for the Company's continuous technological innovation and strategic landing.
AI人才流失率情況	2025年，本公司核心AI人才流失率為2%，整體僱員流失率為39%。我們的核心AI研發與技術人才隊伍保持高度穩定，為公司技術持續創新與戰略落地提供了堅實保障。
Measures for Retaining Core AI Talents	To continuously attract and retain top AI medical talents, the Company has established a multi-level and long-cycle incentive and development system. The specific measures are as follows:
核心AI人才挽留措施	為持續吸引、保留頂尖AI醫療人才，公司建立了多層次、長週期的激勵與發展體系，具體措施如下：

- Equity Incentive: Grant equity incentives to core AI R&D personnel to deeply bind personal interests with the Company's long-term development and share the Company's growth value;
- 股權激勵：為核心AI研發人員授予股權激勵，深度綁定個人與公司長期發展利益，共享公司成長價值；

- Technical Partner Program: Provide core technical talents with a promotion channel for technical partners, endow them with the right to speak on technical decisions and project leadership, and build a technology-driven innovation ecosystem;
- 技術合夥人計劃：為核心技術人才提供技術合夥人晉升通道，賦予技術決策話語權與項目主導權，打造技術驅動的創新生態；

- Career Development and Training Empowerment: Provide a complete career development system and special training resources to support core AI talents to continuously deepen in fields such as algorithm R&D, large model training, and AI medical clinical application, and achieve synchronous resonance between personal growth and company development.
- 職業發展與培訓賦能：配套完善的職業發展體系與專項培訓資源，支持核心AI人才在算法研發、大模型訓練、AI醫療臨床應用等領域持續深耕，實現個人成長與公司發展的同頻共振。

8.2 Employee Care and Welfare

We strictly abide by national laws and regulations, and fully pay endowment insurance, medical insurance, unemployment insurance, work-related injury insurance, maternity insurance ("**Five Insurances**") and housing provident fund ("**One Fund**") for all employees in accordance with the law. No violations, arrears or omissions of social insurance occurred in 2025, effectively protecting the statutory rights and interests of employees.

We have built a scientific and improved salary system, which mainly consists of three parts: fixed salary, performance bonus and equity incentive. The salary standard is regularly reviewed and adjusted in combination with the market salary level, industry development trend, employees' job responsibilities and personal performance, ensuring that the salary system has strong market competitiveness and internal fairness. At the same time, we strictly implement the principle of equal pay for equal work, resolutely eliminate salary discrimination caused by any factors such as gender, age, ethnicity, education background and household registration, and protect the fair employment and salary rights and interests of each employee.

To provide better care for employees, we have made a series of adjustments and optimizations to relevant welfare:

- Extended supplementary medical coverage to employees' children, reducing the family burden caused by employees' children's medical treatment;

8.2 員工關愛及福利

我們嚴格遵守國家法律法規，依法為全體員工足額繳納養老保險、醫療保險、失業保險、工傷保險及生育保險(「**五險**」)及住房公積金(「**一金**」)，2025年度未發生任何社會保險違規、欠繳、漏繳情況，切實保障員工法定權益。

我們構建科學完善的薪酬體系，主要由固定薪資、績效獎金及股權激勵三部分構成。薪酬標準結合市場薪酬水準、行業發展趨勢、員工崗位職責及個人績效表現定期進行複盤與調整，確保薪酬體系具備較強的市場競爭力與內部公平性。同時，我們嚴格執行同工同酬原則，堅決杜絕因性別、年齡、民族、學歷、戶籍等任何因素產生的薪酬歧視，保障每位員工的公平就業與薪酬權益。

為讓員工獲得更好的關愛，我們對相關福利進行了一系列調整與優化：

- 增加員工補充醫療覆蓋子女的保障，減輕員工子女就醫造成的家庭負擔；

- Increased the upper limit of rental subsidies to encourage employees to rent houses near the Company and optimize the commuting experience;
- Issued monthly meal subsidies, which can be flexibly used through the welfare platform to effectively improve the daily dining guarantee for employees;
- Regularly organized new employee training, outdoor development training, and carried out cultural and sports activities such as mountain climbing, badminton competitions and various outdoor interactive games to help employees integrate into the team, enrich their spare time life and enhance team cohesion;
- Organized multiple "Bring Health Home" activities, allowing employees to take our equipment back to their hometowns to conduct AI fundus health checks for their families and neighbors, enabling employees to personally experience the social value of the Company's products.

In addition, we continue to provide various supplementary benefits such as annual health check-up, employee AI fundus health detection service, new marriage welfare, child-rearing welfare, public rental housing assistance, and exclusive health welfare for employees' children on Eye Care Day, comprehensively protecting the physical and mental health of employees and their families, and building a warm and sustainable employee care system.

- 提高租房補貼上限，鼓勵員工在公司附近租房，優化通勤體驗；
- 按月發放用餐補貼，透過福利平台靈活使用，切實改善員工日常就餐保障；
- 定期舉辦新人培訓與戶外拓展訓練，開展爬山、羽毛球比賽及各類戶外互動遊戲等文體活動，幫助員工融入集體、豐富員工業餘生活，增進團隊凝聚力；
- 組織多次「把健康帶回家」活動，讓員工攜帶我們的設備回到老家，為家人及周圍鄰居進行AI眼底健康檢測，使員工親身體驗公司產品的社會價值。

此外，我們持續提供年度健康體檢、員工AI眼底健康檢測服務、新婚福利、育兒福利、公租房協辦及愛眼日子女專屬健康福利等多元補充福利，全方位守護員工及其家庭身心健康，構建具溫度、可持續的員工關懷體系。






8.3 Employee Health and Safety

We strictly abide by laws and regulations such as the Work Safety Law of the People's Republic of China and the Law of the People's Republic of China on the Prevention and Control of Occupational Diseases, We places great importance on the occupational health and safety of its employees and has established the following key measures, which are implemented and monitored on an ongoing basis:

- **Safe working environment:** All office premises and the Changsha production factory strictly comply with the Work Safety Law of the People's Republic of China and relevant regulations. Regular safety inspections are conducted to ensure working environments meet national occupational health and safety standards.
- **Health management support:** Annual medical check-ups are provided to all employees, covering key examination items including eye health and cardiovascular health. Employees are encouraged to manage their working hours appropriately, with due regard to their physical and mental wellbeing.
- **Training and emergency drills:** Safety training is provided to new employees upon joining the Company. Regular fire emergency drills are organised to ensure employees are familiar with emergency evacuation procedures.
- **Monitoring mechanism:** The Human Resources Department is responsible for the day-to-day tracking and recording of occupational health and safety matters. Significant safety incidents must be reported to management in a timely manner.

8.3 員工健康與安全

我們嚴格遵守《中華人民共和國安全生產法》、《中華人民共和國職業病防治法》等法律法規，高度重視員工職業健康與安全，已建立以下主要措施並持續推進執行與監察：

- **安全環境保障**：辦公場所及長沙生產工廠均嚴格遵守《中華人民共和國安全生產法》及相關法規，定期開展安全隱患排查，確保工作環境符合國家職業健康安全標準。
- **健康管理支持**：為全體員工提供年度健康體檢福利，覆蓋眼健康、心血管健康等重點檢查專案；鼓勵員工合理安排工作時間，關注員工身心健康狀態。
- **培訓與應急演練**：新員工入職時開展安全教育培訓；定期組織消防應急演練，確保員工掌握緊急疏散程式。
- **監察機制**：由人力資源部門負責日常職業健康安全事項的跟進與記錄，重大安全事項須及時向管理層報告。

No occupational health and safety-related violations or major work-related injury incidents occurred during the reporting period, and the number of natural days lost due to work-related injuries was nil. Furthermore, during the reporting period, we did not experience any work-related fatalities and both the number and rate of work-related fatalities over the past three years were nil.

本報告期內，未發生職業健康安全相關違規事件及重大工傷事故，因工傷損失的自然日天數為0天。此外，報告期內，我們未發生任何因工亡故事件，過去三年工亡人數及比率均為0。

We customized and distributed work clothes for employees in summer, autumn and winter, which not only reflects our unified brand image recognition, but also highlights the neat and positive mental state of employees. Our business does not involve occupational disease hazards.

我們定製並向員工發放夏、秋、冬三季工作服，不僅體現我們統一的品牌形象識別，更彰顯員工整齊劃一、積極向上的精神狀態。我們的業務不涉及職業病危害。

8.4 Employee Development and Training

8.4 員工發展與培訓

Centering on the overall strategic layout and business transformation needs, we continuously integrate high-quality internal and external training resources, take employees' full-cycle career development as the orientation, and build a three-dimensional and systematic talent training system highly matched with the Company's AI medical strategy, promoting the synchronous improvement of organizational capabilities and employees' quality.

我們圍繞整體戰略佈局與業務轉型需求，持續整合內外部優質培訓資源，以員工全週期職業發展為導向，構建與公司AI醫療戰略高度匹配的立體化、體系化人才培訓體系，推動組織能力與員工素能同步提升。

In building the training system, we closely focus on the strategic landing and post competency requirements, and set clear training management objectives:

在培訓體系搭建上，我們緊扣戰略落地與崗位勝任力要求，設立清晰的培訓管理目標：

- Help new employees acquire post competency through new employee and commercialization training;
- 通過新員工和商業化培訓，幫助新員工具備崗位勝任力；
- Improve employees' work efficiency through product knowledge and professional capability training;
- 通過產品知識和業務能力培訓，提升員工工作效率；
- Improve employees' general capabilities through performance management, managers' daily performance feedback and coaching, helping employees better perform their job responsibilities;
- 通過績效管理、經理日常績效反饋和輔導，提升員工通用能力，幫助員工更好地履行工作職責；

- Strengthen team cohesion and collaboration awareness through team building and company-wide meetings.
- Through anti-corruption and whistleblowing training, we strengthen employees' awareness of integrity and compliance as well as risk prevention capabilities.

To achieve strategic capability upgrading, the Company has fully upgraded the content modules on the basis of the original training system. Internal training is divided into six systems according to the target and purpose, and new strategy-oriented special content is added:

- New Employee Training: Systematically understand our culture, business and products;
- Commercialization Training: Improve sales capabilities, customer management and market development skills;
- General Capability Training: Improve cross-position general work skills;
- Leadership Training: Improve management capabilities and strategic thinking for the management;
- Team Experiential Learning (Team Building): Strengthen cross-departmental collaboration and cohesion;
- Company-wide Meetings: Convey our strategic direction, business progress and cultural consensus.

- 通過團建及全員會，加強團隊凝聚力和協作意識。
- 通過反貪污及舉報相關培訓，強化員工廉潔合規意識與風險防範能力。

為實現戰略層面的能力升維，公司在原有培訓體系基礎上全面升級內容模組，內部培訓按對象與目標劃分為六大體系，並新增戰略導向的專項內容：

- 新員工培訓：系統了解我們文化、業務和產品；
- 商業化培訓：提升銷售能力、客戶管理和市場開拓技能；
- 通用力培訓：提升跨崗位通用工作技能；
- 領導力培訓：面向管理層的管理能力和戰略思維提升；
- 團隊體驗式學習（團隊建設）：加強跨部門協作與凝聚力；
- 全員會：傳遞我們戰略方向、業務進展與文化共識。

On this basis, we added the "AI + Clinical Knowledge" cross-training module to build a closed-loop capability of in-depth integration of technology and clinical practice: on the one hand, promote R&D and algorithm engineers to systematically learn clinical pathways, disease diagnosis and treatment standards and real medical scenario needs, ensuring that AI model R&D is closely linked to clinical value; on the other hand, carry out special training on AI ethics, data compliance, medical privacy protection, etc. for commercial and marketing teams, strengthen compliance awareness and professional service capabilities, and achieve synchronous resonance between the professional quality of all employees in the whole chain and strategic requirements.

在此基礎上，我們新增「AI + 臨床知識」交叉培訓模組，構建技術與臨床深度融合的能力閉環：一方面推動研發與演算法工程師系統學習臨床路徑、疾病診療規範與真實醫療場景需求，確保AI模型研發緊扣臨床價值；另一方面面向商業與市場團隊開展AI倫理、數據合規、醫療隱私保護等專項培訓，強化合規意識與專業服務能力，實現全鏈條人員專業素養與戰略要求同頻。

To ensure the quality and landing effect of training, we have established a strict new employee assessment mechanism, requiring all new employees to complete and pass four core assessments within one month of entry:

為保障培訓品質與落地效果，我們建立嚴格的新員工考核機制，要求所有新員工入職一個月內必須完成並通過四項核心考核：

- Complete the learning content of "Understanding Airdoc: New Employee Online Learning Task Package" and pass the exam;

- 完成《了解鷹瞳：新員工在線學習任務包》學習內容並通過考試；

- Complete the "Integrating into Airdoc: Employee Offline Training Graduation Exam" and pass the graduation exam;
- Pass the one-on-one report interpretation assessment;
- Pass the manual equipment operation assessment.

In addition to the above regular training, the Company continues to enrich training forms and expand training dimensions to help employees grow in an all-round way. For new employees, we regularly carry out outdoor integrated development training to strengthen their sense of team belonging and corporate cultural identity through immersive experience, helping them quickly integrate into the organization. At the same time, closely following the business development dynamics and actual needs, we regularly organize special professional training on product knowledge, clinical application, technical solutions, business operation, etc., which accurately matches the post capability requirements, quickly responds to the needs of business iteration and market expansion, and ensures that training is synchronized with business development.

- 完成《融入鷹瞳：員工線下培訓結營考試》並通過結營考試；
- 通過一對一的報告解讀考核；
- 通過手動設備操作考核。

除上述常規培訓外，公司持續豐富培訓形式、拓寬培訓維度，助力員工全面成長。針對新員工，我們不定期開展戶外融入式拓展培訓，以沉浸式體驗強化新員工的團隊歸屬感與企業文化認同感，幫助其快速融入組織。同時，緊扣業務發展動態與實際需求，不定期組織產品知識、臨床應用、技術方案、業務實操等專項專業訓練，精准匹配崗位能力要求，快速回應業務迭代與市場拓展需求，確保培訓與業務發展同頻共振。

In addition, Mr. Zhang Dalei, Chairman of the Company, and the management attach great importance to the improvement of the overall cognition of all employees. From time to time, through online sharing, they bring multi-dimensional and high-level series of special sharing to all employees, covering domestic and foreign management experience, cutting-edge trends of AI technology, trends of the times, interpretation of domestic and foreign situations, thinking on global layout, as well as insights into the real estate industry, knowledge related to stablecoins, in-depth analysis of the government work report and other fields. During the sharing, combining the industry reality and the Company's development, the Chairman deeply analyzed the impact of cutting-edge technologies such as AGI on the Company's business, the development differences between traditional organizations and AI-era organizations, interpreted the opportunities and challenges facing the Company, helping all employees broaden their horizons, update their thinking, deeply grasp the industry trends and the Company's development direction, and gather the joint force of organizational development.

此外，我們的董事長張大磊先生及管理層高度重視全員認知提升，不定期通過線上分享的形式，為全體員工帶來多維度、高格局的系列專題分享，內容涵蓋國內外管理經驗、AI技術前沿動態、時代發展趨勢、國內外局勢解讀、全球化佈局思考，以及房地產行業洞察、穩定幣相關知識、政府工作報告深度解析等多個領域。分享過程中，董事長結合行業實際與公司發展，深入剖析AGI等前沿技術對公司業務的影響、傳統組織與AI時代組織的發展差異，解讀公司面臨的機遇與挑戰，助力全體員工拓寬視野、更新思維，深刻把握行業趨勢與公司發展方向，凝聚組織發展合力。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

In 2025, the total number of trained employees was 213 (including part-time employees and resigned employees during the year), with a training coverage rate of 100%. The training situation by gender and position level is shown in the following table:

2025年度，我們累計受訓員工213（全職+兼職）人，培訓覆蓋率達100%，按性別及職級劃分的培訓情況如下表所示：

Classification 員工培訓	Number of Trainees 受培訓人數	Percentage of Corresponding Headcount 佔對應人數百分比	Average Training Hours 2025 2025年平均受訓時長（小時）	Average Training Hours 2024 2024年平均受訓時長（小時）	YoY Change 同比變化
Gender: Male 性別分類：男	110	100%	35	27	29.6%
Gender: Female 性別分類：女	103	100%	35	27	29.6%
Rank: Management 職級分類：管理層	36	100%	76	82	-7.3%
Rank: Non-management 職級分類：非管理層	177	100%	25	22	13.6%

In the future, we will continue to focus on the AI medical strategic transformation and global business expansion, continuously optimize the training content and training mode, strengthen the construction of the core talent team, and support the long-term and stable development of the Company with high-quality organizational capabilities.

未來，我們將持續圍繞AI醫療戰略轉型與全球化業務拓展，不斷優化培訓內容與培訓模式，強化核心人才隊伍建設，以高素質組織能力支撐公司長遠穩健發展。

09 GREEN SUSTAINABLE DEVELOPMENT AND CLIMATE RESPONSE

We deeply recognise the importance of building a resource-conserving and environmentally friendly society, and regard this as an important responsibility of the Company. Conserving energy and improving energy efficiency not only help reduce operating costs, but also promote technological innovation and sustainable development.

The Group strictly complies with the Environmental Protection Law of the People's Republic of China, the Water Law of the People's Republic of China, the Energy Conservation Law of the People's Republic of China and other relevant laws and regulations. In accordance with the requirements of Aspect A1 "Emissions" under the Environmental, Social and Governance Reporting Code (the "**ESG Reporting Code**") of The Stock Exchange of Hong Kong Limited, we have established corresponding environmental management policies and internal control mechanisms. For major environmental aspects including exhaust emissions, discharges into water and land, and the generation of hazardous and non-hazardous waste, the Group has formulated relevant management measures and continuously monitors their potential environmental impacts.

As an artificial intelligence technology enterprise specialising in healthcare, the Group's core business focuses on the research and development of the "Wanyu" medical large language model, AI-enabled retinal health recognition, myopia prevention and control technologies, and medical AI SaaS services. It is characterised by asset-light operation, low direct emissions, high R&D investment and computing power-driven business models. Given that the Group does not engage in large-scale industrial production activities, its direct emission levels are relatively limited, and relevant environmental impacts mainly arise from office operations and the use of computing resources.

09 綠色可持續發展與氣候應對

我們深刻認識到建設資源節約型、環境友好型社會的重要性，並視之為企業肩負的重要責任。節約能源、提升能源使用效率，既有助於降低運營成本，亦有助於推動技術創新及可持續發展。

本集團嚴格遵守《中華人民共和國環境保護法》、《中華人民共和國水法》及《中華人民共和國節約能源法》等相關法律法規，並根據香港聯合交易所有限公司《環境、社會及管治報告守則》(「**ESG報告守則**」)中層面A1「排放」之要求，建立相應的環境管理政策及內部控制機制。就廢氣排放、向水及土地的排污、有害及無害廢棄物的產生等主要環境範疇，本集團已制定相關管理措施，並持續監察其對環境的潛在影響。

本集團作為專注於醫療健康領域的人工智能科技企業，核心業務聚焦於「萬語」醫療大模型研發、視網膜健康AI識別、近視防控技術及醫療AI SaaS服務，具備輕資產運營、低直接排放、高研發投入及算力驅動等行業特徵。鑒於本集團未涉及大規模工業生產活動，直接排放水平相對有限，相關環境影響主要來自辦公運營及算力資源使用。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

In accordance with the ESG Reporting Code, key environmental performance indicators ("**KPIs**") and related targets such as greenhouse gas emissions and resource use are subject to "Comply or Explain" disclosure requirements. Based on our business nature, operating scale and characteristics of the AI healthcare industry, we have identified material environmental issues relating to energy consumption, computing power efficiency and office operations, and have gradually established corresponding data collection and management mechanisms.

根據ESG報告守則，溫室氣體排放、資源使用等環境類關鍵績效指標(KPI)及相關目標屬「不遵守就解釋」(Comply or Explain)披露要求。我們已結合業務屬性、營運規模及AI醫療行業特點，識別與能源消耗、算力使用效率及辦公運營相關之重大環境議題，並逐步建立相應的數據收集與管理機制。

Considering that no unified accounting standards for computing power energy consumption and indirect emissions have yet been formulated in the medical AI industry, and we are in a development stage of technological iteration and commercialisation, the relevant environmental data systems and indicator targets are still being continuously improved. For environmental KPIs that have not been disclosed or for which specific targets have not yet been set, we have provided explanations in accordance with the "Comply or Explain" principle, and will gradually enhance relevant disclosures when conditions permit.

考慮到醫療AI行業尚未形成統一的算力能耗及間接排放核算標準，且我們處於技術迭代與商業化落地的發展階段，相關環境數據體系及指標目標仍在持續完善中。對於尚未披露或暫未設定具體目標的環境KPI，我們已按照「不遵守就解釋」原則作出說明，並將在條件成熟時逐步完善相關披露。

Meanwhile, we also pay attention to the potential environmental benefits brought about by the AI-enabled healthcare model. Replacing part of repetitive medical procedures with algorithms can effectively reduce the use of medical consumables and the generation of related waste. Remote AI-assisted diagnosis helps reduce unnecessary travel by patients and medical personnel, thereby cutting carbon emissions. Large-scale health screening and early intervention also contribute to lowering resource consumption associated with advanced treatment of chronic diseases.

同時，我們亦關注人工智能醫療模式所帶來的潛在環境效益。通過以算法替代部分重複性醫療操作，可有效減少醫療耗材使用及相關廢棄物產生；依託遠程AI輔助診斷，可降低患者及醫護人員不必要的出行，從而減少碳排放；大規模健康篩查及早期干預亦有助於降低慢性疾病晚期治療所帶來的資源消耗。

Going forward, we will continue to improve our environmental management system, gradually enhance the completeness and transparency of relevant data disclosures, and keep abreast of climate-related regulatory developments, including international frameworks such as TCFD and ISSB. In line with our business development pace, we will progressively advance the establishment and management of environmental KPIs and related targets. On the basis of ensuring data authenticity and stability of measurement methodologies, we will continuously enhance resource use efficiency, promote low-carbon operations, and achieve synergy between corporate development and environmental protection.

未來，我們將持續完善環境管理體系，逐步提升相關數據披露的完整性與透明度，並緊跟氣候相關監管趨勢（包括TCFD及ISSB等國際框架），結合業務發展節奏，循序推進環境KPI及相關目標的建立與管理，在確保數據真實性及計量方法穩定性的基礎上，持續提升資源使用效率，推動低碳運營，實現企業發展與環境保護的協同共進。

9.1 Resource Consumption and Emission Management

9.1 資源消耗與排放管理

Our energy and resource consumption is mainly concentrated in the following three aspects: water resources consumed by toilet water and drinking water; electric energy consumed by daily office and factory workshop lighting, air conditioning and other equipment; copy paper consumed by daily office and production orders.

我們的能源及資源消耗主要集中在以下三個方面：衛生間用水及飲用水消耗的水資源；日常辦公及工廠車間照明、空調等設備消耗的電能；日常辦公及生產制單消耗的復印紙。

Energy Consumption

能源消耗

We actively advocate employees to save electricity and remind them to turn off the power before holidays. We continuously improve energy efficiency through technological transformation and equipment upgrading.

我們積極倡導員工節約用電，並在節假日前提醒員工關閉電源。通過技術改造、設備升級等方式持續提升能源使用效率。

Energy Consumption Indicators 能耗指標	2025 Data 2025年數據
Total Electrical Energy Consumption 電能消耗總量	187,585.64 kWh 187,585.64千瓦時
Annual Electrical Energy Consumption per Square Meter of Building Area 每平米建築面積年耗電量	28.33 kWh/square meter 28.33千瓦時／平米
Annual Per Capita Electrical Energy Consumption 人均年耗電量	880.79 kWh/person 880.79千瓦時／人

Water Resource Consumption

Given that medical device manufacturing mainly relies on assembly processes, water consumption is relatively low. We promote the rational use of water resources by strengthening the education of employees' water-saving awareness, cultivating good water-saving habits, and setting water-saving signs in toilets. In 2025, the water supply was stable, meeting the needs of daily production and operation. Our water use mainly comes from municipal tap water, which is used for daily cleaning, sanitation and drinking water needs in the office area, and does not involve high water-consuming processes such as production and manufacturing. Since the water fees of the Beijing office and Shanghai office are uniformly included in the office building property service fee, the water consumption cannot be separately measured and split, and only the Changsha factory can provide independent water meter measurement data. The total independently measurable water resource consumption in 2025 was 1,034.27 cubic meters, and the data source is the tap water payment record of the Changsha factory.

水資源消耗

我們鑒於醫療器械製造主要依賴組裝工藝，用水量相對較低。我們透過加強員工節水意識教育、培養良好節水習慣、在衛生間設置節水標識等方式，推動水資源合理利用。2025年，水源供應穩定，滿足日常生產運營需求。我們用水主要來自市政自來水，用於辦公區域日常清潔、衛生及飲水需求，不涉及生產製造等高耗水工藝。由於北京辦公室、上海辦公室之水費統一包含於寫字樓物業服務費中，無法單獨計量與分拆用水量，僅長沙工廠可提供獨立水錶計量數據。2025年度我們可獨立計量之水資源消耗總量為1,034.27立方米，數據來源為長沙工廠自來水繳費記錄。

We have established water-saving management measures, posted water-saving prompts in the office area, promoted the use of water-saving appliances, and continuously optimized resource use efficiency.

我們已建立節水管理措施，於辦公區域張貼節水提示、推行節水器具使用，並持續優化資源使用效率。

Waste Management

We are mainly engaged in electronic component assembly business and do not involve the production link of electronic components. The scrapped components generated during the production process are uniformly recycled and disposed of by suppliers, which are not included in the Company's waste statistics.

廢棄物管理

我們主要從事電子器件組裝業務，不涉及電子零部件生產環節，生產過程中產生的零部件報廢均由供應商統一回收及處置，不納入本公司廢棄物統計範圍。

Waste Category **廢棄物類別**	**2025 Generation** **2025年產生量**	**Disposal Method** **處置方式**
Non-hazardous Waste (Industrial Foam)	30 Cubic Meters	Since it is not within the scope of domestic waste disposal, it is entrusted to a professional qualified third-party organization for paid and compliant disposal
無害廢棄物(工業泡棉)	30立方米	因不屬於生活垃圾處置範圍，委託具備專業資質的第三方機構付費合規處置
Non-hazardous Waste (Packaging Film Bags, etc.)	A Small Amount	Entrusted to a regular waste recycling unit for recycling and disposal
無害廢棄物(包裝薄膜袋等)	少量	交由正規廢品回收單位回收處理

Note:

The Company's production process is only electronic component assembly, which does not involve high-risk waste such as chemical reagents and radioactive substances. Industrial foam, as an industrial auxiliary material that does not meet the domestic waste disposal standards, has all been entrusted to professional institutions for paid treatment; other recyclables such as packaging films are handled by regular recyclers. The disposal of hazardous waste is entrusted to third-party waste disposal institutions with corresponding qualifications, and relevant contracts and disposal certificates are retained for inspection. In 2025, the Company had no waste irregular disposal or environment-related violations. Office waste is not separately counted due to scattered generation and no centralized statistical conditions, and its disposal complies with the requirements of municipal waste classification to ensure compliance.

Furthermore, the primary packaging materials for our products are cartons and cushioning materials, both of which are recyclable. During the Reporting Period, the Company has not yet established an independent statistical mechanism for packaging material weight. It plans to establish a tracking ledger for packaging material usage in the 2026 reporting period and disclose quantitative data in the next ESG report.

9.2 Greenhouse Gas Emission Data Disclosure

In accordance with the requirements of clause A1.2 of the Stock Exchange, we disclose the greenhouse gas emission situation in 2025 as follows. Given our business nature (focusing on algorithm software and supplemented by hardware assembly), the main emission source is purchased electricity (Scope 2) in offices and factory premises, while direct fuel consumption (Scope 1) of owned vehicles and production equipment is relatively limited.

說明：

公司生產過程僅為電子器件組裝，不涉及化學試劑、放射性物質等高危廢棄物。工業泡棉因屬於工業輔料且不適用生活垃圾處置標準，已全數委託專業機構付費處理；其餘包裝薄膜等可回收物由正規回收商處理。有害廢棄物處置均委託具相應資質的第三方廢棄物處理機構，並留存相關合同及處置憑證備查。2025年度，公司未發生任何廢棄物違規處置或環境相關違規事件。辦公垃圾因產生量零散、無集中統計條件，未單獨統計，其處置均遵循市政垃圾分類相關要求，確保合規。

此外，我們的產品包裝材料主要為紙箱及緩衝材料，均為可回收材質。本報告期內，公司暫未建立獨立的包裝材料重量統計機制，計劃於2026年報告期建立包裝材料用量追蹤台賬，並於下一份ESG報告中披露量化數據。

9.2 溫室氣體排放數據披露

按照聯交所A1.2條款要求，我們對2025年溫室氣體排放情況作出如下披露。鑑於我們業務屬性（以算法軟件為核心，硬件組裝為輔），主要排放源為辦公及工廠場所的外購電力（範圍二），自有車輛及生產設備的直接燃料消耗（範圍一）相對有限。

Pursuant to paragraph 29(a) of Part D of the ESG Reporting Code, the measurement of greenhouse gas ("**GHG**") emissions of the Company has been conducted in strict accordance with the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004). During the Reporting Period, the Company did not receive any separate measurement requirements promulgated by the competent authorities, and accordingly no other measurement standards were adopted.

依據聯交所ESG報告守則第D部分第29(a)段要求，本公司溫室氣體排放計量嚴格遵循《溫室氣體議定書：企業會計與報告標準(2004)》執行，本期內未收到管轄機關另行規定的計量要求，故未採用其他計量標準。

In compliance with paragraph 29(b)(i) of the ESG Reporting Code, the measurement methodologies, input data and assumptions in respect of the current GHG emissions measurement are set out below:

根據ESG報告守則第29(b)(i)段要求，本次溫室氣體排放計量方法、輸入資料及假設如下：

- **Measurement methodologies**: Scope 1 emissions are measured using the fuel consumption method. Following an inventory check, the Company has no direct emission sources, and therefore Scope 1 emissions are calculated as zero. Scope 2 emissions are measured using the electricity consumption method, whereby emissions are calculated based on purchased electricity consumption for office and factory premises, combined with the average carbon emission factor of the local power grid. Scope 3 emissions are currently under collation and calculation, and the Company intends to adopt commonly used industry calculation methodologies, which will be gradually refined in due course.

- **計量方法**：範圍一排放采用「燃料消耗法」，經盤查本公司無直接排放源，故排放量核算為0；範圍二排放采用「電力消耗法」，依據辦公及工廠場所外購電力用量，結合當地電網平均碳排放因子計算排放量；範圍三排放目前處於梳理核算階段，擬採用行業通用核算方法，後續逐步完善。

- **Input data**: Such data mainly include invoices for purchased electricity for the year 2025, carbon emission factor data for the power grid published by the Ministry of Ecology and Environment of the People's Republic of China in 2024, and records relating to the identification of Scope 3 emission sources. No relevant input data was generated for Scope 1 as no emission sources exist.

- **Measurement assumptions**: It is assumed that electricity transmission losses during the period were at industry average levels without abnormal fluctuations; that the carbon emission factor corresponding to purchased electricity remained consistent throughout the year with no material adjustments; that the inventory of Scope 1 emission sources was comprehensive and complete, with data reasonably determined based on actual operating scenarios; and that the identification of Scope 3 emission sources was comprehensive, with subsequent calculation methodologies to comply with industry standards.

- **輸入資料**：主要包括2025年度外購電力繳費單據、中國生態環境部2024年公佈的電網碳排放因子數據，以及範圍三排放源識別相關記錄；範圍一因無排放源，未產生相關輸入資料。

- **計量假設**：假設本期內電力傳輸損耗處於行業平均水平，未發生異常波動；假設外購電力對應碳排放因子全年保持一致，無重大調整；假設範圍一排放源盤查全面、無遺漏，數據基於實際運營場景合理確認；假設範圍三排放源識別全面，後續核算方法符合行業標準。

Greenhouse Gas Emission Data (2025)

溫室氣體排放數據（2025年度）

Scope 1: Direct Emissions

範圍一：直接排放

We are mainly engaged in electronic component assembly and related office operations, and are not equipped with official vehicles, boilers, combustion equipment and other direct greenhouse gas emission sources, nor are there any fixed combustion facilities. After inventory, the Scope 1 greenhouse gas emissions in 2025 were 0 tons CO_2e.

我們主要從事電子器件組裝及相關辦公運營，未配備公務車輛、鍋爐、燃燒設備及其他直接溫室氣體排放源，亦無固定燃燒類設施。經盤查，2025年度範圍一溫室氣體排放量為0噸CO_2e。

Note on Data Limitations: This year is the first systematic greenhouse gas inventory. The Company has no obvious direct emission sources, and the relevant data are reasonably confirmed based on the actual operation scenarios. The inventory mechanism will be continuously improved in the future.

數據局限性說明：本年度為首次系統性溫室氣體盤查，公司無明顯直接排放源，相關數據基於實際運營場景合理確認，後續將持續完善盤查機制。

Scope 2: Energy Indirect Emissions (Market-Based Method)

範圍二：能源間接排放（市場基準法）

Main Source: Purchased electricity for Beijing Office, Shanghai Office and Changsha Factory.

主要來源：北京辦公室、上海辦公室及長沙工廠外購電力。

2025 Electricity Consumption: 187,585.64 kWh

2025年電力消耗：187,585.64千瓦時

Reference Emission Factor: Approximately 0.5703 kg CO_2e/kWh for North China Power Grid (Source: 2024 Data from the Ministry of Ecology and Environment of China)

參考排放因子：約0.5703 kgCO_2e/kWh（來源：中國生態環境部2024年數據）

Estimated Scope 2 Emissions: Approximately 107 tons CO_2e

範圍二排放估算值：約107噸CO_2e

Emission Intensity: Approximately 0.50 tons CO_2e per employee

排放強度：約0.50噸CO_2e／名員工

Scope 3: Value Chain Emissions (Under Assessment)

範圍三：價值鏈排放（評估中）

We have identified the main sources of Scope 3 emissions as: hardware component procurement, business travel, employee commuting, and the use phase of sold equipment. Scope 3 emissions during the Reporting Period are in the stage of data sorting and accounting, and quantification has not been completed yet.

我們已識別範圍三排放主要來源為：硬體零部件採購、商務差旅、員工通勤、已售設備使用階段。報告期內範圍三排放處於數據梳理與核算階段，暫未完成量化。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

The Company will complete the comprehensive accounting of Scope 3 in 2027, and formally disclose the relevant data in the 2027 ESG Report. In the future, we will continuously optimize the accounting method and data quality, and gradually establish a full value chain emission reduction management system.

本公司將於2027年度完成範圍三全面核算工作，並於2027年ESG報告中正式披露相關數據，後續持續優化核算方法與數據品質，逐步建立全價值鏈減排管理體系。

Pursuant to paragraph 29(b)(ii) of the ESG Reporting Code, the reasons for selecting the aforesaid measurement methodologies and assumptions are as follows: First, the "Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004)" is a globally recognised standard for corporate greenhouse gas measurement. The "electricity consumption method" stipulated therein is applicable to the Company's business nature, which is software-centric supplemented by hardware assembly, with straightforward calculation logic and high operability. Second, all input data adopted are derived from the Company's official payment documents and government-published data, ensuring data authenticity and traceability. Third, the relevant assumptions are consistent with the Company's actual business operations without any inconsistency with actual operations, and can objectively reflect the actual level of the Company's greenhouse gas emissions, while taking into account the phased characteristics of Scope 3 emission calculation.

根據ESG報告守則第29(b)(ii)段要求，選擇上述計量方法及假設的原因如下：一是《溫室氣體議定書：企業會計與報告標準(2004)》為全球通用的企業溫室氣體計量標準，其規定的「電力消耗法」等適用於本公司以軟件為核心、輔以硬件組裝的業務屬性，計算邏輯簡潔、可操作性強；二是所采用的輸入資料均來源於公司正式繳費單據及政府公佈數據，確保數據的真實性、可追溯性；三是相關假設符合本公司業務運營實際，未出現與實際運營相悖的情形，能夠客觀反映公司溫室氣體排放真實水平，同時兼顧範圍三核算的階段性特點。

Pursuant to paragraph 29(b)(iii) of the ESG Reporting Code, there were no changes to the measurement methodologies, input data and assumptions for the Company's greenhouse gas emissions during the current period (the year 2025). The main reasons are that there were no material adjustments to the Company's business structure and operating model during the period, no new direct emission sources were added, no material changes occurred in the sources of purchased electricity and local carbon emission factors, and Scope 3 emissions remained under collation without any adjustment to calculation methodologies. As the original measurement methodologies and assumptions continued to meet disclosure requirements, no adjustments were necessary.

根據ESG報告守則第29(b)(iii)段要求，本期內（2025年度），本公司溫室氣體排放的計量方法、輸入資料及假設未發生任何變更。主要原因為本期內公司業務架構、運營模式未發生重大調整，無新增直接排放源，外購電力來源及當地碳排放因子未出現重大變動，範圍三仍處於梳理階段未涉及核算方法調整，原有計量方法及假設仍能滿足披露要求，故無調整必要。

Source of emission factors (paragraph 29(c) of the ESG Reporting Code): In calculating the Company's Scope 2 greenhouse gas emissions (energy indirect emissions), the emission factors adopted are the national and regional power grid average emission factors published by the Ministry of Ecology and Environment of the People's Republic of China in the Notice on Managing Greenhouse Gas Emissions Reporting for Enterprises in the National Carbon Emission Rights Trading Market for 2023 and 2024 (issued in 2024). Specifically, the emission factor of approximately 0.5703 kgCO_2e/ kWh applies to the Company's Beijing and Shanghai offices (North China and East China power grids), and the contemporaneously published Central China regional power grid emission factor is applied to the Changsha factory. The above data are officially published by the Government and are therefore authoritative and traceable.

排放因數來源（ESG報告守則第29(c)段）：本公司在計算範圍二溫室氣體排放量（能源間接排放）時，所採用的排放因數來源為中華人民共和國生態環境部於2024年發佈的《關於做好2023、2024年度全國碳排放權交易市場企業溫室氣體排放報告管理有關工作的通知》附件中公佈的全國及區域電網平均排放因數。具體而言，本公司北京及上海辦公室（華北、華東電網）適用排放因數約為0.5703 kgCO_2e/kWh，長沙工廠（華中電網）亦採用同期公佈的華中區域電網排放因數。上述數據為政府官方公佈數據，具有權威性及可追溯性。

Source of global warming potential (GWP) values (paragraph 29(d) of the ESG Reporting Code): In the course of converting greenhouse gas emissions into carbon dioxide equivalents (CO_2e), the Company adopts the 100-year global warming potential (GWP100) values published in the Sixth Assessment Report (AR6, 2021) of the Intergovernmental Panel on Climate Change (IPCC) as the conversion basis. Given that the Company's primary emission source is purchased electricity (predominantly CO_2), the choice of GWP values has a limited practical impact on the emissions figures for the current reporting period. However, upon commencing Scope 3 accounting in subsequent reporting periods, the Company will consistently apply the AR6 GWP100 values as a long-term comparability benchmark.

全球增溫潛勢(GWP)數值來源(ESG報告守則第29(d)段):本公司在溫室氣體排放換算過程中,採用政府間氣候變化專門委員會(IPCC)第六次評估報告(AR6,2021年)中公佈的100年全球增溫潛勢(GWP100)數值作為換算基準,將各類溫室氣體折算為二氧化碳當量(CO_2e)。鑒於本公司主要排放源為外購電力(以CO_2為主),上述GWP值的選擇對本報告期排放量的實質影響有限,但本公司將在後續報告期範圍三核算啟動後,統一沿用AR6 GWP100數值作為長期一致性基準。

9.3 Governance of Addressing Climate Change

9.3 應對氣候變化的治理

In accordance with the climate-related disclosure requirements of the ESG Reporting Code (with reference to the IFRS S2 framework), we have established a clear governance and oversight mechanism for climate-related matters:

按照聯交所《環境、社會及管治報告守則》氣候相關披露要求(參照IFRS S2框架),我們已就氣候事宜建立明確的治理監督機制:

At the Board level: The Board of Directors of the Company bears ultimate oversight responsibility for ESG matters. As a committee under the Board, the ESG Committee assumes specific oversight responsibilities for climate-related risks and opportunities (the ESG Committee disclosed in other sections of this ESG Report also undertakes corresponding oversight and implementation duties in respect of the relevant ESG affairs).

董事會層面:本公司董事會對ESG事宜負有最終監督責任,環境、社會及管治委員會作為董事會下屬機構,承擔氣候相關風險與機遇的具體監督職責(本ESG報告其他部分所披露的環境、社會及管治委員會,亦在對應ESG事務中承擔相應監督及推進職責)。

The terms of reference of the ESG Committee and applicable policies clearly set out its core responsibilities in relation to ESG affairs, including but not limited to oversight of climate-related risks and opportunities, review of climate response strategies, and tracking of emission reduction targets, in strict compliance with the note to paragraph 19(a) of Part D of the ESG Reporting Code. The ESG Committee holds at least one dedicated meeting on climate issues each year to review climate risk assessment reports and progress against emission reduction targets. The Board has authorised management to formulate and follow up on the implementation of climate response strategies.

環境、社會及管治委員會的職權範圍及相關適用政策中，已清晰載明其在ESG事務方面的核心職責，包括但不限於氣候相關風險與機遇的監督、氣候應對策略的審議、減排目標的跟蹤等，嚴格遵循聯交所ESG報告守則第D部分第19(a)段註釋要求。環境、社會及管治委員會每年至少召開一次氣候議題專項審議，審閱氣候風險評估報告及減排目標進展；董事會授權管理層制定氣候應對策略並跟進執行。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Pursuant to paragraph 19(a)(iii) of Part D of the ESG Reporting Code, the ESG Committee incorporates climate-related risks and opportunities as core considerations in overseeing the Company's strategies, material transaction decisions, risk management procedures and relevant policies. In formulating strategies, the ESG Committee assesses the impact of climate factors on the Company's long-term development strategy with reference to industry climate policy directions, carbon market trends and the requirements of the IFRS S2 Framework, balancing investment in climate emission reduction and sustainable development opportunities to ensure alignment between strategies and climate governance objectives. In material transaction decisions, for transactions involving AI infrastructure upgrades, supply chain collaborations or other matters that may give rise to significant climate impacts, the ESG Committee focuses on assessing climate risks (such as incremental carbon emissions and compliance risks) and potential opportunities (such as benefits from the application of low-carbon technologies), and formulates a balanced assessment report for consideration by the Board. In overseeing risk management procedures and policies, the ESG Committee regularly reviews climate risk identification, assessment and response processes, and optimises risk prevention and control measures to ensure that relevant policies effectively cover climate-related risk points.

根據聯交所ESG報告守則第D部分第19(a)(iii)段要求，環境、社會及管治委員會在監督本公司策略、重大交易決策和風險管理程序及相關政策的過程中，將氣候相關風險和機遇納入核心考量範圍：在策略制定環節，結合行業氣候政策導向、碳市場發展趨勢及IFRS S2框架要求，評估氣候因素對公司長期發展戰略的影響，權衡氣候減排投入與可持續發展機遇的平衡，確保策略與氣候治理目標一致；在重大交易決策中，對涉及AI基礎設施升級、供應鏈合作等可能產生顯著氣候影響的交易，重點評估其氣候風險（如碳排放增量、合規風險）與潛在機遇（如低碳技術應用收益），形成權衡評估報告提交董事會審議；在風險管理程序及政策監督中，定期審查氣候風險識別、評估及應對流程，優化風險防控措施，確保相關政策能夠有效覆蓋氣候相關風險點。

Pursuant to paragraphs 19(a)(iv) and 35 of Part D of the ESG Reporting Code, the Company has incorporated climate-related performance indicators into the remuneration policies of relevant personnel. For members of the ESG Committee, the performance of climate-related oversight duties and the effectiveness of supervising the progress of emission reduction targets form important parts of annual performance evaluation, which are linked to members' duty allowances. For the management and heads of relevant functional departments (such as the technology department and human resources department), indicators including the quality of climate risk assessment completion, progress in advancing low-carbon pathways and effectiveness of climate compliance management are incorporated into the annual performance appraisal system. Appraisal results directly affect remuneration adjustments and promotion assessments, thereby enhancing the emphasis placed by relevant personnel on climate governance and facilitating the implementation of climate-related responsibilities.

根據聯交所ESG報告守則第D部分第19(a)(iv)段及第35段要求，本公司已將氣候相關績效指標納入相關人員薪酬政策：對於環境、社會及管治委員會委員，將氣候相關監督職責履行情況、減排目標推進監督成效作為年度履職評價的重要內容，與委員履職津貼掛鉤；對於管理層及相關執行部門（如技術部、人力資源部）負責人，將氣候風險評估完成質量、低碳化路徑推進進度、氣候合規管理成效等指標納入年度績效考核體系，考核結果直接影響薪酬調整及晉升評定，以此強化相關人員對氣候治理工作的重視程度，推動氣候相關職責落地。

At the management level: The Board Secretary coordinates the assessment of climate-related financial risks. The R&D team evaluates the energy consumption of algorithms and the low-carbon transition pathway of AI infrastructure. The Human Resources, Legal and Compliance departments jointly promote climate compliance management.

管理層層面：由董事會秘書統籌協調氣候相關財務風險評估，由研發團隊負責評估算法能耗及AI基礎設施的低碳化路徑；人力資源及法務合規部門共同推進氣候合規管理。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Reporting mechanism: Management reports annually to the ESG Committee on climate-related risks, emission reduction progress and resource consumption. Following review by the Committee, such information is included in the annual ESG Report for external disclosure, ensuring a transparent and complete governance chain.

報告機制：管理層每年就氣候相關風險、減排進展及資源耗用情況向環境、社會及管治委員會匯報，由委員會審議後納入年度ESG報告對外披露，確保治理鏈條透明完整。

To ensure the Board and the ESG Committee possesses the necessary expertise to oversee climate-related matters, we have adopted the following measures:

為確保董事會及環境、社會及管治委員會具備監督氣候相關事宜的必要能力，我們採取以下措施：

- Provide at least one dedicated training or briefing session annually for members of the ESG Committee on climate-related topics, including industry policy updates, carbon market developments and interpretation of the IFRS S2 framework.
- 每年至少為環境、社會及管治委員會委員提供一次氣候相關議題（包括行業政策動態、碳市場進展及IFRS S2框架解讀）的專項培訓或簡報；
- Before submitting climate risk reports to the ESG Committee, management engages professional consultants with expertise in climate-related financial analysis to provide technical support, bridging any gaps in members' quantitative climate analysis capabilities.
- 管理層在向環境、社會及管治委員會提交氣候風險報告前，委託具備氣候財務分析能力的專業顧問提供技術支持，以彌補委員在氣候量化分析方面的專業差距；
- We plan to assess the introduction of independent non-executive Directors with climate-related professional backgrounds in 2026 to further enhance the Board's climate governance capabilities.
- 我們計劃於2026年評估是否引入具備氣候相關專業背景的獨立非執行董事，以持續提升董事會氣候治理能力。

9.4 Strategies for Addressing Climate Change

The World Economic Forum's Global Risks Report indicates that environmental risks, closely linked to climate change, remain the top concern in terms of likelihood and impact over the next decade. Addressing the severe challenges posed by climate change and developing a low-carbon economy have become a shared consensus of the international community. For enterprises, climate change presents both challenges and opportunities. Integrating climate change response into corporate strategy and daily management is critical to long-term sustainable development.

Although our operations in 2025 and prior years had no material impact on the environment and natural resources, we remain highly attentive to climate change issues and have incorporated climate response into operational management; focus on energy consumption optimisation in the short term; promote the application of low-carbon technologies in the medium term; and achieve a continuous decline in operational carbon footprint in the long term, gradually transitioning to a low-carbon operating model.

Specific measures are as follows:

- Encourage employees to work from home during severe weather to reduce health and safety risks associated with commuting.
- Continuously monitor sea level rise trends and climate change response developments, and actively explore low-carbon development pathways suited to industry characteristics.

9.4 應對氣候變化的策略

世界經濟論壇發布的《全球風險報告》指出，從未來十年風險的發生概率和影響來看，環境風險仍是首要問題，與氣候變化緊密相關。應對氣候變化帶來的嚴峻挑戰、發展低碳經濟已成為國際社會共識。對企業而言，氣候變化既帶來挑戰，亦蘊含機遇 — 如何將應對氣候變化納入企業經營戰略和日常管理，是關係到企業長久持續發展的重要議題。

我們於2025年及既往的經營對環境及天然資源並無重大影響，但仍高度關注氣候變化議題，將應對氣候變化納入運營管理考量，短期聚焦能耗優化，中期推進低碳技術應用，長期實現運營層面碳足跡持續下降，逐步向低碳運營模式轉型。

具體舉措如下：

- 在遇到惡劣天氣時，倡導員工居家辦公，降低員工出行可能面臨的健康安全風險；
- 持續追蹤海平面上升趨勢及氣候變化應對相關動態，積極探索適合行業特點的低碳發展路徑；

- Assess climate-related physical risks (e.g., disruptions to supply chains and data centre operations caused by extreme weather) and transition risks (e.g., impacts of carbon pricing policies on operating costs) to support climate-related decision-making.

- 評估氣候相關實體風險（如極端天氣影響供應鏈和數據中心運營）和轉型風險（如碳定價政策對運營成本的影響），為氣候相關決策提供依據。

Climate risk management process：We have integrated climate risks into the Group's overall risk management system and established a full-cycle management mechanism of "Identification — Assessment — Response — Monitoring — Review", with specific disclosures set out below:

氣候風險管理流程：我們已將氣候風險納入公司整體風險管理體系，建立「識別 — 評估 — 應對 — 監控 — 複盤」全流程管理機制，具體披露如下：

Input data and parameters adopted (paragraph 27(a)(i) of the ESG Reporting Code): Input data mainly include climate-related policy documents issued by the Ministry of Ecology and Environment of the People's Republic of China, industry climate risk research reports, the Company's operating data (such as electricity consumption and supply chain information), and climate risk assessment data provided by third-party professional institutions. The programme covers all of the Company's office premises, production factories, supply chain cooperation links and data centre operations, ensuring full coverage of all core business areas potentially affected by climate risks.

採用的輸入資料及參數（ESG報告守則第27(a)(i)段）：輸入資料主要包括中國生態環境部發佈的氣候相關政策檔、行業氣候風險研究報告、公司運營數據（如電力消耗、供應鏈資訊）、第三方專業機構提供的氣候風險評估數據；程式所涵蓋的業務範圍包括公司所有辦公場所、生產工廠、供應鏈合作環節及數據中心運營，確保覆蓋氣候風險可能影響的全部核心業務領域。

Use of climate-related scenario analysis to inform identification of climate-related risks (paragraph 27(a)(ii) of the ESG Reporting Code): The Company systematically integrates the conclusions of the climate scenario analysis conducted in Section 9.5 (the 1.5°C Orderly Transition Scenario and the 3°C High-Emission Physical Risk Scenario) into its climate risk identification process. Under the 1.5°C scenario, the Company focuses on cost pressures arising from carbon pricing policies and procurement risks resulting from suppliers' low-carbon

氣候情景分析對風險識別的指導作用（ESG報告守則第27(a)(ii)段）：我們將第9.5節開展的氣候情景分析（1.5°C有序轉型情景及3°C高排放物理風險情景）的結論系統性地回饋至氣候風險識別流程。在1.5°C情景下，重點關注碳定價政策帶來的成本壓力及供應商低碳轉型引發的採購風險，並據此將上述風險列入公司風險台賬予以跟蹤管理；在3°C情景下，

transition, and has accordingly included such risks in its risk register for ongoing tracking and management. Under the 3°C scenario, the Company focuses on the physical impact of extreme weather events on the stability of its supply chain and data centre operations, and has incorporated relevant emergency response mechanism sintoit sannual risk management plan. The Company plans to continue to dynamically update its risk register using the conclusions of scenario analyses in subsequent reporting periods, ensuring that climate risk identification remains aligned with the results of scenario analyses.

重點關注極端天氣對供應鏈及數據中心運營穩定性的物理影響，並將相關應急回應機制納入年度風險管控計劃。我們計劃在後續報告期內持續利用情景分析結論動態更新風險台賬，確保氣候風險識別與情景分析結果保持一致。

Assessment of climate-related risks (paragraph 27(a)(iii) of the ESG Reporting Code): The Company adopts a qualitative assessment methodology, evaluating identified climate risks along two dimensions: "magnitude of impact" (rated High/Medium/Low) and "likelihood of occurrence" (rated High/Medium/Low). Factors considered in assessing magnitude of impact include the potential scope of operational disruption (number of office premises, factories or data centres affected), expected remediation costs and potential revenue impact. Factors considered in assessing likelihood of occurrence include the trajectory of relevant policy and regulatory developments, frequency projections drawn from industry climate risk research reports, and climate risk assessment data provided by third-party professional institutions. Building on the above qualitative assessment framework, the Company plans to introduce quantitative financial impact measurement (including potential cost variation ranges under scenario simulations) in 2026 to further enhance the precision of its assessments.

氣候相關風險的評估方法（ESG報告守則第27(a)(iii)段）：我們採用定性評估方法，從「影響程度」（高中低三級）及「發生可能性」（高中低三級）兩個維度對已識別的氣候風險進行綜合評級。影響程度參考因素包括：潛在運營中斷範圍（所涉辦公場所、工廠或數據中心數量）、預期修復成本及對收入的潛在影響；發生可能性參考因素包括：政策法規的演變趨勢、行業氣候風險研究報告中的頻率預測及第三方氣候風險評估數據。在上述定性評估框架的基礎上，我們計劃於2026年引入量化財務影響測算（包括情景模擬下的潛在成本變動區間），進一步增強評估的精確性。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Prioritisation of climate-related risks against other types of risks (paragraph 27(a)(iv) of the ESG Reporting Code): Within the Company's overall risk management system, climate-related risks are classified as medium priority, ranking above general operational risks but below core risks such as financial risks and compliance risks. Among them, material climate risks including operational disruption caused by extreme weather and rising costs arising from carbon pricing policies are categorised as high priority and managed in parallel with core risks to ensure key risks are prioritised for treatment.

氣候相關風險與其他類型風險的優次排列(ESG報告守則第27(a)(iv)段):在公司整體風險管理體系中,將氣候相關風險列為中等優先順序,優先於一般運營風險,但低於財務風險、合規風險等核心風險;其中,極端天氣導致的運營中斷、碳定價政策帶來的成本上升等重大氣候風險,列為高優先順序,與核心風險同步管控,確保重點風險得到優先處置。

Monitoring of climate-related risks (paragraph 27(a)(v) of the ESG Reporting Code): The Company has established the following climate risk monitoring mechanism:

氣候相關風險的監察機制(ESG報告守則第27(a)(v)段):我們已建立以下氣候風險監察機制:

- **Routine monitoring:** Led by the ESG Committee, climate risk tracking is included as a standing item on the Committee's quarterly agenda, with quarterly reviews of climate-related KPIs, including energy consumption, carbon emission intensity and risk register updates;

- **日常監察**:由公司環境、社會及管治委員會負責,將氣候風險跟蹤列入委員會季度議程,每季度審閱氣候相關KPI(包括能源消耗、碳排放強度及風險台賬更新情況);

- **Annual review:** In conjunction with the annual climate scenario analysis, a comprehensive review of all items in the risk register is conducted to assess whether there have been material changes in the assessed magnitude of impact, with risk response strategies adjusted accordingly;

- **專項審查**:每年結合氣候情景分析,對風險台賬中已列專案進行全面審查,評估風險影響程度是否發生實質性變化,並視情況調整風險應對策略;

- **Incident response:** In the event of a significant climate-related operational incident (such as a supply chain disruption caused by extreme weather), management is required to submit a special report to the ESG Committee within 30 business days after the incident, and to initiate an emergency plan review procedure.

- **事件回應**:如發生與氣候相關的重大運營事件(如極端天氣導致的供應鏈中斷),由管理層於事件後30個工作日內向環境、社會及管治委員會提交專項報告,並啟動應急預案復盤程式。

Changes in climate risk management processes compared with the previous reporting period (paragraph 27(a)(vi) of the ESG Reporting Code): In the previous reporting period (2024), the Company only conducted preliminary climate risk identification without establishing a complete management process. In 2025, we refined the full-cycle management mechanism by adding risk assessment, response, monitoring and review procedures, introduced qualitative assessment methodologies, defined responsible parties for each stage, and plan to enhance the quantitative assessment system in 2026 to further improve the scientificity and effectiveness of risk management. Meanwhile, the ESG Committee has been assigned the leading and coordinating role to strengthen the professionalism of risk control.

與上一個匯報期相比，氣候風險管理流程的變化（ESG報告守則第27(a)(vi)段）：上一個匯報期（2024年）僅初步開展氣候風險識別工作，未建立完整的管理流程；2025年，我們完善了全流程管理機制，新增風險評估、應對、監控及複盤環節，引入定性評估方法，明確各環節責任主體，並計劃於2026年完善定量評估體系，進一步提升風險管理的科學性和有效性；同時，新增環境、社會及管治委員會牽頭統籌職責，強化風險管控的專業性。

Processes for identification, assessment, prioritisation and monitoring of climate-related opportunities (paragraph 27(b) of the ESG Reporting Code): We has established a systematic process for managing climate-related opportunities, covering the following four stages:

氣候相關機遇的識別、評估、優先順序釐定及監察流程（ESG報告守則第27(b)段）：我們已建立系統化的氣候相關機遇管理流程，主要涵蓋以下四個環節：

- **Identification:** Drawing on the conclusions of climate scenario analyses (the 1.5°C Orderly Transition Scenario and the 3°C High-Emission Physical Risk Scenario), the Company identifies climate-related opportunities that may have a positive impact on its business model, strategy and financial planning. Under the 1.5°C scenario, the Company has identified the following opportunities: growing demand for AI-assisted diagnostic products driven by low-carbon healthcare policy incentives; potential access to preferential financing through green technology finance policies; and the inherent low-carbon attributes of AI products aligning with the decarbonisation objectives of healthcare systems,

- **識別**：結合氣候情景分析（1.5°C有序轉型情景及3°C高排放物理風險情景）的結論，識別可能對公司業務模式、戰略及財務規劃產生積極影響的氣候相關機遇。在1.5°C情景下，公司重點識別出以下機遇：低碳醫療政策紅利驅動AI輔助診斷產品需求擴大；綠色科技金融支持政策可能為公司提供優惠融資管道；AI產品天然低碳屬性契合醫療系統減排目標，有助於拓展市場份額。在3°C情景下，氣候

supporting market share expansion. Under the 3°C scenario, climate-related public health pressures (such as an increased chronic disease burden arising from extreme weather events) are expected to further drive demand for fundus screening and early-diagnosis AI products.

相關公共健康問題(如極端天氣引發的慢性病負擔加重)將進一步提升對眼底篩查及早期診斷AI產品的市場需求。

- **Assessment:** Following the same assessment framework applied to climate-related risks, identified opportunities are evaluated along two dimensions — "magnitude of impact" (rated High/Medium/Low) and "likelihood of occurrence" (rated High/Medium/Low). The Company also assesses the extent to which its existing capabilities match the opportunity and the resources required to realise it.

- **評估**:參照氣候風險評估框架,從「影響程度」(高中低)及「發生可能性」(高中低)兩個維度對識別出的機遇進行綜合評級,並評估公司現有能力的匹配程度及把握機遇所需的資源投入。

- **Prioritisation:** Opportunities are ranked by their overall assessment rating. Priority is given to those with high impact magnitude and high likelihood of occurrence that align closely with the Company's core AI medical business, and these are incorporated into the annual strategic planning agenda.

- **優先順序釐定**:將機遇按綜合評級排序,優先重點關注影響程度高、發生可能性高,且與公司核心AI醫療業務高度匹配的機遇,並納入年度戰略規劃議程。

- **Monitoring:** The ESG Committee reviews the progress of climate-related opportunities at its quarterly meetings, tracking changes in the external policy environment, assessing whether the pathways to realising such opportunities require adjustment, and incorporating significant changes in opportunities into management reports.

- **監察**:由環境、社會及管治委員會在季度會議上定期審閱氣候相關機遇的進展情況,跟蹤外部政策環境變化,評估機遇實現路徑是否需要調整,並將重大機遇變化納入管理層匯報。

Integration of climate-related risk and opportunity processes into the overall risk management process (paragraph 27(c) of the ESG Reporting Code): We has fully integrated the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities into its overall enterprise risk management framework. The specific manner and extent of this integration are as follows:

Integration approach:

- Unified process management: The identification and assessment of climate-related risks and opportunities follow the same assessment framework applied to all other material risks (including market, operational, technology and legal and compliance risks). The same two-dimensional matrix of "magnitude of impact × likelihood of occurrence" is applied consistently, ensuring that climate factors are comparable and consistent within the overall risk matrix;

- Integrated risk register: Climate-related risk items have been incorporated into the Company's unified enterprise risk register, where they are tracked and managed in parallel with risks in other categories, and are subject to regular joint review by the ESG Committee and management;

氣候相關風險和機遇流程與整體風險管理的整合(ESG報告守則第27(c)段):我們已將氣候相關風險和機遇的識別、評估、優先順序釐定及監察流程,全面融入整體企業風險管理體系,具體整合方式及程度如下:

整合方式:

- 流程統一納管:氣候相關風險和機遇的識別及評估,遵循與公司其他重大風險(包括市場風險、運營風險、技術風險及法律合規風險)相同的評估框架,統一採用「影響程度×發生可能性」雙維度矩陣進行綜合評級,確保氣候因素在整體風險矩陣中具有可比性及一致性;

- 風險台賬整合:氣候相關風險專案已列入公司統一的企業風險台賬,與其他類別風險並列跟蹤、統一管理,並由環境、社會及管治委員會與管理層定期聯合審閱;

- Strategic decision-making input: The conclusions of scenario analyses and climate risk ratings are submitted periodically to management and the Board for deliberation, and serve as an important input into decisions on business model adjustments, resource allocation and medium- to long-term strategic planning.

- 戰略決策輸入：情景分析結論及氣候風險評級結果，定期提交管理層及董事會審議，作為公司業務模式調整、資源配置及中長期戰略規劃的重要輸入依據。

Extent of integration:

整合程度：

- Quarterly climate risk and opportunity monitoring has been aligned with the Company's routine operational risk reviews and incorporated as a standing item on the ESG Committee's quarterly agenda;

- 氣候風險及機遇的季度監察議題，已與公司常規運營風險審查並軌，納入環境、社會及管治委員會季度會議固定議程；

- The escalation mechanism for significant climate risk events is aligned with the Company's existing major risk incident response procedures, without the need for a separate parallel reporting channel;

- 重大氣候風險事件的上報機制，與公司現有重大風險事件回應程式相銜接，無需單獨建立平行的匯報管道；

- At present, the integration of climate processes primarily operates at the levels of identification, assessment and monitoring. As the quantitative assessment system is established in 2026, the Company plans to further incorporate climate financial impact analysis into its annual budget planning and capital expenditure decision-making processes, thereby deepening the extent of integration.

- 目前，氣候流程的整合主要體現在識別、評估和監察層面；隨著2026年定量評估體系的建立，公司計劃進一步將氣候財務影響分析納入年度預算規劃及資本支出決策流程，深化整合程度。

Explanation on carbon emissions disclosure: We have disclosed Scope 1 (direct emissions) and Scope 2 (indirect energy indirect emissions) data relating to our operations. Regarding the non-disclosure of Scope 3 emissions (value chain upstream and downstream emissions), an explanation is provided in accordance with the Stock Exchange's "comply or explain" principle: The Company's business focuses on AI technology research and development and remote assisted diagnosis. Scope 3 emission sources along the value chain are relatively fragmented, and the industry currently lacks unified accounting standards and methodologies, leading to high measurement complexity. We are advancing preparations for Scope 3 emissions accounting with a clear timeline: First half of 2026: complete research and finalisation of Scope 3 accounting methodology. Second half of 2026: conduct the first compilation and calculation of Scope 3 data. 2027: include Scope 3 emissions data in annual ESG disclosure, gradually improving the carbon emission disclosure system.

碳排放相關說明：目前我們已披露運營過程中範圍一（直接碳排放）、範圍二（間接碳排放）相關數據，針對範圍三（價值鏈上下游碳排放）未披露事宜，根據聯交所「不遵守就解釋」規則，說明如下：一是公司業務以AI技術研發、遠程輔助診斷為主，價值鏈上下游碳排放環節相對分散，且目前行業內缺乏統一的範圍三核算標準及方法學，導致核算難度較大；二是我們正推進範圍三碳排放核算籌備工作，明確時間計劃：2026年上半年完成範圍三碳排放核算方法學調研及確定，下半年開展首次範圍三碳排放數據梳理與核算，2027年將範圍三碳排放數據納入年度ESG披露，逐步完善碳排放披露體系。

9.5 Climate Scenario Analysis and Strategic Impact

Definition of time horizons (paragraph 20(d) of the ESG Reporting Code): To assist readers in understanding the timing of the effects of the climate-related risks and opportunities identified by the Company, the time horizons adopted in the Company's climate scenario analysis are defined as follows, and are linked to the Company's strategic planning horizons: Short term: 1–3 years (corresponding to the Company's annual budget plan and three-year rolling business plan); Medium term: 3–10 years (corresponding to the Company' s strategic development plan and mid-term industry development objectives); Long term: over 10 years (corresponding to the national pathways towards achieving "carbon peak" by 2035 and "carbon neutrality" by 2060, as well as the climate evolution pathways covered by IPCC scenarios).

In accordance with the climate-related disclosure requirements of the Environmental, Social and Governance Reporting Guide (the "**ESG Reporting Code**") of the Stock Exchange (with reference to the IFRS S2 and TCFD frameworks), the Company conducted its first climate scenario analysis. Over short-, medium- and long-term time horizons, we assessed potential risks and opportunities under different climate pathways and analysed their impacts on the Company's business model, strategy and financial planning, so as to provide a reliable basis for the Company's strategic decision-making.

9.5 氣候情景分析與策略影響

時間維度定義(ESG報告守則第20(d)段):為便於讀者理解本公司氣候相關風險與機遇的影響時序,本公司對氣候情景分析所採用的時間維度定義如下,並與本公司戰略規劃週期相銜接:短期:1至3年(對應公司年度預算計劃及三年滾動業務規劃);中期:3至10年(對應本公司戰略發展規劃及行業中期發展目標);長期:10年以上(對應2035年「碳達峰」及2060年「碳中和」國家目標路徑,以及IPCC情景所涵蓋的氣候演變路徑)。

按照聯交所《環境、社會及管治報告守則》(以下簡稱「**ESG報告守則**」)氣候相關披露要求(參照IFRS S2及TCFD框架),本公司開展首次氣候情景分析,結合短、中、長期時間維度,評估不同氣候路徑下的潛在風險與機遇,分析其對本公司商業模式、戰略及財務規劃的影響,為本公司戰略決策提供可靠依據。

Scenario 1: 1.5°C Orderly Transition Scenario (IPCC SSP1-1.9)

This scenario assumes the orderly global implementation of the goals of the Paris Agreement and the achievement of net-zero carbon emissions with rapid advancement of low-carbon policies. Its impacts on the Company and corresponding response measures are as follows:

- Opportunities and impacts: Benefiting from the inherent carbon-reduction attributes of our AI-assisted diagnostic technologies, the Company is well positioned to respond to low-carbon healthcare policies and align with industry development trends, thereby gradually expanding relevant businesses and continuously optimising its business model. Expected time horizon of effects: Medium to long term (3–10 years and beyond)

- Transition risks and responses: The Company may face transition risks such as increased costs arising from carbon pricing and procurement pressure driven by suppliers' low-carbon transition. In response to such risks, the Company has formulated corresponding response strategies. Relevant risks are under control, and their impacts will be offset by technological optimisation and infrastructure upgrading in the long run. Expected time horizon of effects: Short to medium term (1–10 years)

情景一：1.5°C有序轉型情景 (IPCC SSP1-1.9)

本情景假設全球有序落實《巴黎協定》目標，實現碳排放淨零，低碳政策快速推進，其對本公司的影響及應對措施如下：

- 機遇及影響：本公司依託AI輔助診斷技術的天然減碳屬性，可有效回應低碳醫療政策，契合行業發展趨勢，逐步拓展相關業務，持續優化商業模式。預計影響時間維度：中期至長期（3–10年及10年以上）

- 轉型風險及應對：本公司可能面臨碳定價帶來的成本增加、供應商低碳轉型帶來的採購壓力等轉型風險；針對上述風險，本公司已制定相應應對策略，相關風險處於可控範圍，長期將通過技術優化及基礎設施升級抵消風險影響。預計影響時間維度：短期至中期（1–10年）

Scenario 2: 3°C High-Emission Physical Risk Scenario (IPCC SSP3-7.0)

This scenario assumes delayed global climate policy implementation, significant temperature rises and frequent extreme weather events. Its impacts on the Company and corresponding response measures are as follows:

- Physical risks and responses: Extreme weather may affect the stability of the Company's operations and supply chain. The Company has established emergency prevention and control measures to mitigate relevant risks and will continue to optimise its supply chain layout and advance disaster-resilient facility retrofitting to enhance operational resilience. Expected time horizon of effects: Medium to long term (over 3 years)

- Opportunities and impacts: Climate-related public health concerns will boost market demand for relevant AI products, driving the optimisation of the Company's product portfolio. In the long run, the Company may expand relevant business areas and form new growth drivers. Expected time horizon of effects: Medium term (3–10 years)

情景二：3°C高排放物理風險情景(IPCC SSP3-7.0)

本情景假設全球氣候政策推進滯後，氣溫升幅顯著，極端天氣頻發，其對本公司的影響及應對措施如下：

- 物理風險及應對：極端天氣可能對本公司運營及供應鏈穩定性造成影響，本公司已建立應急防控措施以降低相關風險，後續將持續優化供應鏈佈局、推進設施抗災改造，提升運營韌性。預計影響時間維度：中期至長期(3年以上)

- 機遇及影響：氣候相關公共健康問題將提升市場對相關AI產品的需求，推動本公司產品結構優化，長期可拓展相關業務領域，形成新的增長動力。預計影響時間維度：中期(3–10年)

9.5.1 Disclosures pursuant to paragraphs 22 and 23 of Part D of the ESG Reporting Code (on a "Comply or Explain" basis)

Changes to business model and resource allocation (paragraph 22(a)(i) of ESG Reporting Code): Having regard to climate-related risks and opportunities, the Company has optimised its business structure, strengthened the deployment of low-carbon-related businesses and allocated resources appropriately to support low-carbon development initiatives, ensuring business development is aligned with climate management objectives.

Adaptation and mitigation efforts (paragraph 22(a)(ii) of ESG Reporting Code): The Company has implemented mitigation and adaptation measures including energy consumption optimisation and risk prevention and control. It will continue to advance low-carbon transition, supply chain optimisation and improvement of risk early warning mechanisms to enhance climate resilience.

Climate-related transition plan (paragraph 22(a)(iii) of ESG Reporting Code): The Company has formulated a climate-related transition plan focusing on three core areas: low-carbon operations, technology empowerment and risk prevention and control. Implementation of the plan relies on R&D investment, supply chain collaboration, policy support and the availability of specialised talents and other relevant factors.

9.5.1根據ESG報告守則第D部分第22段、第23段要求(按「遵守或解釋」原則披露)

業務模式及資源配置變動(對應ESG報告守則第22(a)(i)段):本公司結合氣候相關風險與機遇,優化業務結構,強化低碳相關業務佈局,合理配置資源以支持低碳發展相關工作,確保業務發展與氣候管理目標相匹配。

適應及減緩工作(對應ESG報告守則第22(a)(ii)段):本公司已實施能耗優化、風險防控等減緩及適應相關工作,後續將持續推進低碳轉型、供應鏈優化及風險預警機制完善等相關舉措,提升氣候應對能力。

氣候相關轉型計劃(對應ESG報告守則第22(a)(iii)段):本公司已制定氣候相關轉型計劃,圍繞低碳運營、技術賦能、風險防控三大核心推進,該計劃的實施依賴研發投入、供應鏈協同、政策支持及專業人才保障等相關因素。

Resource support plan (paragraph 22(b) of the ESG Reporting Code): The Company has provided necessary resource support for climate-related initiatives through appropriate budget arrangements and staffing. It will continue to ensure resource investment to steadily implement various climate management measures.

資源保障計劃(對應ESG報告守則第22(b)段):本公司已通過相應的預算安排及人員配置,為氣候相關工作提供必要的資源支持;後續將持續保障資源投入,確保各項氣候管理工作穩步落地。

Progress against previous plans (paragraph 23 of the ESG Reporting Code): Climate-related plans disclosed in the previous reporting period have been gradually implemented. The Company has completed climate risk identification, basic energy consumption optimisation and other relevant work, laying a solid foundation for future climate management.

以往計劃進展(對應ESG報告守則第23段):上一報告期披露的氣候相關計劃已逐步落地,本公司已完成氣候風險識別、基礎能耗優化等相關工作,為後續氣候管理工作的開展奠定堅實基礎。

Explanation (Regarding Paragraphs 22(a)(iv) and 37–40 of the ESG Reporting Code):

說明(關於ESG報告守則第22(a)(iv)段及第37–40段):

In 2025, the Company completed its first climate scenario analysis and greenhouse gas ("GHG") inventory, and is currently in the stage of establishing baseline emission data and assessing the feasibility of setting quantitative targets. The Company has not yet established quantitative climate-related targets (including GHG emission reduction targets) for the following reasons: first, the Reporting Period represents the Company's first systematic GHG inventory, and historical data covering at least one full reporting period is required to scientifically establish a comparable base year and emission reduction targets; second, the quantification of Scope 3 emissions (value chain emissions) is expected to be completed in 2027, and a full-set emission reduction target cannot be formulated until complete value chain emission data is available.

我們2025年度完成首次氣候情景分析及溫室氣體排放盤查,目前正處於建立基準排放數據及評估量化目標可行性的階段。我們暫未設定量化氣候相關目標(包括溫室氣體減排目標),原因如下:一是本報告期為首次系統性溫室氣體盤查,尚需在積累至少一個完整報告期的歷史數據後,方可科學制定具有可比性的基準年及減排目標;二是範圍三排放(價值鏈排放)的核算工作預計於 2027 年完成,在全鏈條排放數據齊備前,難以制定全口徑減排目標。

The Company plans to gradually establish a quantitative climate target system in accordance with the following timeline:

- **2026:** Establish a complete baseline year emission data set;
- **2027:** Complete the first quantification of Scope 3 emissions, and formulate quantitative emission reduction targets for Scope 1 and Scope 2 emissions (including absolute or emission intensity targets) based on baseline data, with reference to IPCC pathways and the national "Dual Carbon" goals to determine the target year;
- **2028:** Explore the formulation of Scope 3 emission reduction targets subject to conditions, and assess the adoption of the Science Based Targets initiative ("SBTi") framework.

本公司計劃按以下時間表逐步建立量化氣候目標體系：

- **2026年**：建立完整的基準年排放數據檔案；
- **2027年**：完成範圍三排放首次核算，並根據基準數據制定範圍一、二排放的量化減排目標（包括絕對量目標或排放強度目標），並參考IPCC路徑與國家「雙碳」目標設定目標年份；
- **2028年**：視條件成熟情況，探索制定範圍三減排目標，並評估是否引入科學碳目標倡議（SBTi）認證框架。

Pending the finalisation of quantitative targets, the Company has proactively promoted low-carbon operations through the following directional measures:

- Continuously optimise energy consumption in office premises. The annual electricity consumption per capita was approximately 880 kWh per person in 2025, which will be gradually reduced through equipment upgrade and behavioural energy conservation;
- Prioritise the procurement of certified high-efficiency equipment;
- Actively participate in research and assessment on the contribution of AI medical technology to the overall carbon emission reduction of the healthcare system.

在量化目標正式確立前，本公司已通過以下方向性措施積極推進低碳運營：

- 持續推進辦公場所能源消耗優化，2025年度人均耗電量約880千瓦時／人，後續將通過設備更新及行為節能逐步降低；
- 優先採購經認證的高能效設備；
- 積極參與AI醫療技術對醫療體系整體碳減排貢獻的評估研究。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

II. Disclosures pursuant to paragraphs 24, 25, 26 and 30 to 34 of Part D of the ESG Reporting Code (on a "Comply or Explain" basis)

二、根據ESG報告守則第D部分第24段、第25段、第26段、第30–34段要求(按「遵守或解釋」原則披露)

Impact of climate-related risks and opportunities on financial position, financial performance and cash flows for the reporting period (paragraph 24(a) of the ESG Reporting Code):

本報告期氣候相關風險及機遇對財務狀況、財務業績及現金流量的影響(ESG報告守則第24(a)段):

Qualitative impact:

定性影響:

The Company's core business primarily comprises AI medical software development and data services, representing an asset-light, low-direct-emission business model with inherent low-carbon attributes. During the reporting period, no significant additional expenditures arose from carbon pricing policy adjustments, extreme weather events or low-carbon transition requirements, and no material asset impairment or business disruption attributable to climate-related factors occurred.

本公司核心業務以AI醫療軟體研發及數據服務為主,屬輕資產、低直接排放的商業模式,具有天然的低碳屬性。報告期內,未發生因碳定價政策調整、極端天氣事件或低碳轉型要求而導致的重大額外成本支出,亦未出現因氣候相關因素引發的重大資產減值或業務中斷情形。

Quantitative impact:

定量影響:

- **Energy costs:** Total energy consumption for the reporting period was 187,585.64 kWh, and the corresponding electricity expenditure accounted for less than 1% of the Company's total operating costs. Fluctuations in climate-related energy prices had a negligible impact on financial performance for the current period.

- **能源成本**:本報告期內,本公司能源消耗總量為187,585.64千瓦時,對應電費支出約佔公司總運營成本的比例低於1%,氣候相關的能源價格波動對當期財務業績的影響可忽略不計。

- **Greenhouse gas emissions:** Scope 2 emissions were approximately 107 tonnes CO_2e, with an emissions intensity of approximately 0.50 tonnes CO_2e per employee; Scope 1 emissions were 0 tonnes CO_2e. Based on the current reference carbon price in the Chinese carbon market (approximately RMB60 per tonne CO_2e), were carbon costs to be fully internalised in the future, the potential impact on the Company's annual operating costs would be approximately RMB6,420, representing a negligible effect.

- **Supply chain:** No material supply chain disruptions caused by extreme weather events or suppliers' low-carbon transition occurred during the reporting period, and no related additional procurement costs were incurred.

In conclusion, the Company assesses that climate-related risks and opportunities did not have any material impact on its financial position, financial performance or cash flows during the reporting period. The Company will continue to monitor the evolution of climate-related financial risks and plans to progressively introduce quantitative financial impact modelling in subsequent reporting periods to enhance the completeness of its disclosures.

Risk of balance sheet adjustments in the next reporting year (paragraph 24(b) of ESG Reporting Code): As at the end of the Reporting Period, the Company assesses that there are no climate-related risks that would result in material adjustments to the carrying values of assets and liabilities in the next reporting year. All relevant risks are under control.

- **溫室氣體排放**：範圍二排放量約為107噸CO_2e，排放強度約為0.50噸CO_2e/名員工；範圍一排放量為0噸CO_2e。按當前中國碳市場參考價格（約60元/噸CO_2e）估算，若未來碳成本完全內部化，對公司年度經營成本的潛在影響約為人民幣6,420元，影響程度極小。

- **供應鏈**：本報告期內，未發生因極端天氣或供應商低碳轉型導致的重大供應鏈中斷事件，亦無相關額外採購成本。

綜上，本公司評估本報告期內氣候相關風險及機遇對公司財務狀況、財務業績及現金流量均未產生重大實質性影響。公司將持續監察氣候相關財務風險的演變，並計劃在後續報告期逐步引入量化財務影響建模，以提升資訊披露的完整性。

下一匯報年度資產負債調整風險（對應ESG報告守則第24(b)段）：經本公司評估，截至本報告期末，不存在將導致下一匯報年度資產負債賬面價值發生重大調整的氣候相關風險，相關風險均處於可控範圍。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Expected changes in financial position (paragraph 25(a) of ESG Reporting Code) With strategies addressing climate-related risks and capturing opportunities, the Company expects its financial position to remain stable and gradually improve, achieving sustainable development and safeguarding the interests of shareholders and stakeholders.

預期財務狀況變化(對應ESG報告守則第25(a)段):結合氣候相關風險應對及機遇捕捉策略,本公司預期財務狀況將保持穩定並逐步優化,形成可持續發展態勢,保障股東及利益相關方權益。

Expected changes in financial performance and cash flows (paragraph 25(b) of ESG Reporting Code): Following the implementation of climate management strategies, the Company expects its financial performance and cash flows to remain stable. In the long run, it will achieve sound growth by capitalising on climate-related opportunities and enhance its sustainable development capabilities.

預期財務表現及現金流變化(對應ESG報告守則第25(b)段):實施氣候管理策略後,本公司預期財務表現及現金流將保持穩定,長期將依託氣候相關機遇實現良性增長,提升可持續發展能力。

Climate resilience assessment (paragraph 26(a) of ESG Reporting Code): As at the end of the Reporting Period, the Company has completed its first climate resilience assessment. It is generally capable of addressing climate risks and capturing opportunities, and will continue to optimise and enhance its climate resilience.

氣候韌性評估(對應ESG報告守則第26(a)段):截至本報告期末,本公司已完成首次氣候韌性評估,整體具備一定的氣候風險應對及機遇捕捉能力,後續將持續優化提升,增強氣候韌性。

Conduct of scenario analysis (paragraph 26(b) of ESG Reporting Code): The Company has conducted its first climate scenario analysis in accordance with the ESG Reporting Code and will perform such analyses regularly. Led by relevant departments, the analysis incorporates industry policies, industry developments and the Company's actual conditions, covering the base year and short-, medium- and long-term horizons to ensure relevance and practicality.

情景分析開展情況(對應ESG報告守則第26(b)段):本公司已按ESG報告守則要求開展首次氣候情景分析,後續將定期開展相關分析工作;分析工作由相關部門牽頭推進,結合行業政策、行業發展及本公司實際情況,涵蓋基準年及短、中、長期時間維度,確保分析結果的針對性及實用性。

Proportion of climate-related assets and businesses (paragraphs 30–32 of ESG Reporting Code): The Company has assets and business activities susceptible to climate-related transition and physical risks, as well as those linked to climate-related opportunities. These have been identified and subject to tracking and management in accordance with the ESG Reporting Code.

氣候相關資產及業務佔比(對應ESG報告守則第30–32段):本公司存在易受氣候相關轉型風險、實體風險影響的資產及業務活動,同時有涉及氣候相關機遇的資產及業務活動,本公司已按ESG報告守則要求完成識別並進行跟蹤管理。

Amount of climate-related investment (paragraph 33 of ESG Reporting Code): During the Reporting Period, the Company invested appropriate resources in addressing climate-related risks and capturing opportunities. It will continue to allocate relevant investment in line with its climate management plan to ensure orderly progress.

氣候相關投入金額(對應ESG報告守則第33段):本報告期內,本公司已投入相應資源用於氣候相關風險應對及機遇捕捉,後續將根據氣候管理計劃持續安排相關投入,保障各項工作有序推進。

Internal carbon pricing arrangements (paragraph 34 of ESG Reporting Code): As at the end of the Reporting Period, the Company has not yet implemented a unified internal carbon pricing mechanism. It plans to gradually introduce such a mechanism, determine application scenarios and relevant standards based on actual operating conditions, and continuously refine it to support low-carbon transition.

內部碳定價安排(對應ESG報告守則第34段):截至本報告期末,本公司尚未實施統一的內部碳定價機制,計劃後續逐步引入,結合本公司實際經營情況確定應用場景及相關標準,並持續優化完善,助力低碳轉型。

Going forward, the Company will continue to strictly comply with the requirements of the ESG Reporting Code, IFRS S2 and the TCFD framework. We will further enhance our climate scenario analysis system, optimise climate risk management and low-carbon transition initiatives, continuously enhance climate governance capability, steadily advance low-carbon operational transformation, and effectively fulfil corporate social responsibilities in addressing climate change, so as to achieve sustainable development while balancing shareholders' interests and social value.

未來,本公司將持續嚴格遵循聯交所ESG報告守則及IFRS S2、TCFD框架要求,不斷完善氣候情景分析體系,優化氣候風險管理及低碳轉型相關工作,持續提升氣候治理能力,穩步推進低碳運營轉型,切實履行企業應對氣候變化的社會責任,實現公司可持續發展,兼顧股東利益與社會價值。

Explanation (paragraph 36 of the ESG Reporting Code): The Company recognises that the Stock Exchange encourages issuers to refer to the IFRS S2 Industry-based Guidance and disclose industry-specific metrics associated with their particular business models. Given that no standardised IFRS S2 industry-based guidance classification has yet been established for the medical artificial intelligence sector, and that the Company is currently in the first phase of building its climate information disclosure framework in 2025, no systematic reference has been made to IFRS S2 industry-based guidance for the disclosure of industry-specific metrics during the current reporting period. The Company plans to assess applicable industry-specific climate and ESG metrics (including, without limitation, computing power energy intensity, AI model carbon efficiency and healthcare data security-related metrics) in the context of the AI healthcare industry in the next reporting period (2026), with a view to incorporating such metrics into its annual ESG Report for disclosure when conditions permit.

說明(對應ESG報告守則第36段):本公司認識到聯交所鼓勵發行人參考IFRS S2行業基礎指引披露與其特定行業商業模式相關的行業指標。鑒於醫療人工智慧行業目前尚未形成統一的IFRS S2行業特定指引分類,且本公司2025年度正處於氣候資訊披露體系的首期建設階段,本報告期暫未系統性地參照IFRS S2行業基礎指引披露行業特定指標。本公司計劃於下一報告期(2026年)結合AI醫療行業特點,評估適用的行業特定氣候與ESG指標(包括但不限於:算力能耗強度、AI模型碳效率、醫療數據安全相關指標),並在條件成熟時納入年度ESG報告予以披露。

9.6 Participation in the BRICS Green Cooperation International Platform

From May 25 to 26, 2025, the "Green BRICS, Golden Future" BRICS Think Tank International Symposium, co-hosted by the China Council for BRICS Think Tank Cooperation and Renmin University of China, was held. As corporate representatives, we were invited to participate in the Think Tank-Enterprise Dialogue on "Green Sci-tech and Product Standards", contributing industry perspectives on the application of AI medical technology in green medical transformation and global inclusive health sectors. We were also invited to participate in the unveiling ceremony of the joint research project on green cooperation and the green cooperation workstation for the "Global South". The above projects, led by the National Academy of Development and Strategy of Renmin University of China, under the guidance of the United Nations 2030 Sustainable Development Goals, unite the think tank forces of BRICS member states and partner countries to support BRICS countries and "Global South" countries in improving their green and sustainable development capabilities.

9.6 參與金磚國家綠色合作國際平台

2025年5月25日至26日，由金磚國家智庫合作中方理事會與中國人民大學聯合主辦的「綠色金磚金色未來」金磚國家智庫國際研討會，我們作為企業代表受邀參與「綠色科技與產品標準」智庫與企業對話會，就AI醫療技術在綠色醫療轉型及全球普惠健康領域的應用貢獻行業視角。我們亦受邀參與了「全球南方」綠色合作聯合研究專案及綠色合作工作站的揭牌儀式。上述專案由中國人民大學國家發展與戰略研究院牽頭，在聯合國2030年可持續發展目標指引下，聯合金磚國家成員國與夥伴國智庫力量，為金磚國家及「全球南方」國家提升綠色可持續發展能力提供支持。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告



Our participation reflects the unique value of AI medical technology in promoting green medical transformation and reducing medical resource consumption, and is also a specific action for us to actively fulfill international sustainable development responsibilities and respond to the United Nations Sustainable Development Goals (SDGs).

我們的參與，體現了AI醫療技術在推動綠色醫療轉型、降低醫療資源消耗方面的獨特價值，亦是我們積極履行國際可持續發展責任、回應聯合國可持續發展目標(SDGs)的具體行動。

In the future, we will further strengthen the concept of green development, continuously optimize energy and resource utilization efficiency, explore the establishment of a carbon emission baseline measurement system, promote low-carbon transformation of the entire operation process, and contribute to addressing climate change and achieving sustainable development.

未來，我們將進一步強化綠色發展理念，持續優化能源與資源利用效率，探索建立碳排放基線測量體系，推動運營全流程低碳轉型，為應對氣候變化、實現可持續發展貢獻力量。

10 APPENDIX: INDEX OF CONTENT IN THE ESG REPORTING CODE

10 附錄：香港聯交所ESG報告守則內容索引

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
Main Category A — Environment 主要範疇A — 環境	Environment-related policies, data and response measures, complying with reporting principles such as quantification and consistency 環境相關政策、數據及應對措施，遵循量化、一致性等匯報原則	09 Green Sustainable Development and Climate Response; 07 AI Medical Inclusive Ecology 09綠色可持續發展與氣候應對；07 AI醫療普惠生態
Aspect A1: Emissions 層面A1：排放物	Policies and compliance information on exhaust gas, greenhouse gas emissions, waste generation, etc., and disclosure of relevant data and emission reduction targets 廢氣及溫室氣體排放、廢棄物產生等政策及合規資料，披露相關數據及減排目標	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A1.1 Types of Emissions and Relevant Data A1.1排放物種類及相關數據	Disclose types of emissions, relevant emission data and disposal methods, and explain the standards and calculation methods used 披露排放物種類、相關排放數據及處置方式，說明所用標準及計算方法	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A1.3 Hazardous Waste A1.3有害廢棄物	Total amount of hazardous waste generated, disposal methods and compliance status; explain the reason if no hazardous waste is generated 所產生有害廢棄物總量、處置方式及合規情況，無產生則說明原因	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A1.4 Non-hazardous Waste A1.4無害廢棄物	Total amount of non-hazardous waste generated and disposal methods, and explain the qualifications of the disposal institution 所產生無害廢棄物總量、處置方式，說明處置機構資質	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
A1.5 Emission Reduction Targets and Measures A1.5排放物減排目標及措施	Set quantitative emission reduction targets (or directional statements), disclose relevant implementation measures, and explain the reason if no targets are set 設定排放物減排量化目標(或方向性聲明)，披露相關實施措施，未設定則說明原因	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A1.6 Waste Reduction Targets and Measures A1.6廢棄物減排目標及措施	Set quantitative waste reduction targets (or directional statements), disclose relevant implementation measures, and explain the reason if no targets are set 設定廢棄物減排量化目標(或方向性聲明)，披露相關實施措施，未設定則說明原因	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
Aspect A2: Resource Use 層面A2：資源使用	Policies, data and optimization measures on energy efficiency and water resource consumption, and disclose relevant targets and implementation steps 能源效率及水資源消耗政策、數據及優化措施，披露相關目標及實施步驟	09 Green Sustainable Development and Climate Response; 07 AI Medical Inclusive Ecology 09綠色可持續發展與氣候應對；07 AI醫療普惠生態
A2.1 Direct and Indirect Energy Consumption A2.1直接及間接能源消耗	Disclose the consumption and density of direct and indirect energy (such as electricity), and explain the calculation standards and methods 披露直接及間接能源(如電力)消耗量及密度，說明計算標準及方法	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A2.2 Water Resource Consumption A2.2水資源消耗	Disclose water consumption and density; explain the reason if separate measurement is not possible, and specify the purpose of water use 披露耗水量及密度，無法單獨計量則說明原因，說明用水用途	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
A2.3 Energy Efficiency Targets A2.3能源效率目標	Set quantitative energy efficiency targets (or directional statements), disclose measures to improve energy efficiency, and explain the reason if no targets are set 設定能源效率量化目標(或方向性聲明)，披露提升能源效率的措施，未設定則說明原因	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A2.4 Water Resource Efficiency Targets A2.4水資源效率目標	Set quantitative water resource efficiency targets (or directional statements), disclose measures to improve water resource efficiency, and explain the reason if no targets are set 設定水資源效率量化目標(或方向性聲明)，披露提升水資源效率的措施，未設定則說明原因	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
A2.5 Total Packaging Material Used for Finished Products A2.5製成品所用包裝材料總量	Disclose the total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced; explain the reason and improvement plan if separate statistics are not kept. 披露製成品所用包裝材料的總量(以噸計)及(如適用)每生產單位佔量；未單獨統計則說明原因及改進計劃。	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
Aspect A3: Environment and Natural Resources 層面A3：環境及天然資源	Policies to reduce the significant impact on the environment and natural resources, and describe the impact of business activities and corresponding management measures 減低對環境及天然資源重大影響的政策，描述業務活動帶來的影響及管理措施	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
A3.1 Description of Significant Impacts of Business Activities on the Environment and Natural Resources A3.1業務活動對環境及天然資源的重大影響描述	Detailedly describe the significant positive and negative impacts of the company's business activities on the environment and natural resources, as well as corresponding management actions 詳細描述公司業務活動對環境及天然資源的重大正面及負面影響，以及對應管理行動	09 Green Sustainable Development and Climate Response 09綠色可持續發展與氣候應對
Main Category B — Social 主要範疇B — 社會	Social-related policies, data and implementation measures, covering core aspects such as employment, supply chain and product responsibility 社會相關政策、數據及實施措施，覆蓋僱傭、供應鏈、產品責任等核心層面	06 Responsible Operations; 07 AI Medical Inclusive Ecology; 08 Talent Training and Development 06負責任運營；07 AI醫療普惠生態；08人才培養與發展
Aspect B1: Employment 層面B1：僱傭	Policies on remuneration and benefits, number of employees, turnover rate and employment, complying with relevant laws and regulations and protecting employees' rights and interests 薪酬福利、僱員人數、流失率及僱傭相關政策，遵守相關法律法規，保障員工權益	08 Talent Training and Development 08人才培養與發展
B1.1 Number of Employees by Gender, Employment Type, Age and Region B1.1按性別、僱傭類型、年齡、地區劃分的僱員人數	Disclose the number and proportion of employees by gender, employment type, age and region respectively, ensuring data accuracy and verifiability 分別披露按性別、僱傭類型、年齡、地區劃分的僱員數量及佔比，確保數據準確可核	08 Talent Training and Development 08人才培養與發展

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
B1.2 Turnover Rate by Gender, Age and Region B1.2按性別、年齡、地區劃分的流失率	Disclose the turnover rate and change range of employees by gender, age and region respectively, and explain the relevant reasons (if applicable) 分別披露按性別、年齡、地區劃分的僱員流失率及變化幅度，説明相關原因（如適用）	08 Talent Training and Development 08人才培養與發展
Aspect B2: Health and Safety 層面B2：健康與安全	Workplace safety measures, occupational health protection (including physical and mental health) and relevant data, and disclose relevant management measures 工作場所安全措施、職業健康保障（含身心健康）及相關數據，披露相關管理措施	08 Talent Training and Development 08人才培養與發展
B2.1 Number of Work-related Deaths and Rate B2.1因工死亡人數及比率	Disclose the number of work-related deaths and the corresponding rate during the reporting period; clearly disclose if there are no relevant incidents 披露報告期內因工死亡人數及對應比率，無相關事件則明確披露	08 Talent Training and Development 08人才培養與發展
B2.2 Work Days Lost Due to Work-related Injuries B2.2因工傷損失天數	Disclose the number of work days lost due to work-related injuries during the reporting period; clearly disclose if there are no relevant incidents 披露報告期內因工傷導致的損失工作日數，無相關事件則明確披露	08 Talent Training and Development 08人才培養與發展
B2.3 Description of Occupational Health and Safety Measures B2.3職業健康與安全措施描述	Describe the occupational health and safety measures adopted by the issuer, and how they are implemented and monitored. Measures should cover physical and mental health, workplace safety inspections, training and emergency response. 描述所採納的職業健康與安全措施，以及相關執行及監察方法，應涵蓋身心健康、工作場所安全檢查、培訓及應急響應等方面。	08 Talent Training and Development (Employee Health and Safety) 08人才培養與發展（員工健康與安全）

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
Aspect B3: Development and Training 層面B3：發展及培訓	Employee training policies, training data and training system construction, and disclose training-related information by gender and position level 員工培訓政策、受訓數據及培訓體系建設，按性別及職級披露受訓相關資訊	08 Talent Training and Development 08人才培養與發展
B3.1 Training Percentage by Gender and Position Level B3.1按性別及職級劃分的受訓百分比	Disclose the training percentage of employees by gender and position level respectively, ensuring complete data coverage 分別披露按性別、職級劃分的員工受訓百分比，確保數據完整覆蓋	08 Talent Training and Development 08人才培養與發展
B3.2 Training Hours by Gender and Position Level B3.2按性別及職級劃分的培訓時數	Disclose the average training hours of employees by gender and position level respectively, ensuring the authenticity and traceability of data 分別披露按性別、職級劃分的員工平均受訓時長，確保數據真實可追溯	08 Talent Training and Development 08人才培養與發展
Aspect B4: Labour Standards 層面B4：勞工準則	Policies and compliance status on the prohibition of child labour and forced labour, implement relevant management measures to ensure compliance with laws and regulations 禁止童工及強制勞工政策、合規情況，執行相關管理措施，確保符合法律法規	08 Talent Training and Development 08人才培養與發展
B4.1 Policies and Compliance Status on the Prohibition of Child Labour B4.1禁止童工政策及合規情況	Disclose the policies on the prohibition of child labour and the compliance status during the reporting period, and explain the age verification measures during recruitment 披露禁止童工的政策及報告期內合規情況，說明招聘時的年齡核實措施	08 Talent Training and Development 08人才培養與發展

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
B4.2 Policies and Compliance Status on the Prohibition of Forced Labour B4.2禁止強制勞工政策及合規情況	Disclose the policies on the prohibition of forced labour and the compliance status during the reporting period, and explain the relevant supervision measures 披露禁止強制勞工的政策及報告期內合規情況，說明相關監督措施	08 Talent Training and Development 08人才培養與發展
Aspect B5: Supply Chain Management 層面B5：供應鏈管理	Identification of environmental and social risks in the supply chain, management practices and promotion measures, and integrate ESG requirements into supplier management 供應鏈環境及社會風險識別、管理慣例及推動措施，將ESG要求納入供應商管理	06 Responsible Operations; 09 Green Sustainable Development and Climate Response 06負責任運營；09綠色可持續發展與氣候應對
B5.1 Number of Suppliers by Region B5.1按地區劃分的供應商數目	Disclose the number of suppliers by region respectively; explain the reason and disclose the management system if it involves commercial confidentiality 分別披露按地區劃分的供應商數量，涉及商業保密的說明原因並披露管理體系	06 Responsible Operations 06負責任運營
B5.2 Description of Supplier Management Practices B5.2供應商管理慣例描述	Detailedly describe supplier management practices such as access, evaluation and supervision, and explain the application of ESG evaluation in management 詳細描述供應商准入、評價、監督等管理慣例，說明ESG評估在管理中的應用	06 Responsible Operations 06負責任運營
B5.3 Identification of ESG Risks in the Supply Chain B5.3供應鏈ESG風險識別	Disclose the identification mechanism and identification results of environmental and social risks in the supply chain, including climate-related supply chain risks 披露供應鏈環境、社會相關風險的識別機制及識別結果，含氣候相關供應鏈風險	06 Responsible Operations; 09 Green Sustainable Development and Climate Response 06負責任運營；09綠色可持續發展與氣候應對

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
B5.4 Measures to Promote ESG Management in the Supply Chain B5.4供應鏈ESG推動措施	Disclose specific measures to promote the improvement of ESG management in the supply chain, including encouraging suppliers to obtain relevant certifications and conducting ESG audits 披露推動供應鏈ESG管理提升的具體措施，包括鼓勵供應商獲取相關認證、開展ESG審查	06 Responsible Operations; 09 Green Sustainable Development and Climate Response 06負責任運營；09綠色可持續發展與氣候應對
Aspect B6: Product Responsibility 層面B6：產品責任	Product quality, consumer data privacy, complaint handling and intellectual property protection, etc., ensuring compliance with relevant laws and regulations 產品質量、消費者數據隱私、投訴處理及知識產權保護等，確保符合相關法律法規	05 Core Technology and R&D Innovation; 06 Responsible Operations 05核心技術與研發創新；06負責任運營
B6.1 Product Quality Assurance Policies and Compliance Status B6.1產品質量保障政策及合規情況	Percentage of total products sold or shipped subject to recalls for safety and health reasons. 已售或已運送產品總數中因安全與健康理由而須回收的百分比。	06 Responsible Operations 06負責任運營
B6.2 Number of Product and Service Complaints/ Handling Methods B6.2產品及服務投訴數量／處理方式	Disclose the number of product and service complaints, handling processes and handling results; explain the reason and improvement measures if no separate statistics are kept 披露產品及服務投訴數量、處理流程及處理結果，未單獨統計則說明原因及改進措施	06 Responsible Operations 06負責任運營

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
B6.3 Description of Practices Relating to Observing and Protecting Intellectual Property Rights B6.3維護及保障知識產權相關慣例描述	Describe the issuer's practices relating to observing and protecting intellectual property rights, including policies on patent applications, confidentiality agreements, brand protection, IP infringement monitoring and employee IP training. 描述與維護及保障知識產權有關的慣例，包括專利申請政策、保密協議、品牌保護、知識產權侵權監察及員工知識產權培訓等。	05 Core Technology and R&D Innovation (Intellectual Property Protection) 05核心技術與研發創新（知識產權保護）
B6.4 Description of Quality Assurance Process and Recall Procedures B6.4質量檢定過程及產品回收程序描述	Describe the issuer's quality assurance process and recall procedures, including pre-market product testing and validation, post-market surveillance, complaint handling, and recall classification and execution procedures in compliance with applicable regulations. 描述質量檢定過程及產品回收程序，包括上市前產品測試及驗證、上市後監察、投訴處理，以及符合相關法規要求的產品召回分類及執行程序。	06 Responsible Operation (Quality Assurance and Recall Procedures) 06負責任運營（產品質量保證與召回）
B6.5 Description of Consumer Data Protection and Privacy Policies B6.5消費者數據保障及隱私政策描述	Detailedly describe the protection measures and privacy policies for the collection, use and storage of consumer (patient) data, complying with data security laws and regulations 詳細描述消費者（患者）數據收集、使用、存儲的保障措施及隱私政策，符合數據安全法規	06 Responsible Operations 06負責任運營
Aspect B7: Anti-corruption 層面B7：反貪污	Policies, training and case status on the prevention of bribery, extortion and money laundering, etc., and establish relevant implementation and supervision mechanisms 防止賄賂、敲詐勒索及洗黑錢等政策、培訓及案件情況，建立相關執行及監督機制	06 Responsible Operations 06負責任運營

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Aspects and KPI of the ESG Reporting Code ESG 報告守則層面及KPI編號	Summary of Disclosure Requirements 披露要求摘要	Corresponding Chapters in the Report 報告對應章節
B7.1 Number of concluded anti-corruption cases during the reporting period B7.1於報告期內對已審結的貪污訴訟案件的數目	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases. 於報告期內對發行人或其僱員提出並已審結的貪污訴訟案件的數目及訴訟結果。	06 Responsible Operations 06負責任運營
B7.2 Preventive measuresand whistle-blowing procedures B7.2描述防範措施及舉報程序	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored. 描述防範措施及舉報程序，以及相關執行及監察方法。	06 Responsible Operations 06負責任運營
B7.3 Anti-corruption training B7.3反貪污培訓	Description of anti-corruption training provided to directors and staff. 描述向董事及員工提供的反貪污培訓。	06 Responsible Operations 06負責任運營
Aspect B8: Community Investment 層面B8：社區投資	Policies, focus areas and resource input for contributions to target communities, and disclose information related to public welfare services 為目標社區所作貢獻的政策、聚焦領域及資源投入，披露公益服務相關資訊	07 AI Medical Inclusive Ecology 07 AI醫療普惠生態
B8.1 Focus Areas of Community Investment B8.1社區投資聚焦領域	Disclose the core focus areas and relevant plans of community investment, and carry out public welfare activities in combination with the company's business characteristics 披露社區投資的核心聚焦領域及相關規劃，結合公司業務特色開展公益活動	07 AI Medical Inclusive Ecology 07 AI醫療普惠生態
B8.2 Resource Input in Community Investment B8.2社區投資資源投入	Disclose quantitative data on resource input in community investment (such as funds, equipment, service person-times, etc.); explain the improvement plan if it is not yet improved 披露社區投資的資源投入量化數據（如資金、設備、服務人次等），未完善則說明改進計劃	07 AI Medical Inclusive Ecology 07 AI醫療普惠生態

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 19(a) (including notes) 第19(a)段(含註釋)	1. Disclose information about the governing body/individual(s) responsible for overseeing climate-related risks and opportunities; 2. Clearly specify the ESG responsibilities of the ESG Committee in its terms of reference and other relevant policies. 1.披露監督氣候相關風險和機遇的治理機構／個人資訊；2. 環境、社會及管治委員會職權範圍及政策中明確其ESG職責	Chapter 03 Board Statement (Content related to the ESG Committee) 第03章董事會聲明(環境、社會及管治委員會相關內容)	Comply 遵守
Paragraph 19(a)(i) 第19(a)(i)段	Oversight: Governance Body/ Individual Information 監督：治理機構個人資訊 Disclose information about the governing body or individual(s) responsible for overseeing climate-related risks and opportunities, including how the governing body is informed about climate-related issues. 披露監督氣候相關風險和機遇的治理機構個人資訊，包括治理機構如何獲悉氣候相關事宜。	Chapter 03 Board Statement (ESG Committee); Chapter 09 Green Sustainable Development and Climate Response (Climate Governance Structure) 第03章董事會聲明(環境、社會及管治委員會)；第09章綠色可持續發展與氣候應對(氣候治理架構)	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守/解釋情況
Paragraph 19(a)(ii) 第19(a)(ii)段	Oversight: Role of Governance Body/Individual 監督:治理機構個人的角色 Describe the role of the governing body or individual(s) in assessing and managing climate-related risks and opportunities, including how related targets are set and progress is monitored. 描述治理機構個人在評估和管理氣候相關風險和機遇中的角色,包括如何制定相關目標並監察進度。	Chapter 03 Board Statement; Chapter 09 Green Sustainable Development and Climate Response (Climate Governance Structure) 第03章董事會聲明;第09章綠色可持續發展與氣候應對(氣候治理架構)	Comply 遵守
Paragraph 19(a)(iii) 第19(a)(iii)段	Disclose how the governing body/individual(s) consider climate-related risks and opportunities, including any trade-off assessments related to such climate-related risks and opportunities, in overseeing strategies, major decision-making processes, etc. 披露治理機構/個人在監督策略、重大決策等過程中,如何考慮氣候相關風險和機遇及相關權衡評估	Chapter 03 Board Statement, Chapter 04 Sustainable Development Management System 第03章董事會聲明、第04章可持續發展管理體系	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 19(a)(iv) and Paragraph 35 第19(a)(iv)段、第35段	Disclose how the body(s) or individual(s) oversees the setting of, and monitors progress towards, targets related to climate-related risks and opportunities, including whether and how relevant performance indicators are incorporated into the remuneration policy. 披露該機構或個人如何監督有關氣候相關風險和機遇的目標制定並監察達標進度，包括相關績效指標是否及如何納入薪酬政策	Chapter 08 Talent Development and Growth 第08章人才培養與發展	Explain 解釋
Paragraph 20 第20段	Identification of Climate-related Risks and Opportunities 氣候相關風險和機遇的識別 Disclose climate-related risks and opportunities the issuer has identified over the short, medium and long term, and how the issuer defines these time horizons and links them to its strategic planning horizons. 披露已識別的氣候相關風險和機遇(短期、中期及長期)，以及時間維度的定義和與戰略規劃周期的聯繫。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4 & 9.5) 第09章綠色可持續發展與氣候應對(第9.4節及第9.5節)	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 20(a) 第20(a)段	Identification: Description of Climate-related Risks 識別：氣候相關風險描述 Disclose the climate-related risks the issuer has identified over the short, medium and long term that could reasonably be expected to affect the issuer's business model, strategy and financial planning. 披露已識別的、預期可能在短期、中期及長期對發行人的商業模式、策略及財務規劃產生影響的氣候相關風險。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4 Climate Risk Identification) 第09章綠色可持續發展與氣候應對(第9.4節氣候風險識別)	Comply 遵守
Paragraph 20(b) 第20(b)段	Identification: Description of Climate-related Opportunities 識別：氣候相關機遇描述 Disclose the climate-related opportunities the issuer has identified over the short, medium and long term that could reasonably be expected to affect the issuer's business model, strategy and financial planning. 披露已識別的、預期可能在短期、中期及長期對發行人的商業模式、策略及財務規劃產生影響的氣候相關機遇。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.5 Climate Scenario Analysis) 第09章綠色可持續發展與氣候應對(第9.5節氣候情景分析)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 20(c) 第20(c)段	Identification: Time Horizons of Each Risk/Opportunity 識別：各風險機遇的影響時間維度 Specify, for each climate-related risk and opportunity the issuer has identified, over which time horizons — short, medium or long term — the effects of each climate-related risk and opportunity could reasonably be expected to occur. 就已識別的每項氣候相關風險和機遇，說明其影響預計在短期、中期抑或長期發生。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.5 — time horizon labels added per risk/opportunity) 第09章綠色可持續發展與氣候應對(第9.5節 — 各風險機遇時間維度標注)	Comply 遵守
Paragraph 20(d) 第20(d)段	Identification: Definition of Time Horizons 識別：時間維度定義 Explain how the issuer defines "short term", "medium term" and "long term" and how these definitions are linked to the planning horizons used by the issuer for strategic decision-making. 說明如何定義「短期」、「中期」及「長期」，以及上述定義如何與發行人戰略決策所用的規劃周期掛鉤。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.5 — time horizon definition paragraph) 第09章綠色可持續發展與氣候應對(第9.5節—時間維度定義段落)	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 21 第21段	Description of Climate-related Risks and Opportunities 氣候相關風險和機遇的描述 Disclose how the issuer describes and classifies the climate-related risks and opportunities identified, covering both transition risks and physical risks, as well as opportunities. 披露如何描述及分類已識別的氣候相關風險(轉型風險及實體風險)和機遇。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4 & 9.5) 第09章綠色可持續發展與氣候應對(第9.4節及第9.5節)	Comply 遵守
Paragraph 21(a) 第21(a)段	Description: Transition Risks 描述：轉型風險 For each climate-related transition risk identified, disclose a description of the risk, including information about the current and anticipated regulatory or policy environment relevant to the risk, and whether the risk has been assessed as a material risk. 就每項已識別的氣候相關轉型風險，披露風險描述，包括與該風險相關的當前及預期監管或政策環境，以及該風險是否被評估為重大風險。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4 — Transition Risk Table; Section 9.5 — 1.5°C Scenario) 第09章綠色可持續發展與氣候應對(第9.4節 — 轉型風險表格；第9.5節 — 1.5°C情景)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 21(b) 第21(b)段	Description: Physical Risks and Opportunities 描述：實體風險及機遇 For each climate-related physical risk and opportunity identified, disclose a description, including the specific location(s) of assets or business activities susceptible to the risk and, where relevant, the anticipated time horizon of the effect. 就每項已識別的氣候相關實體風險及機遇，披露描述，包括受影響的資產或業務活動的具體地點，以及(如相關)預計影響發生的時間維度。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4 — Physical Risk Table; Section 9.5–3°C Scenario) 第09章綠色可持續發展與氣候應對(第9.4節 — 實體風險表格；第9.5節 — 3°C情景)	Comply 遵守
Paragraph 22(a)(i) 第22(a)(i)段	Disclose changes to the current and expected future business model (including resource allocation) in response to climate-related risks and opportunities. 披露因應氣候相關風險和機遇，對當前及預期將來業務模式(含資源配置)的變動	Chapter 02 About Us, Chapter 09 Green Sustainable Development and Climate Response 第02章關於我們、第09章綠色可持續發展與氣候應對	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 22(a)(ii) 第22(a)(ii)段	Disclose any direct or indirect adaptation or mitigation efforts that have been or are expected to be carried out. 披露已經或預期將進行的任何直接或間接的適應或減緩工作	Chapter 04 Sustainable Development Management System (SDG 13 Climate Action), Chapter 09 Green Sustainable Development and Climate Response 第04章可持續發展管理體系(SDG 13氣候行動)、第09章綠色可持續發展與氣候應對	Comply 遵守
Paragraph 22(a)(iii) 第22(a)(iii)段	Disclose climate-related transition plans (including key assumptions and dependent factors); make a negative statement if no such plans exist. 披露氣候相關轉型計劃(含主要假設、依賴因素);無計劃則作否定聲明	Chapter 09 Green Sustainable Development and Climate Response (Climate Response Strategy) 第09章綠色可持續發展與氣候應對(氣候應對策略)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 22(a)(iv) 第22(a)(iv)段	Strategy: Plans to Achieve Climate-related Targets 策略：實現氣候相關目標的計劃 Disclose how the issuer plans to achieve any climate-related targets it has set (including any greenhouse gas emissions targets), described in accordance with paragraphs 37 to 40 of Part D of the ESG Reporting Code. If no such targets have been set, make a negative statement and explain the reason. 披露發行人如何計劃實現其氣候相關目標(含溫室氣體減排目標，如有)，並依照ESG報告守則第D部分第37至40段的要求進行描述；如尚未設定目標，則作否定聲明並說明原因。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.5.1 — Para 22(a)(iv) Explanatory Statement) 第09章綠色可持續發展與氣候應對(第9.5.1節 — 第22(a)(iv)段說明段落)	Explain 解釋
Paragraph 22(b) 第22(b)段	Disclose current and future plans for providing resources for the actions disclosed under Paragraph 22(a). 披露當前及將來計劃如何為第22(a)段披露的行動提供資源	Chapter 05 Core Technology and R&D Innovation (R&D Investment), Chapter 09 Green Sustainable Development and Climate Response 第05章核心技術與研發創新(研發投入)、第09章綠色可持續發展與氣候應對	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 23 第23段	Disclose the latest progress of the plans disclosed under Paragraph 22 in the previous reporting period. 披露以往報告期間根據第22段已披露計劃的最新進展情況	Chapter 03 Board Statement (Progress of ESG Goals), Chapter 09 Green Sustainable Development and Climate Response 第03章董事會聲明（ESG目標進度）、第09章綠色可持續發展與氣候應對	Comply 遵守
Paragraph 24(a) 第24(a)段	Financial Effects: Impact on Financial Position, Performance and Cash Flows for the Reporting Period 財務影響：對本報告期財務狀況、財務業績及現金流量的影響 Disclose qualitative and quantitative information about how climate-related risks and opportunities have affected the issuer's financial position, financial performance and cash flows for the reporting period. If the impact is not material, a clear negative statement with supporting rationale must be provided. 披露氣候相關風險和機遇在本報告期如何影響發行人的財務狀況、財務業績及現金流量的定性及定量資訊；如影響不重大，須作出明確的否定性聲明並說明判斷依據。	Chapter 09 Green Sustainable Development and Climate Response (Para 24(a) Financial Impact Disclosure) 第09章綠色可持續發展與氣候應對（第24(a)段財務影響專項披露）	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 24(b) (including Notes 1 and 2) 第24(b)段(含註釋1、2)	When there are material risks that would lead to a significant adjustment in the book value of assets and liabilities in the next reporting year, disclose information about the climate-related risks and opportunities identified under Paragraph 24(a). 當存在導致下一匯報年度資產負債賬面價值重大調整的重大風險時，披露第24(a)段識別的氣候相關風險和機遇資訊	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 25(a) (including Notes 1–5) 第25(a)段(含註釋1–5)	Disclose the expected changes in the short-term, medium-term and long-term financial position after considering climate-related strategies, taking into account its investment and disposal plans; and its planned funding sources for implementing the strategies. 結合投資處置計劃、資金來源計劃，披露考慮氣候相關策略後，短期、中期、長期財務狀況預期變化	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 25(b) (including Notes 1–5) 第25(b)段(含註釋1–5)	Disclose quantitative and qualitative information on the expected changes in the company's short-term, medium-term and long-term financial performance and cash flow on the premise of implementing strategies for managing climate-related risks and opportunities. 披露實施氣候相關風險和機遇管理策略前提下，短期、中期、長期財務表現及現金流的定量、定性預期變化	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 26(a) 第26(a)段	As at the end of the reporting period, disclose the company's assessment of climate resilience to enable readers to understand the contents set out in Paragraph 26(a)(i)-(iii). 截至報告期末，披露公司就氣候韌性的評估，以便讀者理解第26(a)(i)-(iii)項內容	Chapter 04 Sustainable Development Management System, Chapter 09 Green Sustainable Development and Climate Response 第04章可持續發展管理體系、第09章綠色可持續發展與氣候應對	Comply 遵守
Paragraph 26(b) (including i, ii, iii) 第26(b)段(含i、ii、iii)	Disclose how and when climate-related scenario analysis is conducted, including the input data, key assumptions used in such analysis and the reporting period covered by the analysis. 披露氣候相關情景分析的進行方式、時間，及所採用的輸入數據、關鍵假設、涵蓋期間	Chapter 09 Green Sustainable Development and Climate Response (Related to Climate Scenario Analysis) 第09章綠色可持續發展與氣候應對(氣候情景分析相關)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 27(a)(i) 第27(a)(i)段	Disclose the input data and parameters used to identify and assess climate-related risks (such as data sources and the scope of business covered by the process). 披露識別、評估氣候相關風險所採用的輸入資料及參數(如資料來源、業務範圍)	Chapter 04 Sustainable Development Management System (Materiality Assessment), Chapter 09 Green Sustainable Development and Climate Response 第04章可持續發展管理體系(重要性評估)、第09章綠色可持續發展與氣候應對	Comply 遵守
Paragraph 27(a)(ii) 第27(a)(ii)段	Risk Management: Use of Climate-related Scenario Analysis to Identify Risks 風險管理：氣候情景分析用於識別風險的方式 Disclose whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related risks, including how the conclusions of scenario analysis are reflected in the risk register and risk management process. 披露是否及如何運用氣候相關情景分析識別氣候相關風險，包括情景分析結論如何反映在風險台賬及風險管理流程中。	Chapter 09 Green Sustainable Development and Climate Response (Climate Risk Management Process — Para 27(a)(ii) bullet point) 第09章綠色可持續發展與氣候應對(氣候風險管理流程 — 第27(a)(ii)段要點)	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 27(a)(iii) 第27(a)(iii)段	Risk Management: Assessment of Nature, Likelihood and Magnitude of Risks 風險管理：風險的性質、可能性及影響程度評估 Disclose how the issuer assesses the nature, likelihood and magnitude of the effects of climate-related risks, including whether the issuer considers qualitative factors, quantitative thresholds or other criteria in its assessment. 披露如何評估氣候相關風險影響的性質、可能性及影響程度，包括評估中是否採用定性因素、定量門檻或其他標準。	Chapter 09 Green Sustainable Development and Climate Response (Climate Risk Management Process — Para 27(a)(iii) bullet point) 第09章綠色可持續發展與氣候應對(氣候風險管理流程—第27(a)(iii)段要點)	Comply 遵守
Paragraph 27(a)(iv) 第27(a)(iv)段	Disclose the prioritization method of climate-related risks relative to other types of risks. 披露氣候相關風險相對於其他類型風險的優次排列方式	Chapter 04 Sustainable Development Management System (Materiality Issue Matrix) 第04章可持續發展管理體系(重要性議題矩陣)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 27(a)(v) 第27(a)(v)段	Risk Management: Monitoring of Climate-related Risks 風險管理：氣候相關風險的監察 Disclose how the issuer monitors climate-related risks, including the frequency and mechanism of risk reviews, the responsible parties for monitoring, and how significant changes in risk levels are escalated and reported. 披露如何監察氣候相關風險，包括風險審查的頻率及機制、負責監察的主體，以及風險水平重大變化的上報機制。	Chapter 09 Green Sustainable Development and Climate Response (Climate Risk Management Process — Para 27(a)(v) bullet point) 第09章綠色可持續發展與氣候應對(氣候風險管理流程—第27(a)(v)段要點)	Comply 遵守
Paragraph 27(a)(vi) 第27(a)(vi)段	Disclose whether and how the process for identifying and assessing climate-related risks has changed compared with the previous reporting period. 披露與上一匯報期相比，識別、評估氣候相關風險的流程是否及如何改變	Chapter 04 Sustainable Development Management System (Materiality Assessment Process) 第04章可持續發展管理體系(重要性評估流程)	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 27(b) 第27(b)段	Disclose the processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities, including whether and how the issuer uses climate-related scenario analysis to identify climate-related opportunities. 披露發行人用於識別、評估氣候相關機遇，以及釐定優先順序並保持監察的流程(含情景分析的使用情況)。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4 — Para 27(b) Climate Opportunity Management Process) 第09章綠色可持續發展與氣候應對 (第9.4節—第27(b)段氣候機遇管理流程)	Comply 遵守
Paragraph 27(c) 第27(c)段	Disclose the extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer's overall risk management process. 披露氣候相關風險和機遇的識別、評估、優先順序釐定及監察流程，是如何融入發行人的整體風險管理流程，以及融入的程度如何。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.4— Para 27(c) Integration with Overall Risk Management) 第09章綠色可持續發展與氣候應對 (第9.4節—第27(c)段與整體風險管理的整合)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 28 第28段	Metrics: Cross-industry and Industry-specific Metrics 指標：跨行業及行業特定指標 Disclose cross-industry metrics that are relevant to climate-related risks and opportunities, including greenhouse gas emissions metrics and any other metrics that the issuer uses to measure and manage climate-related risks and opportunities. 披露與氣候相關風險和機遇相關的跨行業指標，包括溫室氣體排放指標及任何其他用以計量及管理氣候相關風險和機遇的指標。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.2 GHG Emissions Data) 第09章綠色可持續發展與氣候應對(第9.2節溫室氣體排放數據)	Comply 遵守
Paragraph 28(a) 第28(a)段	Metrics: Scope 1, 2 and 3 Greenhouse Gas Emissions 指標：範圍一、二、三溫室氣體排放量 Disclose Scope 1, Scope 2 and, if applicable, Scope 3 greenhouse gas emissions, and the related risks. The issuer shall disclose its Scope 3 emissions or explain why they are not included. 披露範圍一、範圍二及(如適用)範圍三溫室氣體排放量及相關風險；如未披露範圍三，則說明原因。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.2: Scope 1: 0 tCO_2e; Scope 2: ~107 tCO_2e; Scope 3: under assessment) 第09章綠色可持續發展與氣候應對(第9.2節：範圍一：0噸CO_2e；範圍二：約107噸CO_2e；範圍三：評估中)	Comply (Scope 1 & 2) Explain (Scope 3) 遵守(範圍一、二) 解釋(範圍三)

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 28(b) 第28(b)段	Metrics: Scope 3 Greenhouse Gas Emissions (Detail) 指標：範圍三溫室氣體排放量(詳情) If Scope 3 emissions are not disclosed, explain the reason and disclose the timeline for including Scope 3 emissions in future reporting. 如未披露範圍三排放量，說明原因及計劃納入範圍三排放披露的時間表。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.2 — Scope 3 explanation and timeline) 第09章綠色可持續發展與氣候應對(第9.2節 — 範圍三說明及時間表)	Explain 解釋
Paragraph 28(c) 第28(c)段	Metrics: Internal Carbon Pricing 指標：內部碳定價 Disclose any internal carbon pricing arrangements used by the issuer (such as for investment decisions, transfer pricing and scenario analysis), including the price applied. 披露任何內部碳定價安排(如用於投資決策、轉移定價及情景分析)，包括所採用的碳價格。	Chapter 09 Green Sustainable Development and Climate Response (Internal Carbon Pricing Arrangements) 第09章綠色可持續發展與氣候應對(內部碳定價安排說明)	Explain 解釋
Paragraph 29(a) 第29(a)段	Greenhouse gas emissions shall be measured in accordance with the Greenhouse Gas Protocol: Corporate Accounting and Reporting Standards (2004), unless otherwise specified by the competent authority. 溫室氣體排放按《溫室氣體議定書：企業會計與報告標準(2004)》量度，管轄機關另有規定的除外	Chapter 09 Green Sustainable Development and Climate Response (Greenhouse Gas Emission Measurement) 第09章綠色可持續發展與氣候應對(溫室氣體排放計量)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 29(b)(i) 第29(b)(i)段	Disclose the measurement methods, input data and assumptions for greenhouse gas emissions. 披露溫室氣體排放的計量方法、輸入資料及假設	Chapter 09 Green Sustainable Development and Climate Response (Greenhouse Gas Emission Measurement) 第09章綠色可持續發展與氣候應對(溫室氣體排放計量)	Comply 遵守
Paragraph 29(b)(ii) 第29(b)(ii)段	Disclose the reasons for selecting the measurement methods and assumptions for greenhouse gas emissions. 披露選擇溫室氣體排放計量方法及假設的原因	Chapter 09 Green Sustainable Development and Climate Response (Greenhouse Gas Emission Measurement) 第09章綠色可持續發展與氣候應對(溫室氣體排放計量)	Comply 遵守
Paragraph 29(b)(iii) 第29(b)(iii)段	Disclose any changes in the measurement methods and assumptions for greenhouse gas emissions during the reporting period and the reasons for such changes. 披露報告期間內溫室氣體排放計量方法、假設的任何變更及原因	Chapter 09 Green Sustainable Development and Climate Response (Greenhouse Gas Emission Measurement) 第09章綠色可持續發展與氣候應對(溫室氣體排放計量)	Comply (No changes occurred) 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 29(c) 第29(c)段	GHG Measurement: Source of Emission Factors 溫室氣體計量：排放因子來源 Disclose the emission factors used in greenhouse gas emissions calculations and their sources. Where government-published emission factors are used, identify the specific publication and data year. 披露溫室氣體排放計算中所採用的排放因子及其來源；如採用政府公佈的排放因子，說明具體公佈文件及數據年份。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.2 — Emission Factor Sources) 第09章綠色可持續發展與氣候應對(第9.2節 — 排放因子來源段落)	Comply 遵守
Paragraph 29(d) 第29(d)段	GHG Measurement: Source of Global Warming Potential (GWP) Values 溫室氣體計量：全球增溫潛勢(GWP)數值來源 Disclose the global warming potential (GWP) values used in greenhouse gas emissions calculations and their sources (e.g. IPCC Assessment Report and the specific edition relied upon). 披露溫室氣體排放計算中所採用的全球增溫潛勢(GWP)數值及其來源(如IPCC評估報告及所依賴的具體版本)。	Chapter 09 Green Sustainable Development and Climate Response (Section 9.2 — GWP Values Source: IPCC AR6, GWP100) 第09章綠色可持續發展與氣候應對(第9.2節 — GWP數值來源：IPCC第六次評估報告AR6，GWP100)	Comply 遵守

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 30 第30段	Disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks. 披露易受氣候相關轉型風險影響的資產或業務活動的金額及百分比	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 31 第31段	Disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks. 披露易受氣候相關實體風險影響的資產或業務活動的金額及百分比	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 32 第32段	Disclose the amount and percentage of assets or business activities involving climate-related opportunities. 披露涉及氣候相關機遇的資產或業務活動的金額及百分比	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 33 第33段	Disclose the amount of capital expenditure, financing or investment allocated to climate-related risks and opportunities. 披露投放於氣候相關風險及機遇的資本性開支、融資或投資金額	Chapter 05 Core Technology and R&D Innovation (R&D Expenditure), Chapter 09 Green Sustainable Development and Climate Response 第05章核心技術與研發創新(研發開支)、第09章綠色可持續發展與氣候應對	Comply 遵守

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraph 34 第34段	Disclose any internal carbon pricing arrangements (such as for investment decisions, transfer pricing and scenario analysis). 披露任何內部碳定價的安排(如投資決策、轉移定價及情景分析)	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 36 第36段	Industry-based Metrics (Encouraged Disclosure) 行業特定指標(鼓勵性披露) Issuers are encouraged to disclose industry-based metrics associated with one or more particular business models, activities or other common features that characterise participation in an industry, with reference to the IFRS S2 Industry-based Guidance and other international ESG reporting frameworks. 鼓勵發行人參考IFRS S2行業基礎指引及其他國際ESG框架，披露與本行業特有商業模式或活動相關的行業特定指標。	Chapter 09 Green Sustainable Development and Climate Response 第09章綠色可持續發展與氣候應對	Explain 解釋

Paragraphs of Part D of the ESG Reporting Code ESG報告守則第D部分條款段落	Disclosure Requirements (on a "comply or explain" basis) 披露要求(按「遵守或解釋」原則)	Corresponding Disclosure Location in the Report 報告對應披露位置	Compliance/ Explanation Status 遵守／解釋情況
Paragraphs 37–40 第37–40段	Disclose information required in respect of climate-related targets (including greenhouse gas emissions reduction targets, if any), covering: description of target and target type (paragraph 37); base year and base year value (paragraph 38); milestones and progress towards targets (paragraph 39); and type of carbon credits used (paragraph 40). 就氣候相關目標(含溫室氣體減排目標，如有)披露以下資訊：目標描述及類型(第37段)；基準年及基準值(第38段)；實現目標的里程碑及進度(第39段)；所用碳信用類型(第40段)。	Chapter 03 Board Statement (ESG Goals), Chapter 09 Green Sustainable Development and Climate Response 第03章董事會聲明(ESG目標)、第09章綠色可持續發展與氣候應對	Explain 解釋
Paragraph 41 第41段	Refer to cross-industry and industry indicators when preparing disclosures of climate-related indicators. 編製氣候相關指標披露時，參照跨行業及行業指標的要求	Chapter 04 Sustainable Development Management System (SDG Alignment), Chapter 09 Green Sustainable Development and Climate Response 第04章可持續發展管理體系(SDG對應)、第09章綠色可持續發展與氣候應對	Comply 遵守


Airdoc鹰瞳